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Pulmonary arterial hypertension (PAH) is a devastating and progressive vasculopathy of 
the pulmonary arteries for which there is no cure. There is an urgent need for more 
effective therapies. PAH is characterised by elevated pulmonary arterial pressures and 
obstructive vascular lesions in the distal vasculature by excessive cellular proliferation. As 
a result, the right ventricle is placed under excessive strain resulting in adaptive 
hypertrophy which progresses to maladaptive hypertrophy and failure. PAH is more 
common in women than in men suggesting that estrogens may be integral to disease 
pathogenesis. Understanding the biological basis for this sex difference would offer a new 
treatment paradigm in this devastating cardiovascular disease. Here, we challenged the 
concept that the estrogen metabolic axis is dysregulated in PAH. 
New insights have revealed a potential contribution of the estrogen metabolizing enzyme, 
cytochrome P450 1B1 (CYP1B1) in the development of PAH. 17β-estradiol (17β-E2) and 
estrone (E1) are metabolized by the activity of CYP1B1 to the 2-, 4- and 16-hydroxylated 
estrogens. Here, we defined the role of CYP1B1 in the pathogenesis of PAH. CYP1B1 
expression was increased in both experimental (hypoxia and SU5416+hypoxia) and in 
heritable and idiopathic PAH (HPAH and IPAH, respectively). Both male and female 
CYP1B1 knockout mice (CYP1B1-/-) were challenged with chronic hypoxia to induce 
PAH as assessed by right ventricular systolic pressures (RVSP), right ventricular 
hypertrophy (RVH) and pulmonary vascular remodeling. CYP1B1-/- mice were protected 
against hypoxia-induced pulmonary hypertension (PH). CYP1B1 inhibition with the highly 
potent and selective inhibitor 2,3',4,5'-tetramethoxystilbene (TMS; 3 mg/kg/day by intra-
peritoneal injection) attenuated the development of hypoxia-induced PH. Only moderate 
effects were observed with CYP1B1 inhibition in monocrotaline-induced PH, despite 
improving survival rates. Female mice that over-express the human serotonin transporter 
gene (SERT+ mice) develop a spontaneous PAH phenotype at 5 months of age which is 
dependent on circulating levels of 17β-E2. Here, we provide evidence that the estrogen 
metabolic axis is dysregulated in these mice and this may underlie their PAH phenotype. 
The estrogen synthesizing enzyme aromatase and CYP1B1 was increased in whole lung 
homogenates of female SERT+ mice compared to wild-type mice. Despite increased 
expression of aromatase, 17β-E2 concentrations were unchanged. CYP1B1 inhibition with 
TMS (1.5mg/kg/day by intra-peritoneal injection) attenuated the PAH phenotype in female 
SERT+ mice as assessed by RVSP and pulmonary vascular remodeling. 
xxiv 
 
Other studies have identified that the 16-hydroxylated metabolites of estrogens (17β-E2 
and E1) are the only CYP1B1 metabolites to induce cellular proliferation, with the most 
profound effects observed with 16α-hydroxyestrone (16α-OHE1). In mice exposed to 
chronic hypoxia, urinary concentrations of 16α-OHE1 were increased. Chronic dosing of 
16α-OHE1 in mice (1.5mg/kg/day by intra-peritoneal injection for 28 days) resulted in the 
development of a PAH phenotype in female mice only. 16α-OHE1 induced cellular 
proliferation in human pulmonary arterial smooth muscle cells (hPASMCs) and this was 
inhibited by a scavenger of reactive oxygen species (ROS) and an inhibitor of extracellular 
regulated kinase 1/2 (ERK 1/2). 4-hydroxylation is the predominant metabolic pathway 
activated by CYP1B1 activity and we therefore investigated the effects of the 4-
hydroxylated metabolite of 17β-E2 in vivo. 4-hydroxyestradiol (4-OHE2) had no effects on 
PAH parameters in mice (1.5mg/kg/day by intra-peritoneal injection for 28 days). 
However, serotonin-induced vasoconstriction of the intra-pulmonary arteries was 
dramatically reduced in arteries harvested from mice dosed with 4-OHE2. More recent 
studies have identified that 4-hydroxyestrone (4-OHE1) is the predominant CYP1B1 
metabolite in the lungs of mice. Interestingly, despite evidence for a pathogenic function of 
CYP1B1 activity in vivo, 4-OHE1 inhibited cellular proliferation in hPASMCs as assessed 
by thymidine incorporation whilst no effects were reported on cell viability. 
We provide evidence for an altered estrogen metabolic axis in PAH, by in part, 
overexpression of the putatively pathological CYP1B1. Yet, the dynamic estrogen 
metabolic profile in pulmonary vascular cells remains undetermined. To address this, we 
developed a high fidelity HPLC method to quantitatively fate map estrogen metabolism in 
hPASMCs to determine the dynamic regulation of estrogen metabolism in PAH. We 
provide the first direct evidence that hPASMCs metabolize 17β-E2 and that estrogen 
metabolism is pathologically altered in PAH. Our metabolic screen revealed a prominent 
role for 17β-hydroxysteroid dehydrogenase enzymes in hPASMCs by rapid formation of 
E1 in all groups studied, increasing with time, with the highest activity in male control 
hPASMCs and the lowest activity in female control hPASMCs. In female control 
hPASMCs there was no evidence of CYP activity, whilst numerous metabolites were 
formed in the other groups studied. The formation of the pathogenic 16α-hydroxylated 
estrogens was only evident in PASMCs from both male and female PAH patients at 24 and 
48 hours. Globally, this study introduces a platform to elucidate effects of PAH insults and 
potential therapies on the estrogen-metabolic profile in pulmonary vascular cells. 
xxv 
 
Overall, we provide eminent evidence that the estrogen metabolic axis is pathologically 
altered in PAH and is influenced by gender. This provides a strong rationale for the 
application of estrogen-sensitive therapies in the management of this highly female 
discriminating disease. 
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 The pulmonary circulation 1.1
At birth we are primed to take our first breath. Instantly there is a dramatic reduction in 
pulmonary vascular resistance (PVR) accompanied by closure of the ductus arteriosus, 
which is used in foetal life to bypass the pulmonary circulation. Subsequently the 
pulmonary arterial pressures (PAPs) rise and the lungs assume their prime function of 
gaseous exchange. 
 Pulmonary vascular structure and function 1.1.1
Deoxygenated blood drains into the right atrium of the heart from the superior and inferior 
vena cava returning blood from the upper and lower extremities. During the diastolic 
contraction of the heart, the tricuspid valves open allowing blood to flow into the right 
ventricle. During systole of the heart, the tricuspid valves close and blood is pushed 
through the semi-lunar valves into the main pulmonary artery which bifurcates into the left 
and the right pulmonary arteries. Each artery then enters its respective lung at the hilum 
through the parenchyma and is thereafter referred to as the intra-lobar pulmonary artery. 
This runs parallel to the respiratory tree alongside the bronchus to the alveoli where it 
becomes a mesh-like network of millions of capillaries from which gas exchange can 
occur. Only a very thin barrier exists between the pulmonary capillaries and alveoli 
allowing for passive diffusion of carbon dioxide and oxygen. There are approximately 480 
million alveoli in the lungs with the prime purpose of increasing the surface area for gas 
exchange (Ochs et al., 2004). The pulmonary arteries and veins each have 15 orders of 
branching between the main pulmonary artery and the capillaries and between the 
capillaries and left atrium, respectively (Huang et al., 1996).  
The lungs are unique in that they are the only organ that receives the entire cardiac output 
(CO) resulting in a high flow system of about 5 litres of blood per minute, which increases 
to about 25 litres during exercise. The primary function of the pulmonary circulation is gas 
exchange. Hence the pulmonary arteries have thin walls with a minimal smooth muscle 
cell layer resulting in a low-pressure, low-resistance system. The pulmonary artery is the 
only artery in the entire body that carries deoxygenated blood and similarly, the pulmonary 
vein is the only vein that carries oxygenated blood. The normal mean PAP is between 
14mmHg and 20mmHg (Badesch et al., 2009), which allows for adequate oxygen 
replenishment and unloading of carbon dioxide. In contrast, in the systemic circulation, 
mean pressures are of the order of 100mmHg. PAP is a result of CO and PVR and thus 
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PAP = CO X PVR. PVR is related to the intraluminal vessel wall diameter - the smaller the 
diameter, the greater the PVR. For this reason, arteries in the pulmonary circulation are 
normally fully dilated. Distension and recruitment of closed arteries are important 
mechanisms that are employed to reduce PVR when the cardiac output is increased, for 
example during exercise. 
The lungs also contain a functionally distinct second circulation known as the bronchial 
circulation. The bronchial circulation arises from the systemic circulation and serves as the 
supplier of oxygen and nutrients to the conducting portions within the lung. 
1.1.1.1 Pulmonary arteries, veins and capillaries 
Mesenchymal cells differentiate into the heterogeneous population of vascular cells that 
comprise the vessel walls within the pulmonary circulation. The pulmonary arteries and 
veins have three distinct vascular layers. The tunica intima is the innermost layer of the 
vessel and is composed of a homogenous population of endothelial cells. The medial layer, 
the tunica media, is comprised of smooth muscle cells. The tunica externa is the outermost 
layer that consists primarily of collagen and fibroblasts. Each respective layer is separated 
by an extracellular matrix known as the basement membrane. Within the distal component 
of the lung, an extensive capillary network separates arteries from veins. 
The structural composition of pulmonary arteries is functionally altered as it extends down 
the length of the vessel towards the base of the lung. Pulmonary arteries can be defined 
according to their structural composition as elastic, muscular or partially muscular 
pulmonary arteries. Elastic vessels contain numerous elastic laminae bound by external and 
internal elastic laminae and extend peripherally into transitional vessels which contain 
fewer elastic laminae. Once only an internal and external elastic lamina exists around the 
smooth muscle cell layer, these vessels are termed muscular. As the artery extends into the 
more distal portions of the lungs, the smooth muscle cell layer becomes sparse (partially-
muscular) or absent (non-muscular) prior to extension into the capillary bed (deMello & 
Reid, 1991;Jones & Capen, 2011). Pre-acinar arteries (including the main pulmonary 
artery) are associated with bronchi, bronchioles or terminal bronchioles and contain 
numerous elastic laminae between smooth muscle layers and are more than 3200μm in 
diameter. As it extends beyond the ninth airway generation, the vessels become muscular 
and are generally more than 150µm in diameter (Elliot & Reid, 1964;Jones & Capen, 
2011). Partially muscular pulmonary arteries are typically 75µm to 90µm in diameter 
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(Jones & Capen, 2011). Pulmonary arteries are much less muscular than systemic arteries 
as the pressure and resistance is much lower within these arteries. 
Pulmonary arteries follow a branching pattern closely associated with the branching 
pattern of the bronchial tree, although there are many more pulmonary arterial branches 
than there are bronchial branches and these increase within the periphery (Elliot & Reid, 
1964). The pulmonary artery will eventually extend into the alveolar capillaries, which 
form a dense anastomosing hexagonal network for which gas exchange can occur (Weibel, 
1963). Oxygenated blood is then drained into the pulmonary vein, which carries the blood 
to the left atria where it is retained until diastole, allowing it to enter the left ventricle for 
subsequent pumping around the body. 
 The function of the pulmonary circulation 1.1.2
The primary function of the pulmonary circulation is to facilitate gas exchange - unloading 
of carbon dioxide and loading of oxygen. Oxygen is obtained from inspired air and binds 
with haemoglobin within red blood cells and is essential to sustain metabolic processes 
throughout the entire body. Re-oxygenation is exquisitely facilitated by the gas-blood 
interface between the alveoli and the extensive alveolar capillary network. 
In addition to facilitating gas exchange, the pulmonary circulation functions as a filtration 
system to remove fine particles and potentially lethal thromboemboli from the mixed 
venous blood before it returns to the systemic circulation (Comroe, 1966). This process is 
chiefly regulated by the pulmonary endothelium which releases mediators that promotes 
fibrinolysis. The location of the lungs together with the vast surface area of the pulmonary 
vasculature allows for this unique filtration function. Additionally the pulmonary 
circulation also serves as a blood reservoir for the left ventricle (Comroe, 1966).  
 Regulation of blood flow in the pulmonary circulation 1.1.3
Pulmonary blood flow is most profoundly regulated by gravity and increases about 9 fold 
from the apex to the base of the lung (West et al., 1964). Arterial, venous and alveolar 
pressures affect the distribution of blood flow within the lungs (West et al., 1964). Blood 
flow and ventilation is regulated by ventilation-perfusion matching (West & Dollery, 
1960). In 1946, Von Euler and Liljestrand characterised a vital difference in response to 
hypoxia between the systemic and pulmonary circulations (Euler & Liljestrand, 1946). In 
the systemic circulation hypoxia caused vasodilatation. In contrast, they observed that the 
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pulmonary arteries uniquely constricted in response to hypoxia (described in more detail 
below). This is perhaps not surprising considering the functional role of the two separate 
systems. In the pulmonary circulation the vasoconstrictor response to hypoxia aids in 
moving the passage of blood to well aerated areas mediating ventilation-perfusion 
matching. In the systemic circulation, hypoxia results in vasodilation in order to increase 
perfusion to meet the energy requirements of tissues and organs. In the lungs, ventilation-
perfusion matching is also achieved by airway constriction in response to pulmonary 
arterial occlusion. This serves to direct inspired air towards alveoli with a denser blood 
flow. The matching of blood to a sufficient oxygen supply is therefore a critical regulator 
of blood flow in the lungs. 
 Regulation of vascular tone: the endothelium 1.1.4
Endothelial cells form the innermost lining of the vasculature and act as a mediator of 
physiological and injurious stimuli. Under normal physiological conditions there is an 
exquisite control of the production and secretion of vasoactive mediators. The predominant 
vasoconstrictors include endothelin-1 (ET-1) and thromboxane A2 (TXA2) and the 
vasodilators include nitric oxide (NO) and prostacyclin, which can act in a paracrine 
fashion on the vascular endothelium and in an autocrine fashion on the underlying vascular 
smooth muscle cell layer. The endothelium is innervated by adrenergic and cholinergic 
nerve fibres that regulate vascular tone. Activation of adrenergic fibres causes 
vasoconstriction via the release of noradrenaline. In contrast, activation of cholinergic 
fibres causes release of acetylcholine resulting in vasodilation. The pulmonary 
endothelium is also an active participator in the metabolism of circulating mediators such 
as angiotensinogen, serotonin and noradrenaline, which are all regulators of vascular tone. 
The endothelium is sensitive to alterations in blood flow and this can have dramatic 
consequences for the endothelial cell fate and it is therefore an extremely important 
regulator of vascular tone. The balance of vasodilators and vasoconstrictors is therefore 
critical in important in maintaining the normal function of the endothelium. 
 Excitation-contraction coupling 1.1.5
Pulmonary vascular smooth muscle cell (PVSMC) tone is regulated by excitation-
contraction coupling whereby a generated action potential drives depolarisation of the cell 
membrane resulting in PVSMC contraction. This process is driven by the interactions 
between actin and myosin. During cross-bridge cycling, myosin (an ATPase) interacts with 
actin resulting in vascular smooth muscle cell contraction, which is exquisitely mediated 





) (Ward & Knock, 2011). This process is mediated by phosphorylation of 
myosin light chain (MLC) and the Ca
2+
-calmodulin activated myosin light chain kinase 
(MLCK). Thereby, vasoconstriction is predominantly mediated by Ca
2+
 mobilization. 
PVSMC contraction is terminated by dephosphorylation of MLC by myosin light chain 
phosphatase (MLCP). 
 Effect of hypoxia on pulmonary vasoconstriction and 1.1.6
remodeling 
In the pulmonary vasculature, exposure to acute hypoxia induces vasoconstriction and 
exposure to chronic hypoxia results in vascular remodeling. The most profound hypoxia-





 are key regulators of pulmonary vascular tone in response to 
hypoxia. PASMCs have a resting membrane potential equivalent to the estimated 
equilibrium of K
+
 ions (Weir & Olschewski, 2006). Hypoxia inhibits K
+
 conductance in 
PASMCs resulting in cell depolarisation and the opening of L-type Ca
2+
 channels causing 
entry of Ca
2+
 ions and subsequent vasoconstriction (Post et al., 1992). Ca
2+ 
entry in to the 
smooth muscle cells is a key regulator of hypoxia-induced vasoconstriction. This is evident 
from studies showing that hypoxic pulmonary vasoconstriction in the rat lungs is inhibited 
with Ca
2+
 antagonists (McMurtry et al., 1976). In chronic hypoxia, endothelial prostacyclin 
production is decreased in both proximal and distal pulmonary arteries together with a 
decreased formation of the vasoconstrictor prostaglandin E2 (PGE2) (Badesch et al., 
1989). Furthermore, chronic hypoxia results in an increased production of vasoconstrictors 
such as ET-1 and serotonin (Eddahibi et al., 2000;Li et al., 1994). This creates an 
imbalanced environment that favours pulmonary vasoconstriction.  
Chronic hypoxia causes medial thickening of the pulmonary artery by smooth muscle cell 
hypertrophy and an increase in extracellular connective tissue, microfibrils, collagen fibres 
and elastin (Meyrick & Reid, 1980). In particular, hypoxia results in the muscularisation of 
previously non-muscular pulmonary arteries. Additionally, in the large elastic pulmonary 
arteries, structural changes including thickening of the media and adventitia contribute to 
altered flow dynamics that may influence both the right ventricle and the distal vasculature 
(Stenmark et al., 2006). Interestingly, despite dramatic alterations in vascular morphology, 
the increases in medial and adventitial thickness of the pulmonary arteries and the 
corresponding right ventricular hypertrophy (RVH) recover to normal once returned to 
normoxic conditions (Meyrick & Reid, 1980). However, the structural effects induced by 
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hypoxia are irreversible and are associated with increases in extracellular collagen fibres, a 
reduced distensibility and lumen narrowing (Meyrick & Reid, 1980). 
 Pulmonary hypertension 1.2
Pulmonary hypertension (PH) is a complex, insidious and devastating vascular disease 
characterised by persistent elevations in PAPs and remodeling of the pulmonary vascular 
network. This includes obliterative remodeling of the pulmonary vasculature by excessive 
endothelial and smooth muscle cell proliferation and loss of the distal pulmonary 
circulation. The increased pulmonary pressures and vascular resistance challenges the right 
heart causing excessive strain that instigates adaptive hypertrophy that will eventually lead 
to maladaptive hypertrophy resulting in dilatation and right ventricular heart failure. PH 
can manifest itself through a plethora of aetiologies and it has therefore been necessary to 
group PH into subcategories to assist medical practitioners in providing the most suitable 
treatment options. 
 Classification of pulmonary hypertension 1.2.1
Since 1973 the World Symposium on Pulmonary Hypertension (WSPH) has brought 
together experts within pulmonary vascular diseases together to discuss and collate the 
latest scientific contributions within the field. From this, the World Health Organisation 
(WHO) classification of PH is derived, which is categorised according to shared 
histologies and vascular pathologies. Identification of PH WHO category is essential to 
direct the correct treatment regimen and to predict the potential outcome. The most recent 
WSPH was held in Nice in February 2013 from which the table below is derived (Table 
1-1) (Simonneau et al., 2013). The WHO classification is subcategorised into five groups 
of disorders that are known to cause PH: PAH (group 1); PH owing to left heart disease 
(group 2); PH owing to lung diseases and/or hypoxia (Group 3); chronic thromboembolic 
PH (Group 4); and PH with unclear multifactorial mechanisms (Group 5). 
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Table 1-1 WHO classification of pulmonary hypertension 
Group 1 Pulmonary arterial hypertension (PAH) 
1.1 Idiopathic (IPAH) 
1.2 Heritable (HPAH) 
 1.2.1 BMPR-2 
 1.2.2 ALK1, ENG, SMAD9, CAV1, KCNK3 
 1.2.3 Unknown 
1.3 Drug- and toxin-induced 
1.4 Associated PAH 
 1.4.1 Connective tissue diseases 
 1.4.2 HIV infection 
 1.4.3 Portal hypertension 
 1.4.4 Congenital heart diseases 
 1.4.5 Schistosomiasis 
 1.4.6 Chronic haemolytic anemia 
1' Pulmonary veno-occlusive disease and/or pulmonary hemangiomatosis 
1'' Persistent pulmonary hypertension of the newborn 
Group 2 Pulmonary hypertension owing to left heart disease 
2.1 Systolic dysfunction 
2.2 Diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies 
Group 3 Pulmonary hypertension owing to lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental abnormalities 
Group 4 Chronic thromboembolic pulmonary hypertension (CTEPH) 
Group 5 Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Hematologic disorders: chronic haemolytic anemia, myoproliferative disorders, splenectomy 
5.2 Systemic disorders:sarcoidosis, pulmonary Langerhans cell histiocytosis: 
lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
5.3 Metabolic disorders:glycogen storage disease, Gaucher disease, thyroid disorders 
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis, segmental 
PH 
BMPR-2 = bone morphogenic protein receptor 2; ALK1 = activin receptor-like kinase; CAV1 = 
caveolin 1; KCNK3 = potassium channel subfamily K member 3 
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 Pulmonary arterial hypertension 1.2.2
PH is characterised as PAPs exceeding 25mmHg at rest (Badesch et al., 2009). The 
diagnosis of group 1 PH, PAH, requires the additional diagnosis of pulmonary wedge 
pressures equal or greater than 15mmHg (Badesch et al., 2009). PAH is the most fatal 
subtype of PH and is a progressive and devastating vasculopathy of the pulmonary arteries 
characterised by dysregulated endothelial cell proliferation and apoptosis paired with 
exuberant proliferation of apoptotic-resistant smooth muscle cells (Schermuly et al., 2011). 
Previously non-muscular pulmonary arteries develop a smooth muscle layer eventually 
leading to obliteration and loss of the small distal arteries and the formation of complex 
vascular lesions (Cool et al., 1999). There is currently no cure for the treatment of PAH 
and newer, more effective therapies are urgently required. The WHO have subcategorised 
PAH as is shown in Table 1-1: idiopathic PAH (IPAH), heritable PAH (HPAH), and drug 
and toxin-induced and PAH secondary to other diseases.  
1.2.2.1 Idiopathic and heritable pulmonary arterial hypertension 
In IPAH, the cause is neither inherited nor does it carry any identified risk factor. Germline 
mutations in the bone morphogenic receptor 2 gene (BMPR-2), a member of the 
transforming growth factor-β signaling (TGF-β) family, are accountable for at least 70% of 
HPAH and 10% to 40% of apparently sporadic cases of IPAH (Lane et al., 2000;Machado 
et al., 2001;Thomson et al., 2000). In a few cases, mutations in other genes belonging to 
the TGF-β super family have been reported: activin receptor-like kinase type 1 (ALK1), 
endoglin (ENG) and Sma and Mad (mothers against decapetaplegic)-related proteins 
(SMAD) 9. Additionally novel gene mutations in caveolin-1 (CAV1) (Austin et al., 2012a) 
and the gene encoding the potassium channel super family K member-3 (KCNK3) (Ma et 
al., 2013) have been identified. 
1.2.2.2 Drug and toxin-induced pulmonary arterial hypertension 
Anorectic drugs have been associated with the development of PAH. In the 1960s there 
was an epidemic of PAH amongst obese patients taking the anorectic drug aminorex. 
These findings were later confirmed by the observation that patients taking the 
pharmacologically related drug dexfenfluramine for more than 3 months were at a high 
risk of developing PAH (Abenhaim et al., 1996;Kramer & Lane, 1998). To date, there are 
now several drugs and toxins that have been associated with the development of PAH and 
these have been classified on the strength of evidence for their association with PAH into 
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definite, possible, likely and unlikely (Simonneau et al., 2013). Definite associations 
according to the updated clinical classification of PAH (Simonneau et al., 2013) include 
aminorex, fenfluramines, dexfenfluramines, toxic rapeseed oil, benfluorex and selective 
serotonin reuptake inhibitors. Possible associations include cocaine, phenylpropanolamine, 
St. John’s wort, chemotherapeutic agents, interferon α and β and amphetamine-like drugs. 
Likely risk factors include amphetamines, tryptophan, methamphetamines and dasatinib. 
Unlikely risk factors include estrogen, oral contraceptives and cigarette smoke (Simonneau 
et al., 2013). 
1.2.2.3 Associated pulmonary arterial hypertension 
The development of PAH is also recognised to occur secondary to other diseases. These 
include connective tissue diseases, such as scleroderma, human immunodeficiency virus 
(HIV), portal hypertension, congenital heart disease in adults, schistosomiasis and chronic 
haemolytic anaemia (Simonneau et al., 2013).  
 The diagnosis, prognosis and epidemiology of pulmonary 1.2.3
arterial hypertension 
The symptoms of PAH are non-specific and include breathlessness, fatigue and syncope 
(Rich et al., 1987) making a prompt diagnosis challenging. Electrocardiograms provide 
valuable information on right ventricular function by measuring RVH. Chest radiographs, 
pulmonary functional tests and echocardiography amongst other tests are all useful 
indicators of lung and heart functions. However, right heart catheterisation is essential for 
the diagnosis of PAH and to test the vasoreactivity of the pulmonary circulation (Galie et 
al., 2004). 
The epidemiology of PAH has been outlined by three major registries (Badesch et al., 
2010;Humbert et al., 2006;Ling et al., 2012). In the UK/Ireland (Ling et al., 2012) and 
France (Humbert et al., 2006) the estimated incidence of PAH is 6.6 cases per million and 
15 cases per million, respectively. In all three registries, the median age at diagnosis was 
50 years old and IPAH was the most common form of PAH diagnosed. A higher 
proportion of patients were female with a reported 70% in the UK and Ireland (Ling et al., 
2012), 65.3% in France (Humbert et al., 2006) and 80% in the USA (Badesch et al., 2010). 
In addition, there appeared to be an association with obesity and an increased body mass 
index and the development of PAH. 
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 Pulmonary arterial hypertension arteriopathy 1.2.4
Along the media of the pulmonary artery there is a heterogeneous population of 
phenotypically distinct vascular cells. The main pulmonary artery is composed of three 
distinct layers of cells as mentioned previously; endothelial cells in the tunica intima, 
heterogeneous smooth muscle cells within the tunica media and both muscular and non-
muscular cells in the tunica adventitia (Frid et al., 1994;Stiebellehner et al., 2003). As the 
artery extends from the extra-lobar pulmonary artery and into the intra-pulmonary artery 
the lumen and the arterial wall narrow with fewer vascular cell types. In the distal 
pulmonary artery only a homogeneous population of smooth muscle cells exists 
(Stiebellehner et al., 2003). The smooth muscle cell layer eventually ceases and only a thin 
layer of endothelial cells remains (occasionally with a single smooth muscle cell or 
pericytes: smooth muscle cell precursors). 
In utero, the initial development of larger blood vessels involves the recruitment of pre-
cursor smooth muscle cells by endothelial cells in the mesoderm. Smooth muscle cells will 
proliferate and undergo differentiation and maturation into the quiescent adult smooth 
muscle cell (Stenmark & Mecham, 1997). Pulmonary vascular remodeling is a key feature 
of PAH and is defined as any structural changes that occur within the vascular wall and can 
occur within all three vascular layers. In particular, a key feature of re-structured 
pulmonary arteries includes an increase in smooth muscle cells and endothelial cells. It 
appears that in the vasculature normally quiescent cells resistant to mitogenic stimulation 
exhibit cellular responses similar to developmental processes when injured (Stenmark & 
Mecham, 1997). Non-muscular pulmonary arteries are typically compromised of 
endothelial cells and in some cases, pericytes. In response to injury, pericytes can 
differentiate into vascular smooth muscle cells, which contributes to muscularisation of 
previously non-muscular arteries. Injurious insults include inflammation, hemodynamic 
stress (increased shear stress), mechanical injury and hypoxia.  
There is a general acceptance that the distal pulmonary arteries are the most crucial 
mediators of increased vascular resistance that precede the development of RVH. 
However, recent indications have challenged this notion, suggesting that stiffening of the 
proximal pulmonary artery by deposition of collagen may impact PAPs and RVH in the 
absence of any structural changes in the distal pulmonary circulation (Vanderpool et al., 
2013). Interestingly, distal smooth muscle cells have a very low proliferative capacity 
compared to proximal smooth muscle cells. Furthermore, hypoxia actually reduces their 
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proliferative capacity (Stiebellehner et al., 2003). Thus, a phenotypic switch in the 
homogeneous population of smooth muscle cells in the distal pulmonary arteries is 
presumed to occur to permit vascular proliferation and remodeling. Phenotypic switching 
is defined as a change in the gene expression of a cell that alters its behavioural response to 
various stimuli. For example, a previously non-proliferative cell may undergo phenotypic-
switching into a highly proliferative cell. In addition, mature vascular endothelial cells can 
also transdifferentiate into smooth muscle cells through a mesenchymal transition (Frid et 
al., 2002). Alternatively, proliferative smooth muscle cells of the proximal artery may 
migrate and extend into previously non-muscular pulmonary arteries contributing to distal 
pulmonary vascular remodeling.  
The lung is composed of more than 40 different cell types that are essential to facilitate gas 
exchange and metabolic and endocrine functions. The lung has a remarkable regenerative 
capacity after injurious insults, yet the cell types that contribute to this effect remain 
obscure. There is now evidence for resident stem cells within the lung (Kajstura et al., 
2011) implicating that the phenotypically distinct smooth muscle cells that appear in the 
distal artery could also be differentiated stem cells. Alternatively, the origin of these cells 
could be from distinct regions, such as blood-borne progenitor cells or bone marrow-
derived progenitor cells (Toshner et al., 2009). However, there is currently much 
speculation of the role of progenitor cells in PAH as to whether they play a role in 
repairing damage that has occurred or whether they are indeed intricate to the pathogenesis 
of PAH (Toshner & Morrell, 2010). 
The pathological features observed in PAH are primarily within the pulmonary arteries 
with the veins unaffected. PAH pathology includes pulmonary arterial vascular lesions 
within the distal pulmonary arteries (<500µm in diameter), characterised by medial 
hypertrophy, adventitial thickening, inflammation, complex vascular lesion (plexiform) 
formation and thrombotic lesions (Galie et al., 2009). 
Medial hypertrophy of both muscular and elastic arteries is a common pathological feature 
of all categories of PH (Pietra et al., 1989;Pietra et al., 2004). Alongside, dilatation of 
elastic pulmonary arteries and intimal atheromas and RVH are all manifestations of PH. 
Medial hypertrophy is an increase in the size of the vessel wall by hyperplasia and 
hypertrophy of both pre- and intra-acinar arteries eventually extending into previously non-
muscularised acinar arteries (Pietra et al., 2004). The pulmonary artery runs parallel to the 
respiratory tree and the pulmonary acinus is the region beyond the terminal bronchus. The 
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pulmonary acinus consists of the most delicate arterial structure with a discontinuous 
smooth muscle cell layer, which eventually ceases to exist (Pietra et al., 2004).  
Plexiform, dilatation and arteritis have been classified as complex vascular lesions that 
occur as part of the arteriopathy associated with PH (Pietra et al., 2004). Plexiform lesions 
are formed by extensive hyperplasic and hypertrophic responses of cells that constitute the 
arterial wall. Within their structures, vascular channels, lined with numerous proliferating 
endothelial cells are a typical feature (Jonigk et al., 2011). Plexiform lesions consist of 
numerous cell types, including smooth muscle and inflammatory cells but predominantly 
consist of endothelial cells (Tuder et al., 1994;Jonigk et al., 2011). Plexiform lesions can 
occur in both pre- and intra-acinar regions of the pulmonary arterial tree, but typically 
occur at arterial branching points (Pietra et al., 2004) and are present in 90% of patients 
with PAH (Stacher et al., 2012). It is, however, difficult to determine the stage at which 
plexiform lesions start to occur as we are unable to assess the presence of lesions prior to 
lung transplantation. Thus, plexiform lesions may only be present at end-stage disease.  




Figure 1-1 Pulmonary arterial hypertension arteriopathy 
Pulmonary arterial hypertension (PAH) is a complex arteriopathy that includes muscularisation of 
peripheral pulmonary arteries, medial hypertrophy of muscular arteries, neotima formation, 
plexiform lesion formation and loss of precapillary arteries. SMC, smooth muscle cell; EC, 
endothelial cell. Reproduced with permission from Dr. Marlene Rabinovitch and the Journal of 
Clinical Investigation (Rabinovitch, 2012). 
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 The right heart 1.2.5
In utero, the pulmonary circulation is vasoconstricted and the right ventricle is 
hypertrophied. At birth, the pulmonary pressures fall and the right ventricular structure is 
switched to an adult phenotype within weeks (Haddad et al., 2011). The left and right 
ventricles of the heart are structurally and functionally unique. The right ventricle has a 
much thinner wall and whilst the volume of blood that is pumped out of the heart (stroke 
volume) is the same, it does this with less force due to the low resistance of the pulmonary 
arteries (Voelkel et al., 2006). Chronic PAH results in a pressure overload on the right 
ventricle that initially leads to adaptive hypertrophy. Consistent constraint on the right 
ventricle eventually results in dilatation, contractile dysfunction and heart failure 
(maladaptive right ventricular remodeling). Right ventricular function is the most critical 
factor in the survival of patients with PH (D'Alonzo et al., 1991;Sandoval et al., 1994). 
Several mechanisms have now been identified to contribute to maladaptive right 
ventricular remodeling, including a switch from α-myosin heavy chain (α-MHC) to β-
myosin heavy chain (β-MHC) as the main contractile protein, as well as mitochondrial, 
metabolic and electrical remodeling (Haddad et al., 2011). In particular, RVH is associated 
with altered metabolic gene expression suggesting a switch from fatty acid metabolism to 
glucose metabolism as the main energy source (Sharma et al., 2004). 
Remarkably, despite dramatic alterations in right ventricular structure and function during 
PH, patients with severe PH who have received single-lung transplants show sustained 
improvement in right ventricular function in terms of ejection fraction and right ventricular 
wall thickness (Ritchie et al., 1993). The mechanism by which the right ventricle repairs 
itself are still unclear but may be related to the mechanisms that occur after birth (Voelkel 
et al., 2006).  
 Inflammation and pulmonary arterial hypertension 1.2.6
Inflammatory insults represent well-defined triggers of PAH. For example, HIV is 
associated with the development of PAH in ~0.5% of patients (Sitbon et al., 2008). 
Perhaps the most common cause of PAH recognised is the parasite schistosomiasis which 
migrates through the skin into the venous system where it matures into an adult worm 
before migrating into the lung causing an inflammatory response. 1% of patients infected 
by schistosomiasis will develop PAH, supporting a functional role for inflammation in 
PAH (reviewed by Graham et al., 2010). Furthermore, there is a direct correlation with the 
development of PAH in patients with inflammatory conditions, such as systemic lupus 
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erythematous and scleroderma (reviewed by Johnson & Granton, 2011). Interestingly, it 
has been estimated that approximately 78% of patients affected with autoimmune diseases 
are women, suggesting that female hormones may drive disease pathogenesis and 
inflammatory responses (Fairweather et al., 2008). The importance of inflammation in 
PAH can also be observed in BMPR-2 haploinsufficent mice. These mice do not develop a 
spontaneous PAH phenotype, yet under inflammatory stress these mice are more 
susceptible to a PAH phenotype than wild-type mice (Song et al., 2005). 
The role of inflammation in PAH is further supported by the increased production of 
inflammatory mediators in both experimental and human PAH (reviewed by Price et al., 
2012) and is therefore under intense investigation. T cells, B cells and macrophages are 
observed in the complex vascular lesions that are associated with PAH (Tuder et al., 1994). 
Additionally, perivascular mast cells and dendritic cells are also increased in patients with 
IPAH (Savai et al., 2012). 
Cytokines are key mediators of inflammation and are also dysregulated in the setting of 
PAH. Serum cytokines, including the interleukins and tumour necrosis factor α (TNFα) 
levels are increased in both IPAH and HPAH and are indicative of survival in patients, 
thereby representing potential useful biomarkers (Soon et al., 2010). Furthermore, chronic 
overexpression of TNFα is associated with the development of PAH (Fujita et al., 2002) 
and TNFα administration to isolated rat pulmonary arteries increases vasoconstriction 
(Stevens et al., 1992). Overexpression of interleukin-6 (IL-6) is associated with the 
development of severe PAH with the formation of neointimal occlusive angioproliferative 
vascular lesions (Steiner et al., 2009). Taken together, this provides evidence for an 
association of inflammation with PAH, whether being of a causative nature or a secondary 
mediator.  
 Treatments 1.2.7
The current therapeutic strategy in PH is aimed at targeting the underlying cause of the 
disease as well as the symptoms. Treating WHO group 1 PH, both IPAH and HPAH is 
complicated by the lack of understanding of its complex pathology. Advanced treatments 
are used to improve the symptoms and thereby the quality of life in this subset of patients. 
PH is a multifactorial process with various aetiologies and the treatment regimen will 
therefore depend on the PH classification. The majority of patients will receive Ca
2+
 
channel blockers, endothelin receptor antagonists, prostanoids or phosphodiesterase type 5 
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(PDE5) inhibitors alone or in combination. Patients will also be evaluated to receive 
supportive therapy including oral anticoagulants, diuretics, oxygen and digoxin. Currently 
available treatments are suboptimal and have considerable unmet clinical needs as 
mortality rates remain unacceptably high (Benza et al., 2012) and the need for improved 
therapies is urgently required. 
1.2.7.1 Ca2+ channel blockers 
Ca
2+





channels. Consequently, the hyperpolarisation of vascular smooth 
muscle cells by the accumulation of Ca
2+
 inside the cell that results in a contraction is 
inhibited. This aims to reduce the increased pulmonary vascular tone and pressure. Acute 
vasodilator testing during right heart catheterisation is necessary in most patients (certainly 
in IPAH patients) to identify patients that will respond to long-term Ca
2+
 channel blocker 
therapy (Galiè et al., 2013). 
The use of Ca
2+
 channel blockers to treat patients with PAH was first reported in 1987 by 
Rich and Brundage where they treated a small cohort of patients with a high dose of a Ca
2+
 
channel blocker. This lead to reductions in PAPs and a regression of RVH as measured by 
electro- and echocardiography (Rich & Brundage, 1987). This provided rationale to assess 
the long-term effectiveness of Ca
2+
 channel blockers in PAH. In this study, 26% of patients 
responded to the treatment and it vastly improved the 5-year survival in these patients 
(Rich et al., 1992). In a more recent study, the characteristics of IPAH patients whom 
respond to long-term Ca
2+
 channel blocker therapy were evaluated. Less than 10% of 
IPAH patients responded to the therapy, and all these patients had responded to the initial 
vasodilator test with either epoprostinil or NO (Sitbon et al., 2005). Additionally, 
favourable responses to Ca
2+
 channel blockers has been reported in anorexigen-associated 
PAH, but was absent in PAH associated with HIV, portal hypertension, congenital heart 
disease and connective tissue disease (Montani et al., 2010). Therefore, the use of Ca
2+
 
channel blockers is limited in PAH as it is only effective in a very small subset of patients. 
1.2.7.2 Endothelin receptor antagonists 
ET-1 is a potent vasoconstrictor that is produced and released predominantly by vascular 
endothelial cells, which was characterised by Yanagisawa and colleagues in 1988 
(Yanagisawa et al., 1988). Subsequently, elevated plasma levels of ET-1 were reported in 
 Chapter 1 - Introduction 
18 
 
patients with PH (Stewart et al., 1991). Importantly, the expression of ET-1 by vascular 
endothelial cells is also increased in PH (Giaid et al., 1993).  
ET-1 exerts its effects through binding with either endothelin receptor-A (ETA) or 
endothelin receptor-B (ETB), which are both G-protein coupled receptors (GPCR). In 
larger conduit arteries ET-1 induces vasoconstriction which is predominantly mediated by 
the ETA receptor. In contrast, in the smaller resistance vessels, the ETB mediates 
vasoconstriction (Maclean et al., 1994). Subsequently, it was found that at lower 
concentrations the effects of ET-1 are mediated by the ETB, but at higher concentrations 
responses are mediated via ETA (Mcculloch et al., 1996). ET-1 mediates vasoconstriction 
through the ETA and ETB receptor by activation of phospholipase C resulting in an 
increase in intracellular inositol triphosphate, diacylglycerol and intracellular Ca
2+
 leading 
to sustained vasoconstriction and activation of mitogenic pathways (Galié et al., 2004).  In 
contrast, the ETB receptor also mediates vasodilation by stimulating the production of NO 
and prostacyclin (Hirata et al., 1993). However, the pulmonary vasoconstriction observed 
in response to ET-1 stimulation is mediated by both receptors, as dual blockade is 
necessary for maximal effects (Galié et al., 2004). 
Pre-clinical studies suggested that the use of the non-selective endothelin receptor 
antagonist, bosentan, might be beneficial in the treatment of PH (Chen et al., 
1995;Eddahibi et al., 1995). Bosentan is an orally active drug and has a half-life of 
approximately 5 hours. Clinical trials using bosentan have reported improvements in 
pulmonary haemodynamics, 6-minute walking distance and survival. However, a main 
adverse side effect of bosentan is hepatotoxicity and patients therefore need to be carefully 
monitored to assess their liver function. There is also evidence to suggest that women 
respond better to endothelin receptor antagonists than men, and going forward, this will 
need to be taken into consideration when evaluating treatment effectiveness (Gabler et al., 
2012). 
The use of selective ETA-receptor antagonists has also been evaluated in PAH. For 
example, monotherapy with ambrisentan, an ETA selective antagonist has proven 
beneficial in haemodynamic parameters and 6 minute walking distance with low reported 
hepatotoxicity (Blalock et al., 2010;Oudiz et al., 2009). Whether selective antagonism has 
a therapeutic advantage over non-selective antagonism requires further elucidation. 




Prostacyclin is a member of the prostanoid family. It is a metabolite of arachidonic acid by 
the cyclooxygenase pathway and is predominantly synthesized by endothelial cells. 
Prostacyclin binds with vascular prostacyclin receptors which are GPCR. This increases 
intracellular cyclic adenosine monophosphate (cAMP), which activates protein kinase A 
(PKA) resulting in smooth muscle cell relaxation and inhibition of platelet aggregation. 
Prostacyclins are therefore potent vasodilators in vascular beds and are one of the most 
effective treatments in PAH. Prostacyclins are synthesized by the enzymatic activity of 
prostacyclin synthase and its expression is decreased in PAH (Tuder et al., 1999). 
Prostacyclin and its analogues are therefore utilised in the management of PAH due to their 
vasodilator properties, which can counteract the effects of a shift towards the production of 
vasoconstrictor mediators, such as ET-1. Prostacyclins are therefore a very powerful tool in 
the treatment of PAH. 
The clinical use of prostacyclin is limited by its very short half-life. Prostacyclin analogues 
have therefore been generated to improve their pharmacokinetic properties. There are three 
types of prostacyclin analogues approved for the treatment of PAH; Epoprostenol, iloprost 
and treprostinil are synthetic prostacyclin analogues that have been approved for the 
treatment of PAH. The administration of epoprostenol is invasive and requires an 
intravenous catheter and a portable pump. In contrast, iloprost and treprostinil are available 
as inhalation agents. Treprostinil may also be administered subcutaneously. Beraprost is 
the only prostacyclin analogue that is available for oral administration, but has currently 
not been approved for the treatment of PAH. Although prostacyclins have improved 
survival and exhibit favourable vasodilator properties, they cannot prevent the 
manifestation of advanced plexiform lesions (Pogoriler et al., 2012). Furthermore, there 
are several limitations with prostacyclin analogues including inconvenient routes of 
administration, non-specific activation of receptors and short-half-lives (Sitbon & Morrell, 
2012). 
1.2.7.4 Phosphodiesterase 5 inhibitors 
The cyclic nucleotides, cAMP and cyclic guanosine monophosphates (cGMP) are 
important mediators of pulmonary vasodilation by activation of PKA and protein kinase G 
(PKG), respectively. It is well established that NO is a mediator involved in the activation 
of the cGMP/PKG pathway. Phosphodiesterases (PDEs) catalyse the hydrolysis of cAMP 
and cGMP. PDEs inhibitors are considered an attractive therapeutic to promote 
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vasodilation by increasing the intracellular concentration of cAMP and cGMP. 
Furthermore, PDE isoforms are differentially expressed within tissues allowing for 
selective targeting (Murray et al., 2011). PDE5 is expressed in abundance within the lung 
(Corbin et al., 2005) and PDE5 inhibitors that promote the activation of the vasodilatory 
cGMP/PKG pathway have been very effective in the management of PAH. In addition to 
their vasodilatory properties, PDE5 inhibitors have also shown anti-proliferative effects 
(Wharton et al., 2005) which are highly favourable in this proliferative vasculopathy. 
PDE5 inhibitors including sildenafil, tadalafil and vardenafil are commonly known for 
their application in patients with erectile dysfunction. All three inhibitors are approved for 
the treatment of PAH and show positive therapeutic effects (Galiè et al., 2013). 
There are numerous PDE isoforms that mediate cyclic nucleotide levels within target 
tissues, yet only PDE5 inhibitors have been used to elevate cGMP levels and prostacyclin 
analogues to indirectly regulate cAMP levels through its receptors. More recently, in a 
comprehensive analysis of PDE isoforms within human pulmonary arterial smooth muscle 
cells (hPASMCs) from control and PAH samples demonstrated that the expression of 
PDE1A, PDE1C, PDE3B, and PDE5A were increased in patients with PAH (Murray et al., 
2007). Moreover, hPASMCs from PAH patients had a significant reduction in cAMP 
production in response to agonist stimulation with forskolin and PDE1 and PDE3 activity 
were largely accountable for this (Murray et al., 2007). Specifically, inhibition of PDE1C 
resulted in an accumulation of cAMP and a reduction in hPASMC proliferation, 
highlighting this as a novel therapeutic target to modulate cyclic nucleotide levels in PAH 
(Murray et al., 2007).  
1.2.7.5 Adempas® approved to treat pulmonary arterial hypertension 
In late 2013 Adempas® (riociguat) was approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of PAH based on promising phase 3 clinical trials. 
Riociguat is a soluble guanylate cyclase stimulator and acts in synergy with NO that results 
in vasodilation thereby reducing PAPs. Riociguat was shown to significantly improve 
exercise capacity and clinical end-points in a phase 3 clinical trial in patients with PAH 
(Ghofrani et al., 2013). 
 Emerging therapies 1.2.8
The therapeutic strategy in PAH is two-fold. First, we have to selectively target the disease 
mediators. Second, we have to promote regeneration of the lost distal pulmonary arteries 
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and reverse the extensive remodeling of the pulmonary arterial network that is likely to 
have occurred. Ideally, therapies should also be selective for the pulmonary circulation to 
maximise the therapeutic effects and prevent off-target effects. Current therapies are 
mainly considered for their vasodilatory properties and more recently, the potential anti-
proliferative effects. It has been postulated that for the successful management of PAH, the 
strategy should be to obtain therapies that are pro-apoptotic, regenerative and anti-
inflammatory (Michelakis et al., 2008). 
 Genetic basis of pulmonary arterial hypertension 1.3
In 1951 Dresdale provided the first unique evidence that PAH may have a heritable basis, 
where a mother, her sister and her son all presented with symptoms of PAH (Dresdale et 
al., 1951). More than ten years ago, a genetic basis for the development of PAH was 
finally confirmed and was a remarkable discovery that has paved the way for 
understanding the underlying disease mechanisms (Deng et al., 2000;Lane et al., 2000). It 
was later identified that more than 70% of patients with HPAH carried a mutation in the 
BMPR-2 gene (Machado et al., 2006a). Globally, this identification has made significant 
contributions to our understanding of how such mutations contribute to disease 
pathogenesis.  
 Bone morphogenic protein receptor type II 1.3.1
In 1997, Nichols and colleagues (Nichols et al., 1997) identified six families where there 
was evidence for PAH in the absence of any secondary cause. Inspection of the pedigree 
charts of the six families indicated an autosomal dominant mode of inheritance. By linkage 
mapping, they identified a gene associated with PAH on the long arm of chromosome 2. 
Aforementioned, in 2000 the first gene associated with PAH was identified. Mutations in 
the BMPR-2 gene that encode the bone morphogenic protein receptor type II (BMPR-2), a 
member of the TGF-β, leading to dysregulated signaling were identified (Lane et al., 
2000). The penetrance of HPAH is low with only 20% of carriers actually developing the 
disease (Hamid et al., 2009). Patients with IPAH also have reduced gene and protein 
expression of BMPR-2, although this is more enhanced in HPAH patients (Atkinson et al., 
2002). 
In an attempt to establish the mode of inheritance in patients with HPAH in a large number 
of families, several striking observations were made (Loyd et al., 1995). Firstly, at birth 
there was an abnormal gender ratio, with a greater proportion of female births, suggesting 
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selective loss of male offspring. Secondly, in this cohort studied, the ratio of females to 
males was 2.7:1. Thirdly, if disease had been passed from an asymptomatic heterogeneous 
mother, the mean age of death was strikingly lower than if the disease had been acquired 
from an asymptomatic heterogeneous father. Fourthly, and perhaps the most intriguing 
observation, more females were carriers and more females had PAH (Loyd et al., 1995). 
This provides evidence that an aspect of female gender is implicated in both the 
development and the progression of PAH. 
Bone morphogenic proteins (BMPs) exhibit a plethora of biological activities including 
regulation of growth, differentiation and apoptosis. They are members of the TGF-β 
signaling superfamily that signal through Smad and Smad-independent pathways. On the 
extracellular surface BMPs bind to the tetrameric complex that consists of the type II 
receptor, BMPR-2 and its co-type I receptor (such as BMPR1A, BMPR1B or ALK-1) 
(Machado et al., 2011). Specific ligands for BMPR-2 are BMPs, specifically BMP-2, 
BMP-4, BMP-6, BMP-7 and growth differentiation factors (GDF) -5 and -6 (Morrell, 
2006). Upon activation, the type I receptor undergoes phosphorylation which can activate 
several signaling pathways including phosphorylation of Smad1/5/8, p38 mitogen activated 
protein kinase (p38 MAPK), ERK1/2, c-Jun N-terminal kinase (JNK) and 
Akt/phosphoinositide 3-kinase (PI3K) (as reviewed by Massague, 2003;Morrell, 
2006;Rabinovitch, 2012). Signaling via Smads requires interaction with Smad4 (co-Smad) 
in order to translocate to the nucleus where it can bind with deoxyribonucleic acid (DNA) 
and alter transcription.  
In addition to mutations identified in the BMPR-2 gene, other mutations in the TGF-β 
signaling pathway have also been confirmed. Mutations in ALK-1 (a type I receptor 
cognate to BMPR-2) (Harrison et al., 2003) and ENG (Chaouat et al., 2004) are present in 
patients with hemorrhagic telangiectasia and PAH (Harrison et al., 2003). Rare mutations 
in Smad 9 have also been associated with the development of HPAH (Nasim et al., 2011). 
1.3.1.1 BMPR-2 signaling in the pulmonary vasculature 
Germline mutations in the BMPR-2 gene are accountable for at least 70% of heritable PAH 
(HPAH) and 10% to 40% of apparently sporadic cases of IPAH (Lane et al., 
2000;Machado et al., 2001;Thomson et al., 2000). As a consequence of non-missense 
BMPR-2 mutations there is either reduced trafficking of the receptor to the cell surface or 
compromised phosphorylation of BMP type 1 receptors, which are essential for activation 
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of Smads (Morrell, 2006). In contrast, missense mutations retain normal trafficking to the 
cell surface and ability to activate Smad signaling, but have compromised ability in signal 
transduction via Smads (Morrell, 2006). 
BMPR-2 is expressed in all cell types that comprise the pulmonary vascular wall, but is 
predominantly expressed within endothelial cells (Atkinson et al., 2002). Here they 
maintain normal endothelial cell function by regulating endothelial cell motility, survival 
and proliferation (Valdimarsdottir et al., 2002;de Jesus Perez et al., 2009). Gene silencing 
of BMPR-2 in endothelial cells induces apoptosis (Teichert-Kuliszewska et al., 2006) 
through, in part, recruitment of non-canonical Wnt signaling (de Jesus Perez et al., 2009). 
Phosphorylation of Smads by BMPR-2 in the endothelium activates proliferation (de Jesus 
Perez et al., 2009) and promotes tube formation and migration (Valdimarsdottir et al., 
2002;de Jesus Perez et al., 2009). 
In pulmonary arterial smooth muscle cells (PASMCs) BMPR-2 is present, yet it is much 
less densely populated here than what is observed in endothelial cells (Atkinson et al., 
2002). In this vascular cell, their function confers depending on whether the cell type 
resides in the proximal or distal part of the pulmonary artery (Yang et al., 2005). In the 
proximal pulmonary artery, BMP-4 stimulation inhibits proliferation, yet in the distal 
pulmonary arteries it stimulates proliferation. The inhibitory effects on PASMCs were 
subsequently found to be mediated via Smad1, which is markedly reduced in PAH 
patients, irrespective of BMPR-2 status (Yang et al., 2005). In the setting of a BMPR-2 
mutation, endothelial cells become susceptible to apoptosis, resulting in a leaky barrier that 
permits entry of circulating factors to the underlying smooth muscle cells (Yang et al., 
2005). 
Despite advances in our understanding of the BMPR-2 pathway, there are still no drugs 
that aim to rescue this pathway. Recently, a promising target was identified (Spiekerkoetter 
et al., 2013). Using a high-throughput luciferase reporter assay, FDA approved drugs were 
screened to assess their ability to rescue BMPR-2 signaling. Tacrilomus (FK506), an 
immunosuppressive drug, was able to recapitulate the function of BMP-4 by activating 
pSmad 1/5/8 and the inhibitor of DNA binding-1 (ID-1) in endothelial cells. Targeting this 
pathway may provide a promising therapeutic strategy in the management of HPAH and 
also in cases of IPAH where BMPR-2 signaling is reduced. 
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 Genetic modifiers 1.3.2
1.3.2.1 The serotonin transporter 
Elevated levels of serotonin have been associated with the pathology of both experimental 
and clinical PAH and these effects are mediated in part via the SERT. Polymorphisms 
within the SERT gene have been identified as a genetic risk factor in PAH. SERT is 
encoded by the soluble carrier family 6, member 4 (SLC6A4) and is localised to 
chromosome 17q11.1-17q12 (Ramamoorthy et al., 1993). A short (S) and long (L) 
polymorphism in the upstream regulatory region of SERT affects its transcriptional 
regulation and is a common polymorphism (Lesch et al., 1996). The short polymorphism 
confers reduced transcriptional efficiency of the SERT gene promoter and the long variant 
increases transcriptional efficiency. 
In 2001, Eddahibi and colleagues (Eddahibi et al., 2001b) reported that the L-allelic variant 
of the SERT promoter was present in 65% of patients with PAH whereas it was only 
present in 27% of controls. In HPAH patients, patients homozygous for the LL genotype 
present at an earlier age of diagnosis than patients with either the SS or LS genotypes 
(Willers et al., 2006). In patients with PH secondary to heart failure, the LL variant is also 
associated with higher PAPs (Olson et al., 2007). Given the incomplete penetrance 
(approximately 20% to 30%) that is observed in patients with BMPR-2 mutations 
(Newman et al., 2001;Newman et al., 2004), we therefore assume a multiple-hit hypothesis 
whereby an additional insult may be present. SERT polymorphisms represent one such 
‘insult’ and this data provides evidence for this. In contrast, no associations with SERT 
polymorphisms were reported in patients with IPAH (Willers et al., 2006). Other studies 
have also failed to identify any association with SERT polymorphisms and PAH (Baloira 
et al., 2012;Machado et al., 2006b). There is therefore still much speculation whether 
SERT polymorphisms contribute to PAH pathobiology. 
1.3.2.2 Cytochrome P450 1B1 
In 2008, West and colleagues identified another modifier gene in PAH, cytochrome P450 
1B1, CYP1B1 (West et al., 2008), a xenobiotic and estrogen metabolizing enzyme. 
Subsequently, they genotyped for the CYP1B1 polymorphism that substitutes an 
asparagine for a serine in position 453 in patients with BMPR-2 mutations with and 
without evidence for PAH (Austin et al., 2009). This polymorphism is associated with 
increased proteosomal degradation of CYP1B1 (Bandiera et al., 2005). Interestingly, 
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female patients with BMPR-2 mutations that had been diagnosed with PAH had a 4-fold 
higher penetrance for the wild-type genotype (Austin et al., 2009). This suggests that 
CYP1B1 activity is associated with the development of PAH amongst BMPR-2-mutant 
carriers and represents another potential ‘second-hit’ factor. The contribution of this in 
experimental PAH is intriguing and remains to be determined. 
 Newly identified genetic mutations 1.3.3
1.3.3.1 Potassium channel, subfamily K, member 3 (Ma et al., 2013) 
In 2013, mutations in KCNK3 (also known as TASK-1), a pH sensitive potassium channel 
that regulates the resting membrane potential was identified as a mutation associated with 
PAH (Ma et al., 2013). All the mutations identified in this channel in patients with PAH 
results in a loss-of-function. KCNK3 is postulated to be important in regulating pulmonary 
vascular tone. Furthermore, hypoxia blocks KCNK3 and treprostinil (an FDA approved 
drug for the treatment of PAH) can activate the channel (Olschewski et al., 2006). In 
addition, a phospholipase inhibitor can also rescue the function of this channel and 
represents a novel mechanism by which potassium channel activity can be rescued in 
patients with PAH (Ma et al., 2013). 
 Animal models of pulmonary arterial hypertension 1.4
When describing animal models of PAH, they will be defined as PH (although these 
animals do develop a PAH phenotype). However, the classical models that are utilized are 
currently under scrutiny as to whether they are direct models of human PAH and therefore 
to avoid confusion, they will be termed PH.  
 Hypoxic-induced pulmonary hypertension 1.4.1
Brisket disease is a severe and costly disease that occurs in cattle residing at high altitude, 
named suitably after the swelling that occurs in the brisket. Glower and Newsom in 1915 
first described this phenomenon in cattle living at high altitude with symptoms including 
weakness, dyspnoea on exertion, diarrhoea and oedema (Glover & Newsom, 1915). Upon 
autopsy, abnormalities were reported in the heart structure, including enlargement and thin, 
dilated walls. Furthermore, it appeared that returning the cattle to a lower altitude was 
sufficient to reverse the disease (Glover & Newsom, 1915). Based on these findings, 
together with consistent reports of RVH in brisket disease (Alexander & Jensen, 1959), 
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Will and co-workers pioneered the studies investigating the effect of hypoxic exposure on 
the pulmonary circulation (Will et al., 1962). The effects of high altitude on pulmonary 
haemodynamics were assessed over time in normal cattle. The cattle developed the so-
called brisket disease and all had elevated pulmonary pressures, which increased over time. 
Despite a consistent development of PH in all the animals studied, there was a wide-spread 
in the degree of PH with some animals reaching PAPs of 45mmHg, whilst others reached 
over 100mmHg (Will et al., 1962). Furthermore, there was evidence that the response to 
hypoxia was very species dependent, which lead on to a very unique study that addressed 
the effect of hypoxia in various species (Tucker et al., 1975). In response to chronic 
hypoxia, pigs and calves developed severe PH, rabbits and rats developed moderate PH 
whereas sheep, guinea pigs and dogs developed mild PH. In trying to identify the 
underlying mechanism for these interspecies variations, the researchers identified the 
medial thickness of the small pulmonary arteries in control animals as being strongly 
correlated with the severity of PH developed (Tucker et al., 1975). This identified a key 
role for vascular smooth muscle in the development of hypoxia-induced PH. The extreme 
ease at inducing PH in animals by exposure to chronic hypoxia has made this an extremely 
popular model utilized by researchers.  
 Monocrotaline-induced pulmonary hypertension 1.4.2
The oral administration of crotalaria spectabilis seeds results in the development of PH and 
RVH and is associated with a medial increase in the pulmonary truck and muscular 
pulmonary arteries (Kay et al., 1967). A single injection of monocrotaline (MCT) derived 
from the crotalaria spectabilis plant is sufficient to induce severe PH and RVH in rats 
(Ghodsi & Will, 1981). MCT is activated to dehydromonocrotaline in the liver by the 
activity of cytochrome P450 3A4 (CYP3A4) (Reid et al., 1998). MCT results in 
endothelial damage and extension of smooth muscle into normally non-muscular 
pulmonary arteries (Rosenberg & Rabinovitch, 1988). Despite the evidence for endothelial 
cell damage, this model is characterised by medial smooth muscle thickening in the 
absence of endothelial cell angio-obliterative lesions (Gomez-Arroyo et al., 2012b). 
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 Development of pulmonary hypertension in animal models 1.4.3
that display heightened serotonin activity 
1.4.3.1 Serotonin transporter overexpressing mice 
Female mice that overexpress the serotonin transporter (SERT+ mice) develop 
spontaneous increases in RVSP and pulmonary vascular remodeling at 5-6 months of age, 
which is absent in male SERT+ mice (White et al., 2011b). Interestingly, despite increases 
in RVSP and PVR, this occurs in the absence of RVH (White et al., 2011b).  
1.4.3.2 S100 Ca2+ binding protein A4 overexpressing mice 
The S100 Ca
2+
 binding protein, S100A4/mts1, is expressed in neointimal and complex 
vascular lesions of patients with PAH. Additionally, in approximately 5% of mice that 
overexpress the S100A4/mts1 gene, there have been identified lesions that exhibit similar 
vascular arteriopathy to human PAH (Greenway et al., 2004). Serotonin stimulates the 
release of S100A4/mts1, which enhances the proliferation and migration of hPASMCs via 
the receptor for advanced glycation end products (RAGE). Further upstream, nuclear 
transport of phosphorylated ERK via a serotonin receptor, the 5-HT1B receptor, is 
mediated by SERT and is essential for the up-regulation of S100A4/mts1 (Lawrie et al., 
2005). In parallel with the SERT+ model, only female mice develop elevated RVSP and 
pulmonary vascular remodeling at 5 months of age, and this effect is absent in male mice. 
Additionally, the development of neointimal lesions was only observed in female mice. 
Again, there appeared to be no effect on RVH as a consequence of S100A4/mts1 
overexpression (Dempsie et al., 2011). 
1.4.3.3 The SUGEN-Hypoxic Model of pulmonary arterial hypertension 
Combined inhibition of the vascular endothelial growth factor receptor (VEGF-R) with the 
increased shear stress caused by hypoxia results in apoptosis of endothelial cells, releasing 
vascular endothelial growth factor (VEGF) and TGF-β. This stimulates proliferation and 
inhibits apoptosis of the underlying smooth muscle cell layer. In mice, exposure to 
SUGEN5416 (SU5416 (SU); VEGF-R inhibitor) and hypoxia for three weeks results in the 
formation of occluded vascular lesions. However, when returned to normoxic conditions, 
the developed phenotype reverses to baseline characteristics (Ciuclan et al., 2011). In 
contrast, rats develop more severe lesions after just three weeks and this progressively 
worsens to a severe PH phenotype that recapitulates human PAH arteriopathy when 
returned to normoxic conditions (Abe et al., 2010). Interestingly, serotonin activity is 
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heightened in this model (Ciuclan et al., 2011;Ciuclan et al., 2012). In fact, the 
development of SU-hypoxic induced PAH is dependent on peripheral serotonin synthesis, 
as mice devoid of tryptophan hydroxylase 1 (TPH1), the rate limiting enzyme in the 
synthesis of serotonin, do not develop a PAH phenotype (Ciuclan et al., 2012). 
Furthermore, female rats also develop a more severe disease phenotype in this model 
compared to male rats (Tofovic et al., 2012). 
1.4.3.4 Dexfenfluramine-induced pulmonary hypertension 
Dexfenfluramine is an indirect serotonergic agonist that is an identified risk factor for the 
development of PAH (Abenhaim et al., 1996;Kramer & Lane, 1998). Dexfenfluramine is a 
SERT substrate that causes release of serotonin from intracellular stores (Rothman et al., 
1999). Dexfenfluramine also inhibits the reuptake of serotonin into cells thereby increasing 
extracellular concentrations of serotonin (Eddahibi et al., 2001a). In animals, 
dexfenfluramine induces a PAH phenotype in female mice only, again with no effect 
reported on RVH (Dempsie et al., 2013). 
 Serotonin signaling 1.5
Serotonin is a neurotransmitter and a hormone that is derived from tryptophan. The 
majority of the body’s serotonin is produced by the enterocromaffin cells that line the gut. 
Serotonin is released into the bloodstream where it is rapidly taken-up and stored in 
platelets via the SERT, resulting in extremely low circulating plasma levels. Furthermore, 
serotonin is rapidly metabolized by monoamine oxidase to 5-hydroxyindoleacetic acid. 
There is substantial evidence suggesting that TPH1 activity, the rate limiting step in the 
synthesis of serotonin, contributes to experimental PAH (Abid et al., 2012;Ciuclan et al., 
2012;Izikki et al., 2007;Morecroft et al., 2007;Morecroft et al., 2012). Pulmonary arterial 
endothelial cell expression of TPH1 is increased in both experimental and clinical PAH, 
increasing local serotonin production which can act in a paracrine fashion on underlying 
PASMCs to facilitate proliferation predominantly via the SERT (Eddahibi et al., 1999) and 
the 5-HT1B receptor (Maclean et al., 1996). 
1.5.1.1 The serotonin transporter and pulmonary arterial hypertension 




) family of transporters, which also 
includes noradrenergic, dopamine, γ-aminobutyric acid (GABA) and glycine transporters. 
As mentioned above, SERT is encoded by the SLC6A4, and is localised to chromosome 
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17q11.1-17q12 (Ramamoorthy et al., 1993). Serotonin uptake by the SERT is mediated by 
the co-transport of one Na
+
 and one Cl
-





(Torres et al., 2003).  
Serotonin is a potent smooth muscle mitogen and vasoconstrictor that is released from the 
vascular endothelium or from adrenergic stimulation in the pulmonary arteries. There is 
now a wealth of evidence to support a role for serotonin in the pathobiology of PAH. The 
original ‘serotonin-hypothesis’ of PAH arose from the PAH epidemic in patients taking the 
anorectic drugs, aminorex and dexfenfluramine (Abenhaim et al., 1996). Both aminorex 
and dexfenfluramine are substrates for the SERT and cause release of serotonin from 
intracellular stores (Rothman et al., 1999). This is supported by studies in mice where 
dexfenfluramine induces a PH phenotype, which is dependent on peripheral serotonin 
synthesis as mice deficient in TPH1 do not develop a PH phenotype (Dempsie et al., 
2008). Polymorphisms in the SERT gene that are associated with an increased expression 
of SERT are correlated with an earlier age of diagnosis in patients with BMPR-2 
mutations, yet not in patients with IPAH (Willers et al., 2006). One study reported that the 
L-allelic variant of the SERT gene that increases its expression was more common in 
patients with IPAH compared to controls (Eddahibi et al., 2001b). Furthermore, SERT 
expression was increased in a small cohort of pulmonary arterial smooth muscle cells 
(PASMCs) from patients with PAH (Eddahibi et al., 2001b). However, further 
comprehensive analyses have failed to find any significant associations between SERT 
alleles and PAH (Machado et al., 2006b;Willers et al., 2006). Overexpression of the SERT 
gene in mice, thereby increasing its activity, is sufficient to induce a PH phenotype 
(Maclean et al., 2004;White et al., 2011b;Guignabert et al., 2006;Machado et al., 2006b). 
Intriguingly, this is only evident in female mice and has subsequently been found to be 
dependent on circulating 17β-estradiol (17β-E2), the predominant circulating pre-
menopausal hormone (White et al., 2011b), Overexpression of the human SERT gene in 
mice has dramatic effects on gene expression profiles in the pulmonary arteries resulting in 
an up-regulation of 71 genes and a down-regulation of 84 genes (White et al., 2011a). One 
gene that was up-regulated by SERT overexpression in mice was CYP1B1 (White et al., 
2011a), which is a major estrogen metabolizing enzyme This suggests that that altered 
17β-E2 metabolism may underlie the pathogenic effects of 17β-E2 in this model. On the 
other hand, mice deficient in the SERT gene develop less severe PH phenotypes in 
response to chronic hypoxia (Eddahibi et al., 2000). 
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Although the precise mechanism by which SERT mediates proliferation of pulmonary 
vascular cells remains incompletely defined, serotonin-induced proliferation is heightened 
in PASMCs derived from PAH patients which is associated with an increased expression 
of SERT (Marcos et al., 2004). Although, inhibition of SERT may offer some therapeutic 
value, extracellular concentrations of serotonin available to bind with the 5-HT1B receptor 
may increase, mediating vasoconstriction in human pulmonary arteries (Morecroft et al., 
1999) and proliferation of hPASMCs (Lawrie et al., 2005). Additionally, there is evidence 
for cross-talk between the SERT and the 5-HT1B receptor. For example, the 5-HT1B 
receptor nuclear transportation of phosphorylated ERK1/2 is mediated by the SERT and is 
essential for the up-regulation of the Ca
2+
 binding protein S100A4/mts1, which is 
associated with proliferation and migration of PASMCs (Lawrie et al., 2005). Therefore, a 
greater therapeutic effect may be offered by dual inhibition of the SERT and the 5-HT1B 
receptor. Indeed, the combined 5-HT1B and SERT antagonist LY393558 is more effective 
than SERT inhibition alone in hypoxia-induced PH and SERT+ mice (Morecroft et al., 
2010). 
 Steroidogenesis 1.6
Both epidemiological studies and recent studies in animal models of PAH have highlighted 
a potential role for steroid hormones in the pathogenesis of this devastating vasculopathy. 
Steroid hormones have multi-factorial functions throughout the body and are synthesized 
from cholesterol in the gonads, adrenal glands and placenta and to a lesser extent in the 
adipose tissue, liver and skin. Progesterone, 17β-E2 and testosterone are synthesised by 
oxidative activity of the cytochrome P450 (CYP) enzymes and the hydroxysteroid 
dehydrogenases. The synthesis of steroid hormones is, in part, regulated by the 
hypothalamic-pituitary axis. Gonadotroph cells in the anterior pituitary gland synthesize 
and secrete leutenizing hormone (LH), which regulates estrogen and testosterone synthesis 
in the gonads.  
Estrogens are small lipophilic compounds that have genomic and non-genomic activities 
that are produced from the pre-curser cholesterol, providing the backbone of all steroid 
hormones. The cholesterol for this process can be obtained from the cell membrane, 
synthesized from acetate or obtained from the circulation from high density lipoproteins 
(HDL) or low density lipoproteins (LDL) (Scott et al., 2009). Enzymatic activity of various 
CYP enzymes and the steroidogenic acute regulatory protein (StAR) metabolise 
cholesterol to pregnenolone which is then further metabolised to 
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dehydroepiandrostenedione (DHEA) by CYP catalytic activity. Activity of the 3β 
hydroxysteroid dehydrogenase (3β-HSD) metabolises DHEA to androstenedione. 
Androstenedione can then be converted to testosterone by 17β-hydroxysteroid 
dehydrogenase 3 (17β-HSD3). Testosterone may also be interconverted back to 
androstenedione by the activity of 17β-HSD2. Alternatively, androstenedione can be 
metabolised to 16α-hydroxyandrostenedione by CYP2C11. Androstenedione, testosterone 
and 16α-hydroxyandrostenedione can undergo oxidative metabolism by CYP19A1 
(aromatase) in the presence of nicotinamide adenine dinucleotide phosphate (NADPH) to 
the active estrogens, estrone (E1), 17β-E2 and 17β-, 16α-estriol (E3 or 16α-OHE1), 
respectively. The steroidogenic pathway for the synthesis of estrogens from cholesterol is 





Figure 1-2 Synthesis of estrogens from cholesterol 
Cholesterol is converted to pregnenolone by the activity of CYP11A and the steroidogenic acute regulatory protein (StAR). Pregnenolone is converted to 
dehydroepiandrostenedione (DHEA) by the activity of CYP17 and 17α-hydroxylase. DHEA is converted to androstenedione by 3β-hydroxysteroid dehydrogenase (3β-
HSD). Androstenedione can then be converted to testosterone by 17β-hydroxysteroid dehydrogenase 3 (17β-HSD3) and/or 16α-hydroxyandrostenedione by 




















Aromatase is the critical enzyme in the synthesis of estrogens from androgens mediating 
the formation of E1 and 17β-E2 from androstenedione and testosterone, respectively 
(Figure 1-3). In pre-menopausal women, the primary site of estrogen synthesis occurs in 
the ovaries. In post-menopausal women and in men, the principal site of estrogen synthesis 
is extra-gonadal sites, such as the adipose tissue. Circulating C19 precursors act as a 
reservoir for the synthesis of estrogens within extra-gonadal sites. The principal pre-cursers 
are androstenedione, DHEA and DHEA-sulphate (DHEAS) which circulate at relatively 
high concentrations within the plasma in both men and women (Simpson, 2003). These 
pre-cursers are then converted into testosterone and estrogens within target tissues. The 
catalytic activity of aromatase removes a methyl group from the first carbon ring of 
testosterone, creating an aromatic ring resulting in the formation of 17β-E2 (Figure 1-3). 
Tissue specific expression of aromatase is therefore a powerful regulator of local estrogen 
synthesis in extra-gonadal sites. Locally synthesized estrogens can act in a paracrine or 
intracrine fashion creating a potentially potent estrogenic milieu that may be superior to the 
effects of circulating levels. Although it is difficult to correlate local estrogen synthesis 
with circulating levels, it has been predicted that the concentration of 17β-E2 in breast 
tumours in post-menopausal women is twenty times greater than levels circulating in the 
plasma (Pasqualini et al., 1996). Local estrogen synthesis may therefore have a much 
greater impact on steroidogenic effects within target cells independent of circulating levels. 
It has been hypothesized that excess estrogens or aberrant activity are involved with 
tumorigenesis by exerting pro-proliferative effects and/or postulated that they act as pro-
carcinogens by inducing genotoxicity (Tsuchiya et al., 2005). 
The regulation of aromatase is tissue-specific and is achieved through the use of different 
gene promoters (Simpson, 2003). Follicle stimulating hormone (FSH) regulates aromatase 
expression through cAMP in the proximal promoter II in the ovaries and retinoids regulate 
aromatase expression via the distal promoter I.1 in the placenta (Simpson, 2003). In 
contrast, within the adipose tissue and bone, aromatase expression is regulated by 
glucocorticoids, cytokines and TNFα by the distal promoter I.4 (Simpson et al., 1997). In 
response to various injurious stimuli, such as inflammatory mediators, enhanced aromatase 
expression and subsequent estrogen synthesis is mediated via promoter switching from the 
distal promoter I.4 to the proximal promoter II (Agarwal et al., 1996;Zhao et al., 1996). 
More recently, hypoxia-inducible factor-1α (HIF-1α) has been found to drive increased 
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aromatase expression in breast adipose tissue via promoter switching to the proximal 
promoter II (Samarajeewa et al., 2013). 
In other hormone-sensitive tissues, such as the lung and uterus, estrogens also present as a 
risk factor. For example, women are more likely to develop non-small cell lung cancer 
(NSCLC) than men, although in contradiction, women have a better 5-year survival rate 
(Cerfolio et al., 2006). It has therefore been suggested that both endogenous and 
exogenous sources of estrogens may be associated with the development of lung cancer. 
Aromatase expression is increased in human NSCLC cells and 17β-E2 stimulates 
proliferation within these cells (Marquez-Garban et al., 2009). Furthermore, aromatase 
inhibition in NSCLC xenografted nude mice reduced tumour progression, suggesting that 
endogenously produced estrogens are in fact mediating pathogenic effects in NSCLC 
(Marquez-Garban et al., 2009).  
More recently, a genetic study has provided evidence that aromatase activity may be 
associated with PAH pathobiology. Portopulmonary hypertension (PPHTN) is a 
subcategory of PAH that occurs secondary to portal hypertension. Two promoter single 
nucleotide polymorphisms (SNPs) in aromatase have been associated with an increased 
risk of PPHTN and these SNPs are associated with elevated plasma 17β-E2 levels (Roberts 
et al., 2009). Furthermore, the aromatase inhibitor anastrozole has shown remarkable 
therapeutic potential in the SU-hypoxic rat model where it successfully reversed the PAH 
phenotype in female rats and this correlated with reduced plasma 17β-E2 levels (Mair et 
al., 2013;Tofovic et al., 2013).  
Aromatase inhibitors are already clinically approved for the treatment of estrogen-sensitive 
cancers and are the first line therapy against early and metastatic breast cancer in post-
menopausal women. The application of this line of therapy in PAH may therefore be an 
attractive therapeutic strategy on the basis that PAH is an estrogen-sensitive vasculopathy. 
Anastrozole is currently being evaluated in a phase 2 clinical trial for its safety, ability to 
reduce circulating 17β-E2 levels and to improve right ventricular function in patients with 
PAH. 




Figure 1-3 Aromatisation of testosterone to 17β-estradiol 
 
 Estrogens 1.6.2
There are three major subtypes of estrogens: 17β-E2, E1 and E3. In premenopausal 
women, the predominant circulating estrogen is 17β-E2. In women, circulating levels of 
17β-E2 vary depending on the estrous cycle. In the follicular phase, circulating 
concentrations of 17β-E2 are about 100pg/mL (~0.37nM) and during ovulation these levels 
rise to about 600pg/mL (~2.20nM). After menopause, 17β-E2 levels are dramatically 
reduced up to 20-fold lower (Mendelsohn & Karas, 1999). We are all exposed to 
exogenous estrogen sources in various forms including contraception’s, hormone-
replacement therapy, dietary sources and chemical products. Furthermore, vascular cells 
can modulate their own estrogenic milieu by the local conversion of testosterone or 
androstenedione to 17β-E2 and E1 respectively (Harada et al., 1999). 
Estrogens (and androgens) circulate in the blood bound to the sex hormone binding 
globulin (SHBG), regulating circulating concentrations of free steroids and their transport 
to target tissues. The androgens, testosterone and dihydrotestosterone (DHT) have the 
highest binding affinities for SHBG followed by 17β-E2, E1 and E3 (Dunn et al., 1981). In 
contrast, androstenedione has a relatively low binding affinity for SHBG (Dunn et al., 
1981). It is thought that steroids reach their target sites by binding of the SHBG with its 
receptor on the plasma membrane thereby resulting in either co-internalisation or release of 
the steroid. The true identification of the SHBG receptor and the mechanisms that underlie 
transport of steroids to target tissues still remains uncertain. Steroids may also circulate 
bound to albumin or other plasma proteins. It is assumed that only free unbound steroids 
are biologically active. 




Figure 1-4  Chemical structure of estrone and 17β-estradiol  
 
 Tissue regulation of estrogens 1.6.3
The formation of biologically active estrogens within target tissues may also occur via the 
sulfatase and hydroxysteroid dehydrogenase pathways. Estrone-sulfate (E1-S) acts a 
reservoir for estrone synthesis through the sulfatase pathway. Steroid sulfatase hydrolyses 
both E1S and dehydroepiandrostenedione-sulfate (DHEA-S). The estrone formed by this 
reaction can then be converted to 17β-E2 by the activity of 17β-hydroxysteroid 
dehydrogenase 1 (17β-HSD1). In a similar fashion, 17β-E2 can also be converted to E1 by 
the activity of 17β-HSD2. Thus, multiple pathways exist in maintaining the estrogenic 
milieu within target cells and fluctuations in enzyme activity and expression can therefore 
have dramatic consequences on the estrogenic potential of a cell. 
Aromatase inhibitors have been successfully used in the management of breast cancer but 
endocrine resistance remains a problem associated with cancer relapse. Both steroid 
sulfatase inhibitors and 17β-HSD inhibitors are therefore currently being evaluated for 
their treatment in breast cancer. In breast cancer tumours, it appears that the sulfatase 
pathway may be superior to the aromatase pathway in regulating intra-tumoral 17β-E2 
levels as its activity for estrone synthesis was dramatically higher than aromatase activity 
(Santer et al., 1984). STX64 is a potent irreversible steroid sulfatase inhibitor that has been 
evaluated in a phase I clinical trial (Stanway et al., 2006). After a five-day dosing period, 
steroid sulfatase activity in peripheral blood and breast cancer tissue was decreased almost 
100% and E1, 17β-E2, androstenediol, DHEA, testosterone and androstenedione levels 
were significantly decreased (Stanway et al., 2006). Patients that had previously had breast 
cancer progression with aromatase inhibitor therapy, showed evidence of a stable disease 
Estrone (E1) 17β-estradiol (E2)
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with STX64 therapy (Stanway et al., 2006). STX64 is currently being evaluated for its 
potential in reducing breast cancer growth and its safety and effectiveness in estrogen 
receptor positive and metastatic breast cancer. 
As discussed previously, estrogenic E1 which is synthesized by steroid sulfatase and 
aromatase is converted to the potent estrogen 17β-E2 by the activity of 17β-HSD1. 
Inhibitors of 17β-HSD1 may therefore be a useful tool in regulating levels of 17β-E2 
within tissues. 17β-HSD1 activity is associated with enhanced breast cancer cell 
proliferation by increasing 17β-E2 synthesis and inactivating dihydrotestosterone (DHT) 
(Aka et al., 2010). Increased levels of 17β-HSD1 in breast cancer have been associated 
with a worse prognosis (Gunnarsson et al., 2008;Oduwole et al., 2004). Interestingly, in 
NSCLC, a high intra-tumoral expression of both 17β-HSD1 and 17β-HSD2 were 
positively associated with tumour stage (Verma et al., 2013). Accordingly, a high intra-
tumoral E1 concentration was associated with a high expression of 17β-HSD2 and a low 
intra-tumoral E1 concentration was associated with a high expression of 17β-HSD1 
(Verma et al., 2013). However, 17β-E2 intra-tumoral concentrations did not vary with 
isoform expression (Verma et al., 2013). This study highlights a key role for both 17β-
HSD isoforms within NSCLC. 
 Estrogen receptors 1.6.4
Estrogens are small lipophilic compounds that play critical roles in sexual development 
and reproductive function. However, it is now recognised that estrogens contribute to a 
plethora of mechanisms in physiology and disease in both sexes. It has become 
increasingly apparent that estrogens can influence multiple biological functions, including 
inflammatory responses (Straub, 2007), cardiovascular function (Mendelsohn & Karas, 
1999) and bone homeostasis (Weitzmann & Pacifici, 2006). Estrogens are lipophilic and 
can therefore penetrate the cell membrane into the cytosol. Once inside the cell, estrogens 
can be further metabolised by various CYP enzymes to active metabolites or can interact 
with its nuclear receptors, estrogen receptor α (ERα) or estrogen receptor β (ERβ), encoded 
by the ESR1 and ESR2 gene, respectively. ERα and ERβ are transcription factors that alter 
gene expression upon activation. Alternatively, estrogens can also signal through non-
genomic (do not affect gene transcription) mechanisms either by ERα or ERβ tethered on 
the plasma cell membrane (Simoncini et al., 2000) or the orphan GPCR, GPR30/GPCR-
estrogen receptor (GPER-1), mediating acute effects. ERα is a 66kDa protein whereas ERβ 
is a 59kDa protein. ERα and ERβ both have a DNA binding domain, a ligand binding 
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domain in the COOH terminal and a NH2 terminal domain, through which they interact 
with regulatory binding proteins (Heldring et al., 2007). There is significant homology 
amongst the two receptors in the DNA binding domain and the ligand binding domain. In 
contrast, ERα and ERβ differ in the terminal domain, activation function-1 (AF-1), which 
regulates target gene transcription. The functionally unique aspect of signaling through 
ERα and ERβ is that it is dependent on the environment in which it is activated. Therefore, 
the response will be different in a ‘normal’ cell compared to a ‘diseased’ cell. As hormones 
are key modulators of transcription, its activity depends on the signaling pathways that are 
activated when the ligand binds with the receptor, as well as the cellular composition of co-
regulatory proteins and the promoters on estrogen responsive genes (Heldring et al., 2007). 
1.6.4.1 Ligand-mediated regulation of estrogen receptor signaling 
Estrogen binding with either of its nuclear receptors results in its translocation to the 
nucleus where it regulates gene transcription. ERα and ERβ have distinct, often opposing 
effects on gene transcription. Thus, the relative expression of each receptor subtype within 
a cell may underlie the pleiotropic effects that are often observed with estrogens. Estrogen 
binds with the activation function-2 (AF-2) within the ligand binding domain of the 
estrogen receptor which results in a conformational change that promotes 
homodimerization and binding to the estrogen response element (ERE) within the 
promoters of target genes. The resultant increase or decrease in gene expression is 
mediated by the recruitment (tethering) of either co-activators or co-repressors. Estrogen 
can also regulate gene expression indirectly by tethering with other transcription factors, 
such as activator protein-1 (AP-1), and by protein-protein interactions (Murphy, 2011). 
This process has recently been demonstrated to be dependent on ligand-mediated induction 
of transcription factors (Heldring et al., 2011). 
1.6.4.2 Ligand-independent regulation of estrogen receptor signaling 
In addition to the direct and indirect effects of ligand-mediated regulation of transcription 
through the estrogen receptors, estrogen receptors can undergo post translational 
modification including phosphorylation, acetylation ubiquitilation and sumoylation 
(Murphy et al., 2011). Phosphorylation of the estrogen receptors can occur by various 
growth factors or membrane-bound estrogen receptors which permits binding to the ERE. 
Phosphorylation at specific serine sites within the receptor has been demonstrated to 
facilitate transcription. For example, phosphorylation at serine 118 (Ser118) by mitogen 
activated protein kinases (MAPK) of the estrogen receptor regulates the activity of the AF-
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1 (Kato et al., 1995). Phosphorylation can also occur at other serine residues including 
Ser104 and Ser106, amongst others. The exact role of phosphorylation of estrogen 
receptors remains under-investigated, yet it is thought to contribute to drug resistance to 
selective estrogen receptor modulators (Murphy et al., 2011). 
1.6.4.3 Non-genomic signaling effects of estrogen receptors 
Estrogen receptors that are localised on the plasma membrane as well as GPER-1 mediate 
non-genomic effects by acute activation of signaling kinases. 17β-E2 has been associated 
with the stimulation of adenylate cyclase activity, cAMP, MAPK and PI3K signaling 
pathways. Activation of these pathways results in rapid cellular effects, such as activation 
of eNOS. For example, ERα binds to a regulatory subunit of PI3K in a ligand-dependent 
manner, thereby increasing its activity and the activation of eNOS (Simoncini et al., 2000). 
GPER-1 is a 7-transmembrane GPCR that regulates secondary messenger pathways. 
GPER-1 is unique in that it couples to a stimulatory and an inhibitory G protein, Gαs and 
Gαi/o respectively, regulating intracellular levels of cAMP. GPER-1 is an important 
mediator of the rapid, transient non-genomic effects of 17β-E2 by ERK1/2 activation, 
which is dependent on transactivation of the epidermal growth factor receptor (Filardo et 
al., 2000). Furthermore, GPER-1 mediates increases in cAMP in response to 17β-E2 to 
restore epidermal growth factor activated ERK (Filardo et al., 2000). GPER-1 is 
ubiquitously expressed in both normal and malignant tissues, with high levels in the heart, 
lungs, liver, ovaries and brain (Prossnitz et al., 2008). In addition, GPER is also expressed 
in vascular endothelial cells and smooth muscle cells (Prossnitz et al., 2008). Several 
studies have reported the expression of GPER-1 in cancerous tissues and its contribution to 
17βE2 induced cellular proliferation (Prossnitz et al., 2008). GPER-1 protein expression 
has also been positively correlated with tumour size (Filardo et al., 2006). It should 
however be noted that estrogen is not the sole activator of GPER-1 signaling which has 
also been shown to be activated by other mediators including aldosterone (Gros et al., 
2011).  
In addition to GPER, several truncated isoforms of ER have been identified on the plasma 
membrane and are thought to contribute to the rapid, non-genomic effects of 17β-E2. 
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1.6.4.4 Estrogen receptor variants and their signaling 
Estrogens mediate a plethora of activities within target cells and a persistent challenge is 
that not all findings can be understood through known properties of the ‘classical’ estrogen 
receptors. This complexity can be, in part, explained by the existence of splice variants of 
the estrogen receptors. At least two splice variants of ERα have been identified, ER36 
(Wang et al., 2005) and ER46 (Flouriot et al., 2000). These are truncated ERα receptors 
that lack the NH2 terminal domain. Both ER36 and ER46 can form heterodimers with ERα 
and regulate target gene transcription.  
Estrogen receptors on the plasma membrane are important regulators of the rapid non-
genomic signaling of estrogens, in particular by mediating the formation of eNOS and 
subsequent NO synthesis. ER46 is expressed in abundance within endothelial cells and is 
localized on the plasma membrane, cytosol and nucleus (Li et al., 2003). In particular 
ER46 is localised within plasmalemmal caveolae and has been found to be a more potent 
inducer of eNOS than ERα (Li et al., 2003). ER46 can also regulate genomic effects 
contributing to cellular proliferation. In estrogen receptor negative tissues, transfection of 
ER46 results in the activation of ERα-related genes and in ERα positive tissues, ER46 
forms a heterodimer with ERα and acts as a competitive inhibitor of DNA binding thereby 
reducing transcription (Flouriot et al., 2000). Moreover, the proliferative status of MCF-7 
(breast cancer) cells is altered depending on the ratio of ERα to ER36 suggesting that ER46 
plays a role in cellular proliferation (Flouriot et al., 2000). 
More recently, ER36 was characterised and cloned (Wang et al., 2005). ER36 contains 
myristoylation sites giving it the potential to be localized within the plasma membrane 
(Wang et al., 2005). Later studies confirmed that ER36 is predominantly a membrane-
associated receptor (Wang et al., 2006). ER36 lacks the transcriptional domains of ERα 
and functionally cannot regulate transcription in the absence or presence of 17β-E2 (Wang 
et al., 2006). Moreover, ER36 inhibits the genomic signaling pathways of 17β-E2 -
independent and -dependent transactivation activities of both ERα and ERβ (Wang et al., 
2006). ER36 is associated with the rapid, non-genomic effects of 17β-E2 and results in 
dramatic elevations in phosphorylated ERK1/2. These effects are mediated via a 
membrane-bound receptor as BSA-conjugated 17β-E2 (a membrane impermeable 17β-E2) 
was also found to dramatically induce ERK1/2 phosphorylation (Wang et al., 2006). 
Interestingly, ER36 is expressed in triple-negative estrogen receptor breast cancer tumours 
and mediates 17β-E2 induced mitogenic signaling by cross-talk with the epidermal growth 
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factor receptor, Src and ERK (Zhang et al., 2011). This challenges the convention that 
estrogen-receptor negative breast cancer is not associated with pathogenic estrogen 
signaling. Further contributing to the complexity of estrogen signaling is the presence of 
splice variants of ERβ (ERβ2, -4, -5, Δexon5).  
1.6.4.5 Estrogen and the cardiovascular system 
In contrast to the numerous pathogenic effects of estrogen signaling in hormone-sensitive 
cancers, 17β-E2 is renowned for its protective effects against cardiovascular disease in pre-
menopausal women. However, it appears that fluctuations from physiological levels 
present as risk factors in a myriad of cardiovascular diseases (Barros & Gustafsson, 2011).  
Estrogen receptors have been identified throughout the cardiovascular system in the 
endothelium, smooth muscle, adventitia and macrophages. Whilst estrogen signaling is 
probably a complex process that involves signaling through receptors, metabolism and 
non-receptor mediated effects, studies on estrogen receptor knock-out mice have been 
extremely informative to delineate its functions. Conditional knock-out of ERβ in mice 
causes right and left ventricular hypertrophy (Forster et al., 2004), systemic hypertension 
(Zhu et al., 2002), ovarian dysfunction (Cheng et al., 2002) and fewer alveoli in the lungs 
(Patrone et al., 2003). Interestingly, at 5 months of age, both male and female ERβ 
deficient mice have fibrosis in their lungs and underdeveloped alveoli (Morani et al., 
2006).  
Studies using estrogen receptor knock-out mice have revealed that ERα is the predominant 
receptor mediating the cardio-protective effects of 17β-E2 on the heart by regulation of 
VEGF (Jesmin et al., 2010). VEGF is a cytokine, mitogen and pro-survival factor for 
endothelial cells and its reduction is associated with the pathogenesis of numerous 
cardiovascular diseases, including PAH (Farkas et al., 2009). In ERα and ERβ knock-out 
mice there is a reduced expression of VEGF and its receptors, signaling effectors 
endothelial nitric oxide synthase (eNOS) and the serine/threonine protein kinase akt, 
although the effects are much more pronounced in ERα knock-out mice (Jesmin et al., 
2010).  
17β-E2 is recognized to mediate protective effects on the heart via inhibition of 
angiotensin II (Ang II). Ang II infusions results in left ventricular hypertrophy in female 
mice and this is exacerbated by ovariectomy (Pedram et al., 2008). These effects are 
predominantly mediated via the ERβ as exogenously administered 17β-E2 partially 
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reversed the hypertrophy in ERβ knock-out mice, but inhibited this in wild-type and ERα 
knock-out mice (Pedram et al., 2008). 
In systemic vascular smooth muscle cells (VSMC), 17β-E2 inhibits cell proliferation by 
increasing the mitochondrial antioxidant enzyme, manganese superoxide dismutase 
(MnSOD) (Sivritas et al., 2011). Furthermore, 17β-E2 reduces aortic neotima formation 
through MnSOD, which is dependent on the transcriptional activation of Kruppel-like 
factor-4 (KLF-4) (Sivritas et al., 2011). The transcriptional activation of KLF-4 is 
mediated via ERα (Sivritas et al., 2011). Interestingly, whilst 17β-E2 mediates protective 
effects in the cardiovasculature, these effects are lost in patients with diabetes mellitus 
(Orchard, 1996), suggesting that hyper/hypoglycaemia may affect 17β-E2 signaling. High 
glucose is associated with an accelerated rate of VSMC proliferation (Yasunari et al., 
1996). Interestingly, 17β-E2 inhibits VSMC proliferation under normal glucose levels 
(5.5mM) and has no effects in high glucose conditions (25mM) (Ortmann et al., 2011). 
Selective activation of ERα with the agonist MPP inhibits high-glucose-induced VSMC 
proliferation, which is overcome with dual activation of ERα and ERβ (Ortmann et al., 
2011). Furthermore, these selective inhibitory effects mediated by activation of ERα are 
associated with a decrease in intracellular reactive oxygen species (ROS) formation and 
ERK activation (Ortmann et al., 2011). Others have shown an importance for 17β-E2 in 
glucose homeostasis by studying aromatase knock-out (estrogen-deficient) mice. Both 
male and female aromatase knock-out mice have reduced glucose oxidation and increased 
insulin levels (Jones et al., 2000). 
 Cytochrome P450 Enzymes 1.7
CYP heme-thiolate monooxygenase enzymes are catalytic molecules commonly known for 
their role in drug detoxification processes in the liver. As such they are abundantly 
expressed in the liver. CYP enzymes also play an extremely important role in the synthesis 
and metabolism of various endogenous compounds. The lung, aside from its major role in 
gas exchange, acts as a protective filter from the external environment and contains 
numerous CYP enzymes. Whilst CYP enzymes are detoxifying enzymes, they 
paradoxically lead to the formation of reactive intermediates that can induce cellular and 
DNA damage. In addition to their vast role in xenobiotic metabolism, CYP enzymes are 
critical in the metabolism of eicosanoids, the synthesis of cholesterol and the synthesis and 
metabolism of steroids, amongst others. Metabolism by the activity of CYP enzymes has a 
genotoxic capacity via the generation of reactive oxygen intermediates (ROMs) that can 
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interact with nucleic acids and proteins and initiate tumourigensis (Nebert & Dalton, 
2006).  
CYP enzymes are haemoproteins in that they contain an iron (Fe
3+
), serving as a docking 
site for oxygen, which in the presence of NADPH is reduced to Fe
2+
. CYP enzymes are 
part of a super-family subdivided according to sequence homology whereby if 40% of their 
sequence are identical then they belong to the same family (Gibson & Skett, 2001). 
Conserved sequence homology amongst CYP enzymes is only about 10-30%. CYP 
enzymes are critical enzymes in the phase 1 metabolism of drugs and endogenous 
compounds that lead to hydroxylated products. This is the first step in preparing a 
compound for elimination by increasing its polarity thereby making it more soluble in 
water. The liver is the prime site for CYP activity. Other prominent organs capable of CYP 
metabolism include the lung, kidney and brain, amongst others (Gibson & Skett, 2001). 
CYP enzymes are found in abundance within the microsomal fraction of the endoplasmic 
reticulum. 
Numerous drugs and compounds are hydroxylated by the mixed-function oxidase (MFO) 
reaction which is catalysed by the activity of CYP enzymes. The criterion for substances to 
be metabolized by this pathway appears to be high lipophilicity, such as steroid compounds 
(Gibson & Skett, 2001). The overall chemical reaction is characterised by the following: 
NADPH H
+ 
+ O2 + RH  NADP
+ 
+ H2O + ROH 
where RH represents an oxidisable substance such as a drug or steroid compound and ROH 
is the hydroxylated compound. This MFO reaction is catalysed and dependent on the 
activity of CYP enzymes. 
 Catalytic cycle of cytochrome P450 enzymes 1.7.1
Exogenous and endogenous compounds can undergo oxidation by the catalytic activity of 
CYP enzymes, including the estrogens, 17β-E2 and E1 (Figure 1-5). The first step in the 
catalytic cycle involves binding of the estrogens with the oxidised ferric (Fe
3+
) of the CYP 
enzyme. NADPH-cytochrome P450 is a reducing agent that donates an electron for CYP 
hydroxylation resulting in Fe
2+
. Molecular oxygen binds to the Fe
2+
-steroid complex. 
Thereafter, electron rearrangement occurs between the oxygen and the iron and a second 
electron is introduced by the reduction reaction of NADPH-cytochrome P450. 
Subsequently a hydroxylated (-OH) product of the parent compound is released. 




Figure 1-5 Catalytic cycle of cytochrome P450 enzymes 
E represents an estrogen (either 17β-estradiol or estrone) and Fe represents iron. NADPH, 


















 Chapter 1 - Introduction 
45 
 
 Oxidative metabolism of estrogens: 17β-estradiol and 1.7.2
estrone 
CYP enzymes that metabolize estrogens are present in various target tissues and can 
dramatically alter the function of estrogens. Metabolites can exert biological effects by 
interactions with estrogen receptors and/or receptor-independent effects. 17β-E2 and E1 
undergo oxidative metabolism by CYP enzymes in the presence of NADPH to their 
corresponding hydroxylated metabolites (Figure 1-6). Accumulating evidence suggests that 
certain estrogen metabolites formed by this pathway are biologically active and estrogenic 
and possess unique biological functions that may not be directly associated with their 
parent hormone. CYP enzymes are expressed in abundance within the liver and this is 
therefore a prime sight of estrogen metabolism. CYP enzymes promote the hydroxylation 
(addition of an –OH group) on a carbon at any position within the chemical structure. 
Different CYP isoforms exhibit differential hydroxylation activities at different positions 
within the carbon structure of both 17β-E2 and E1. Therefore, the unique expression of 
CYP enzymes within target tissues can modulate metabolite formation. The consequences 
of estrogen metabolism can therefore have dramatic consequences for vascular cell fate by 
in part, regulating the formation of either anti- or pro-proliferative metabolites. The 
predominant hydroxylation pathways of 17β-E2 and E1 include 2-, 4- and 16α-
hydroxylations. 
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Figure 1-6 Metabolism of estrone and 17β-estradiol and the effects of downstream 
metabolites 
Estrone (E1) and 17β-estradiol (17β-E2) are synthesized from androstenedione and 
testosterone respectively by the activity of aromatase. E1 and 17β-E2 can then be further 
metabolized by the activity of cytochrome P450 enzymes (CYPs) to the 16α-, 2, 4-
hydroxylated estrogens. The 2- and the 4-hydroxylated estrogens can then be further 
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1.7.2.1 The oxidative metabolism of 17β-estradiol 
CYP1A1, CYP1A2, CYP3A4 and CYP3A5 have preferential 2-hydroxylation 
(hydroxylation at the second carbon) activities for 17β-E2 (Lee et al., 2003). CYP1A1 also 
catalyses the formation of 15α-, 6α-, 4- and 7α-hydroxyestradiol (15α-OHE2, 6α-OHE2, 4-
OHE2 and 7α-OHE2, respectively) and CYP1A2 and CYP3A5 can also mediate formation 
of 4-OHE2 (Lee et al., 2003). CYP3A4 also catalyses the formation of 4-OHE2 and 16β-
hydroxyestradiol (16β-OHE2) (Lee et al., 2003). In contrast, CYP1B1 exhibits preferential 
catalytic activity for the 4-hydroxylation of 17β-E2, but has the additional capacity to 
generate 2-hydroxyestradiol (2-OHE2) and 16α-hydroxyestradiol (16α-OHE2) (Badawi et 
al., 2001;Hanna et al., 2000;Lee et al., 2003). CYP2A6, CYP2B6, CYP2C8, CYP2C9 and 
CYP2D6 all have low estrogenic oxidative activities of 17β-E2 (Lee et al., 2003).  
1.7.2.2 The oxidative metabolism of estrone 
A similar oxidative metabolic pathway by the activity of CYP enzymes is observed with 
E1. CYP1A1, CYP1A2 and CYP3A4 predominantly catalyses the formation of 2-
hydroxyestrone (2-OHE1) followed by 4-hydroxyestrone (4-OHE1) CYP1B1 
preferentially catalyses the formation of 4-OHE1 (Lee et al., 2003). CYP2A6, CYP2B6, 
CYP2C8, CYP2C9 and CYP2D6 have low estrogenic oxidative activities for the C2 
position (Lee et al., 2003). The formation of 16α-hydroxyestrone (16α-OHE1) is catalysed 
predominantly by CYP1A1, CYP2C19 and CYP3A5 (Cribb et al., 2006). 




Figure 1-7 Cytochrome P450 mediated metabolism of estrone and 17β-estradiol 
The metabolism of estrone (E1) and 17β-estradiol (17β-E2) by the catalytic activity of various 
cytochrome P450 (CYP) enzymes. Diagram modified and reproduced with permission from 
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There are three members of the CYP1 family (CYP1A1, CYP1A2 and CYP1B1) and these 
are key enzymes in the metabolism and activation of hydrophobic xenobiotic pro-
carcinogens. The aryl hydrocarbon receptor (AHR) regulates the expression of the CYP1 
family (Figure 1-8). CYP1B1 is a member of the cytochrome P450 enzyme family I, 
subfamily B, polypeptide 1. 
1.7.3.1 Regulation of CYP1B1 
CYP1B1 transcriptional activity is predominantly regulated by the AHR (Figure 1-8). 
Various endogenous and exogenous compounds including dioxins and poly aromatic 
hydrocarbons bind with the AHR complex (consisting of the AHR, AHR-interacting 
protein (AIP) and heat shock proteins (hsp90)). Upon binding, the AHR dissociates from 
its AIP and hsp90 and translocates into the nucleus where it dimerizes with the AHR 
nuclear translocator (ARNT). This complex then binds to specific DNA enhancer 
sequences known as dioxin-response elements (DRE) which results in transcription of the 
CYP1 family, including CYP1B1. 
17β-E2 is a substrate for CYP1B1 and can regulate its transcriptional activity. In Ishikawa 
cells (human endometrial adenocarcinoma cells), over-expression of ERα induces the 
transcriptional activation of CYP1B1 in the presence of 17β-E2 and this may be via a 
direct interaction with ERα and estrogen responsive elements on CYP1B1 rather than via 
the AHR pathway (Tsuchiya et al., 2004). In hPASMCs, 17β-E2 at physiologically 
relevant concentrations (1nM) increases the protein expression of CYP1B1 (White et al., 
2011a). In addition, the profound PAH insults serotonin and dexfenfluramine also increase 
the expression of CYP1B1 in hPASMCs (Dempsie et al., 2013;White et al., 2011b). In 
vascular endothelial cells, increased shear stress increases the expression of CYP1B1 
(Conway et al., 2009). Additionally, the transcription of CYP1B1 is induced by the 
environmental toxics 2,3,7,8-tetrachlorodinezo-p-dioxin (TCDD) and benzo(a)pyrene. Co-
treatment of TCDD with 17β-E2 in human lung cells results in an accumulation of 4-
methoxyestradiol (4-MeOHE2), a key downstream metabolite indicative of CYP1B1 
activity (Cheng et al., 2007). 




Figure 1-8 Transcriptional activation of cytochrome P450 enzymes by the aryl hydrocarbon 
receptor 
Endogenous and exogenous compounds bind with the aryl hydrocarbon receptor (AhR) 
dissociating it from its complex consisting of AhR-interacting protein (AIP) and heat shock 
proteins (hsp90) and translocates to the nucleus. The AhR associates with the AhR nuclear 
translocator (ARNT) and binds with specific DNA enhancer sequences known as dioxin-
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1.7.3.2 CYP1B1 and cancer 
Increased CYP1B1 expression has been reported in virtually all types of cancer including 
breast cancer (McKay et al., 1995), lung cancer (Murray et al., 1997) and ovarian cancer 
(McFadyen et al., 2001). The relatively low expression of CYP1B1 within normal tissues 
makes this an attractive therapeutic target. This suggests that CYP1B1 activity could be 
used to bio-transform anti-cancer agents into their active form specifically only within 
target tissues. Furthermore, the therapeutic value of CYP1B1 inhibition in cancer is 
currently under phase 2 clinical trials (Luby, 2008). CYP1B1 is predominantly an extra-
hepatic enzyme that hydroxylates 17β-E2 and E1 predominantly to the catechol 4-
hydroxyestrogens (4-OHE2 and 4-OHE1, respectively). CYP1B1 is expressed within 
estrogen target tissues including the mammary, ovary and uterus (Tsuchiya et al., 2005). 
The 4-hydroxyestrogens are recognised to contribute to tumorigenesis via the formation of 
ROS resulting in the formation of quinones and semiquinones that can cause DNA damage 
via the formation of depurinating DNA adducts (Nutter et al., 1991;Nutter et al., 1994). 
Although steroids may influence cellular function in terms of proliferation, a genotoxic 
event that induces cellular damage is essential for the initiation of cancer (Cavalieri et al., 
1997). The abundant expression of CYP1B1 in cancerous tissues including breast, colon, 
lung, oesophagus, skin, lymph node, brain and testis supports a pathological role for 
CYP1B1 in tumorigenesis, in particular since its expression was undetectable in normal 
tissues (Murray et al., 1997). This is further supported by a high concentration of 4-
hydroxylated estrogens in uterine leiomyoma and breast cancer (Lemon et al., 1992;Liehr 
et al., 1995;Liehr & Ricci, 1996). In human breast cancer biopsies, 4-hydroxylated 
estrogens are up to three times higher than 2-hydroxylated estrogens (Rogan et al., 2003). 
In line with this, catechol estrogen quinone levels were also three times higher in breast 
cancer specimens compared to control (Rogan et al., 2003). In addition to its 4-
hydroxylation activity, CYP1B1 has the additional capacity to hydroxylate at the C2 and 
C16 positions on the carbon ring of 17β-E2 and E1. 
In the liver, 4-hydroxylation is a minor metabolic pathway of estrogens with 2-
hydroxylation being the predominant pathway (Hammond et al., 1997;Suchar et al., 1995). 
However, in extrahepatic tissues, 4-hydroxylase activity is much more profound. For 
example, in uterine myometrium and myomata (tumour tissue), 4-hydroxylation of 17β-E2 
is the predominant pathway for catechol estrogen formation and this is elevated in 
myomata (Liehr et al., 1995). Certain target tissues are susceptible to 17β-E2-induced 
carcinogenesis including the Syrian hamster kidney (Liehr et al., 1986), CD-1 mouse 
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uterus (Newbold et al., 1990) and the rat pituitary (Clifton & Meyer, 1956). More 
interestingly, in all these tissues the 4-hydroxylation pathway of catechol estrogen 
formation predominates, suggesting that metabolic activation of this pathway is associated 
with carcinogenesis (Bui & Weisz, 1989;Weisz et al., 1992;Paria et al., 1990). Microsomes 
isolated from human mammary adenocarcinomas and fibroadenoma show elevated 4-
hydroxylation activities compared to normal tissue (Liehr & Ricci, 1996). However, more 
recently, in a comprehensive analysis of estrogen metabolites within breast cancer tissue 
and urine, there appeared to be no evidence for 4-hydroxylation activity in breast tissue, 
although 4-OHE1 was detected within in the urine (Taioli et al., 2010). Both 4-OHE1 and 
4-OHE2 retain strong estrogenic activity and have high binding affinities at both estrogen 
receptors ERα and ERβ (Zhu et al., 2006). 
CYP1B1 also has the additional capacity to promote the 2-hydroxylation of estrogens, 
although this is a relatively minor pathway. In contrast to the carcinogenic effects observed 
with the 4-hydroxylation pathway, both 2-OHE1 and 2-OHE2 lack carcinogenic activity. 
This is possibly due to its prompt and exceptionally high metabolic clearance rate by the 
activity of catechol-O-methyl transferase (COMT) to its methoxylated metabolites (Ball et 
al., 1983;Merriam et al., 1980). The products formed by this reaction, 2-methoxyestrone 
(2-MeOHE1) and 2-methoxyestradiol (2-MeOHE2), possess little estrogenic activity with 
a low binding affinity for estrogen receptors (Zhu et al., 2006). Furthermore, 2-MeOHE2 
has distinct antimitogenic, antiangiogenic, anti-inflammatory and apoptotic effects that are 
mediated independently of the estrogen receptors and has therefore been considered as an 
anti-cancer agent (Lakhani et al., 2003). 
16α-hydroxylation represents a potentially pathogenic pathway that may be activated by 
CYP1B1 activity (Badawi et al., 2001;Hanna et al., 2000). In contrast to the evidence of a 
pathogenic role for the 4-hydroxylation pathway in cancer, the evidence for 16α-
hydroxylation is less concrete. 16α-OHE1 binds to the estrogen receptor in two different 
ways. First, it binds in a similar non-covalent fashion to that of 17β-E2 and second, it 
forms an irreversible covalent bond with the receptor (Swaneck & Fishman, 1988). 
Furthermore, 16-hydroxylated metabolites stimulate proliferation of breast cancer cells 
(Seeger et al., 2006;Lippert et al., 2003). An increased ratio of 2-OHE1/16α-OHE1 has 
been inversely associated with an increased risk of breast cancer in some studies (Muti et 
al., 2000;Dallal et al., 2013) whereas other studies have failed to report any correlation 
(Cauley et al., 2003;Eliassen et al., 2008). 
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1.7.3.3 CYP1B1 and cardiovascular diseases 
Within the cardiovascular system, the contribution of estrogen metabolism by CYP1B1 in 
the pathogenesis of cardiovascular diseases is less well-defined. However, a pathogenic 
role of CYP1B1 activity is thought to mediate the development of hypertension, cardiac 
hypertrophy and fibrosis. However, these effects are not through estrogen metabolism, but 
rather through arachidonic acid metabolism. However, given the profound effects that 
estrogens mediate within the cardiovascular system, it is likely that in the coming years an 
increasing role for estrogen metabolism may emerge. 
Arachidonic acid metabolism is mediated via the activity of CYP1B1 in vitro towards the 
formation of epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic acids (HETEs) 
(Choudhary et al., 2004). In the vasculature, CYP1B1 is predominantly expressed within 
smooth muscle cells, yet its expression is increased by shear stress within the vascular 
endothelium (Conway et al., 2009). In vascular smooth muscle cells, Ang II and 
arachidonic acid cause migration, proliferation and hypertrophy which is inhibited by the 
highly potent and selective CYP1B1 inhibitor, 2,3',4,5'-tetramethoxystilbene (TMS) 
(Yaghini et al., 2010). This is associated with a reduced formation of ROS and its 
downstream signaling molecules ERK1/2 and p38MAPK (Yaghini et al., 2010).  
Ang II and deoxycorticosterone acetate (DOCA)-salt induced hypertension, cardiac 
hypertrophy and fibrosis are inhibited by CYP1B1 inhibition with TMS (Jennings et al., 
2010;Sahan-Firat et al., 2010). Furthermore, increases in mean arterial pressures and 
cardiac hypertrophy by Ang II is reduced in CYP1B1-/- mice (Jennings et al., 2010). The 
increased vascular reactivity associated with Ang II and DOCA-salt induced hypertension 
in aortic, mesenteric and femoral arteries is inhibited in CYP1B1-/- mice and by TMS 
treatment (Jennings et al., 2010;Sahan-Firat et al., 2010). Ang II induces aortic endothelial 
dysfunction as assessed by an impairment in the vasorelaxant response to acetylcholine and 
this is prevented with TMS (Jennings et al., 2010). 
Ang II induced hypertension and cardiac hypertrophy is associated with an increase in 
NADPH oxidase activity and ROS formation and this is inhibited by CYP1B1 inhibition 
and in CYP1B1-/- mice (Jennings et al., 2010). The elevated ROS signaling by Ang II is 
potentially mediated via the metabolism of arachidonic acid by the activity of CYP1B1 
resulting in increased activity of the downstream signaling effectors ERK1/2 and 
p38MAPK (Malik et al., 2012). 
 Chapter 1 - Introduction 
54 
 
Taken together, this provides evidence that CYP1B1 is associated with the pathology of 
cardiovascular diseases in particular through elevated ROS signaling. This highlights a 
therapeutic potential of CYP1B1 inhibition within cardiovascular diseases.  
1.7.3.4 Physiological role for CYP1B1 
The formation of genotoxic intermediates by the activity of CYP1B1 together with its 
activity towards the formation of ROS via hydroxylation of estrogens and metabolism of 
arachidonic acids has uncovered speculation of why such a detrimental enzyme would 
exist. There appears to be no beneficial effects associated with the activity of CYP1B1. In 
support of this, the CYP1B1-/- mouse has a normal phenotype and is protected against the 
toxic effects of many poly aromatic hydrocarbons which are known to induce malignancies 
(Nebert & Dalton, 2006). However, the CYP1B1-/- mouse exhibits key pathological 
features associated with primary congenital glaucoma, including abnormalities in ocular 
drainage and the trabecular meshwork in the eye (Vasiliou & Gonzalez, 2008). This 
highlights at least one physiological advantage of normal CYP1B1 activity. 
 Phase 2 metabolism of hydroxylated estrogens 1.7.4
Catechol estrogens (the 2- and 4-hydroxylated estrogens) are further metabolized by 
methylation by the activity of COMT. The activity of COMT represents a key deactivation 
process, in particular by reducing the ability of 4-hydroxylated estrogens to generate 
quinones and semiquinones that have the capacity to induce harmful DNA transformations 
(Acharya et al., 2010). Catechol estrogens can also be metabolized by other conjugation 
reactions including sulfation and glucuronidation.   
 Gender and pulmonary arterial hypertension 1.8
In 1951, Dresdale reported a greater incidence of PAH in females (Dresdale et al., 1951). 
These findings were later confirmed by the national institutes of health (NIH) registry, 
which reported 1.7:1 female to male ratio (Rich et al., 1987). More recently, large-scale 
epidemiological studies from registries in France, UK/Ireland and the USA have reported 
an even higher incidence of PAH amongst females at ~65%, 70% and 80%, respectively 
(Badesch et al., 2010;Humbert et al., 2006;Ling et al., 2012). However, despite an 
increased prevalence amongst females, better survival is reported in females and in 
younger patients (Benza et al., 2010;Humbert et al., 2010). More recently, a 
comprehensive study characterised the relationship of sex and haemodynamics in PAH 
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(Ventetuolo et al., 2014). In young patients (<45 years), male patients had higher mean 
PAPs compared to females and these differences were attenuated in older patients. 
Furthermore, mean PAPs were higher in younger patients compared to older patients, 
despite survival being reportedly poorer in the older patients. 
The cardio-protective effects of 17β-E2 may contribute to the improved survival in female 
patients compared to males as  improved right ventricular systolic function is superior in 
both healthy and PAH-affected women compared to men and is associated with higher 
circulating levels of 17β-E2 (Kawut et al., 2009;Ventetuolo et al., 2011).  
In addition, a few reports have described an association with physiological and 
pharmacological estrogen exposure. Morse and colleagues reported an interesting scenario 
that highlighted a risk for estrogen exposure and the development of HPAH (Morse et al., 
1999). They reported the significant onset of PAH in a 46-year old obligate carrier after 3 
months on hormone replacement therapy. Interestingly, HPAH had been diagnosed in 
several of her family members, all of which were female. More recently, a survey was 
conducted to measure prolonged exogenous estrogen exposure in patients attending the 8
th
 
international Pulmonary Hypertension Association (Sweeney & Voelkel, 2009). More than 
81% of patients reported prior use of hormone therapy and 70% reported prolonged use 
(more than 10 years) (Sweeney & Voelkel, 2009). Whilst this may provide a link between 
exogenous estrogen exposure and PAH, the study did not compare PAH patients with the 
general population. In another study, there was evidence that hormone replacement therapy 
prevented the development of PAH in patients with systemic sclerosis (Beretta et al., 
2006). In PPHTN, circulating 17β-E2 levels are increased, which is associated with a 
single nucleotide polymorphism (SNP) in aromatase, as discussed previously (Roberts et 
al., 2009). The reason for these sexual dimorphisms in reported incidence and survival is 
incompletely understood and under-investigated. 
In review of epidemiological findings, it was initially hypothesized that estrogens, 
particularly 17β-E2, would be associated with the pathogenesis of PAH. However, 
numerous pre-clinical studies suggest that 17β-E2 mediates protective effects in the 
pulmonary circulation and on the right ventricle. Previously, the majority of pre-clinical 
studies have utilised male rodents as they develop a much more robust and severe disease 
phenotype (Rabinovitch et al., 1981). Additionally, it provides a basis to study molecular 
pathways in the absence of any influence of female-derived hormones. Recently, in light of 
epidemiological studies, there has been increased interest in assessing the role of steroids, 
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in particular, female-derived hormones on the development and progression of PAH. 
However, there has been conflicting reports of the role of estrogens in PAH, which has so 
far obscured and diffused our understanding of the relative impact that female hormones, 
or lack thereof, may have in PAH. 
 Estrogens and experimental pulmonary hypertension 1.8.1
1.8.1.1 Estrogens and monocrotaline-induced pulmonary hypertension 
Several lines of evidence converge to support a protective role for 17β-E2 in the MCT 
model of PH. In particular, ovariectomy exacerbates the PH phenotype, suggesting a 
protective role for 17β-E2 in this model (Ahn et al., 2003;Farhat et al., 1993;Tofovic et al., 
2006;Umar et al., 2011;Yuan et al., 2013). MCT disrupts the vascular endothelium in the 
pulmonary artery, leading to microvascular leakage which is prevented by 17β-E2 (Farhat 
et al., 1993). Other studies have shown that 17β-E2 can reverse established severe MCT-
induced PH leading to 100% survival, mediated by the estrogen receptor, ERβ (Umar et 
al., 2011). The protective effects of 17β-E2 in this model included suppression of 
inflammation as assessed by a reduction in the inflammatory marker ED-1 as well as a 
reduction in IL-6 (Umar et al., 2011). Circulating IL-6 levels are increased in PAH 
(Humbert et al., 1995) and overexpression of IL-6 in the lungs induces PH in mice (Steiner 
et al., 2009). Furthermore, 17β-E2 reversed blood vessel loss in both the lungs and right 
ventricle and even promoted angiogenesis (Umar et al., 2011).  
2-MeOHE2 is a CYP/COMT metabolite of 17β-E2 that is a more potent inducer of 
prostacyclin synthesis and inhibitor of ET-1 production in human umbilical vein 
endothelial cells than its parent compound (Seeger et al., 1999;Dubey et al., 2001). This 
metabolic pathway therefore highlights a potential protective pathway. Indeed, 2-MeOHE2 
prevents the development of MCT-induced PH and reverses established MCT-induced 
PAH (Tofovic et al., 2005). However, whilst 2-MeOHE2 increases prostacyclin production 
in human umbilical vein endothelial cells, 16α-OHE1 caused the most profound induction 
of prostacyclin synthesis (Seeger et al., 1999). Elevated circulating levels of 16α-OHE1 
has been associated with the incidence of HPAH (Austin et al., 2009). It is likely that 
estrogen metabolites may infer divergent signaling in diverse cell types. Thus, further 
studies are needed to confirm the effects of estrogen metabolites on prostacyclin synthesis 
in the pulmonary artery.  
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1.8.1.2 Estrogens and hypoxic-induced pulmonary hypertension 
The sexual dimorphism in response to hypoxia has been reported in chickens (Burton et 
al., 1968), swine (McMurtry et al., 1973) and rats (Rabinovitch et al., 1981). Whilst 
reports of gender differences in hypoxic PAH in humans is lacking, we can obtain insight 
from individuals living at high altitude (a hypoxic environment). Whilst most studies have 
been carried out in men, or have not segregated for gender, one study characterised a 
gender difference in high-altitude PH in the Kyrgyz population from Central Asia living 
3,000m above sea level (Aldashev et al., 2002). Electrocardiograms were performed in 347 
males and 394 females and signs of cor pulmonale were reported in 23% of males and 6% 
of females, indicating a greater effect of hypoxia on males in humans. However, it should 
be noted that 43% of the men were smokers compared to none in the females. Further 
studies are required to confirm these findings, as this would have implications for the use 
of this model in studying IPAH and HPAH, which predominates in females (Badesch et 
al., 2010;Humbert et al., 2006;Ling et al., 2012). Nonetheless, this model has provided a 
basis to study the molecular pathways that may underpin disease pathogenesis. 
Both gender and the menstrual cycle can affect pulmonary arterial reactivity. Pulmonary 
artery rings from pro-estrous females (high levels of circulating 17β-E2) reduce pulmonary 
arterial vasoconstrictions under both normoxic and hypoxic conditions (in comparison to 
estrous and di-estrous female and male pulmonary artery rings) (Lahm et al., 2007). 
However, only high doses of exogenous 17β-E2 (500µM and 1mM) attenuate hypoxic and 
phenylephrine-induced pulmonary arterial vasoconstriction, independent of sex or estrous 
cycle and were likely through a non-genomic effect as the response was observed instantly 
(Lahm et al., 2008b). Further studies have provided evidence that the protective effects of 
17β-E2 in hypoxic-induced PH are mediated by the ERα and are independent of 17β-E2 
metabolism, as the general CYP inhibitor, 1-aminobenzotriazole (ABT) has no effects 
(Lahm et al., 2012). Initially, it was reported that intermittent hypoxia increased the 
expression of both ERα and ERβ in rats (Wu et al., 2008). In contrast, chronic hypoxia 
increased the expression of ERβ, whereas levels of ERα were unchanged (Lahm et al., 
2012).  ERβ inhibition abolished the beneficial effects of 17β-E2 on the right ventricle 
(Lahm et al., 2012). This is consistent with reports that ERβ knockout mice have RVH 
(Forster et al., 2004). 17β-E2 treated hypoxic rat lungs displayed a reduction in 
phosphorylated ERK and increased expression of p27
kip
, a cell cycle inhibitor (Lahm et al., 
2012).  
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ET-1 is a potent vasoconstrictor produced from the vascular endothelium and its synthesis 
is decreased by 17β-E2 (Akishita et al., 1996). Hypoxia is a potent inducer of ET-1 
synthesis (Rakugi et al., 1990) and it is regulated by the AHR (Lund et al., 2008). 
Interestingly, transcriptional activity of the precursor to ET-1, pre-pro ET-1, is increased in 
the lungs of ovariectomized rats but not in rats with intact ovaries (Earley & Resta, 2002), 
suggesting that circulating estrogens are suppressing ET-1 synthesis. In addition, 17β-E2 
replacement in rats prevents increases in ET-1 mRNA and protein expression by 
interfering with hypoxia-inducible factor (HIF) activity (Earley & Resta, 2002).  
Endothelium-dependent relaxation is an important physiological response that is impaired 
by exposure to chronic hypoxia and is thought to contribute to PAH. Phytoestrogens are 
plant-derived estrogen-like compounds that have the ability to restore the function of the 
endothelium by promoting relaxation.  In pulmonary arteries isolated from chronically 
hypoxic male rats, the phytoestrogens genistein and daidzen (derived from soy) can restore 
the impaired vasorelaxation response to agonists that stimulate release of NO (Karamsetty 
et al., 2001). 
1.8.1.3 Estrogens in genetically-susceptible and drug-induced pulmonary 
hypertension 
Whilst 17β-E2 appears to exert protective effects in the classical models of PH (MCT and 
hypoxic), in genetically susceptible and drug-induced pulmonary hypertensive models, 
17β-E2 appears to be a risk factor. These models are therefore perhaps much more relevant 
to studying the gender effects associated with the development of IPAH and HPAH. 
Overexpression of the human SERT gene in mice leads to a spontaneous PH phenotype in 
female mice at 5-6 months of age (White et al., 2011b). To establish whether these effects 
are facilitated by ovarian-derived estrogens, female SERT+ mice were ovariectomized and 
assessed for a PH phenotype after 12 weeks. Ovariectomy successfully attenuated the PH 
phenotype as assessed by pulmonary vascular remodeling and RVSPs in these mice and 
this could be re-established by exogenous administration of 17β-E2. In contrast, 
administration of 17β-E2 in male SERT+ mice had no effects (White et al., 2011b). 
Decreased expression of the estrogen metabolizing enzyme CYP1B1 has been reported in 
patients harbouring mutations in the BMPR-2 gene (West et al., 2008). In contrast, a 
CYP1B1 genetic polymorphism Asn453Ser (N453S) which is associated with an increased 
post-transcriptional proteosomal degradation of CYP1B1 (Bandiera et al., 2005) is more 
common in patients without any evidence of PAH, despite harbouring mutations in the 
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BMPR-2 gene (Austin et al., 2009). In female SERT+ mice and in IPAH, CYP1B1 
expression is increased (White et al., 2011a). Differential estrogen metabolism may be 
species and gender specific and may therefore contribute to the divergent effects of 
exogenous 17β-E2 in male and female SERT+ mice.  
Another model that displays female selectivity is the mouse model that overexpresses a 
member of the S100A4/mts1 (Dempsie et al., 2011). Additionally, complex vascular-like 
lesions were present in approximately 25% of females (Dempsie et al., 2011). Serotonin 
induces the expression and release of S100A4/mts1 in hPASMC, inducing cellular 
proliferation via RAGE (Lawrie et al., 2005). 17β-E2 increases the expression of 
S100A4/mts1, whilst soluble RAGE (which can bind RAGE agonists) inhibits the 
proliferative capacity of 17β-E2. This suggests that 17β-E2 mediates an increased 
expression of S100A4/mts1 which can then bind to RAGE promoting PASMC 
proliferation. 
1.8.1.4 Estrogens in SU-hypoxic-induced pulmonary arterial hypertension 
The combined vascular insult SU5416 with hypoxia in rats is to date the model that most 
closely and robustly recapitulates human PAH pathology, with dramatically elevated 
pressures and the formation of complex vascular lesions. In contrast to the classical models 
of PH, female SU-hypoxic rats develop a more severe PAH phenotype compared to male 
rats as measured by RVSP, yet develop less pronounced RVH (Tofovic et al., 2012). 
Whilst both genders developed occlusive vascular lesions, female rats developed complex 
vascular lesions (Tofovic et al., 2012). In this model, ovariectomy reduced the elevated 
RVSP, yet worsened the degree of RVH (Tofovic et al., 2013). To further support a 
pathogenic role for 17β-E2 in this model, rats were dosed with an aromatase inhibitor 
anastrozole, which inhibits endogenous synthesis of 17βE2. Similar with ovariectomy, 
aromatase inhibition significantly reduced RVSP, yet only had a modest effect on right 
ventricular remodeling (Mair et al., 2013;Tofovic et al., 2013). 
1.8.1.5 Estrogens and dexfenfluramine-induced pulmonary hypertension 
Finally, chronic administration of the anorectic drug dexfenfluramine in mice leads to 
increased RVSP in female mice only (Dempsie et al., 2013). In contrast, in female obese 
rats, dexfenfluramine did cause a decrease in the weight of the animals but did not cause 
PH (Mitani et al., 2002). Interestingly, paradoxical effects were observed in MCT treated 
female rats, where dexfenfluramine attenuated the effects of MCT (Mitani et al., 2002). 
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Dexfenfluramine alone induced the activity of elastase, an enzyme that is pathobiologically 
linked to the development and progression of PAH, and conversely, in combination with 
MCT, reduced its activity (Mitani et al., 2002). More recently, synergistic effects have 
been observed in hPASMCs treated with dexfenfluramine and 17β-E2 leading to enhanced 
cellular proliferation (as measured by thymidine incorporation), suggesting that the effects 
of dexfenfluramine may be facilitated via 17β-E2 (Dempsie et al., 2013). Given that 17β-
E2 exerts protective effects in the MCT model of PH, dexfenfluramine may be enhancing 
these effects. Additionally, 17β-E2 metabolism by activity of CYP enzymes may 
contribute to these divergent effects in the MCT model and requires clarification. 
1.8.1.6  Estrogen effects in vitro 
In isolated perfused rat lungs, 17β-E2 potentiates vasoconstriction to a TXA2 mimic (U-
46619) (Farhat & Ramwell, 1992). Additionally, the vasoconstrictive effects to U-46619 
alone were enhanced in sexually mature female rats compared to sexually mature male rats 
(Farhat & Ramwell, 1992). Removal of the pulmonary endothelium increases thymidine 
uptake (a measure of cell mitosis) in canine PASMC and this effect is abolished in the 
presence of an intact endothelium (Farhat et al., 1992). In distal hPASMCs, cellular 
proliferation assays revealed that of the three main estrogens, (E1, 17β-E2, E3) and 
progesterone, 17β-E2 is the only estrogen to stimulate increased proliferation as measured 
by thymidine incorporation assays (White et al., 2011b). 
Arachidonic acid stimulates endothelium-dependent contractions in both male and female 
pulmonary arteries from rabbits, yet these effects are potentiated in females and mediated 
by 17β-E2 (Pfister, 2011). Arachidonic acid is the pre-curser in the production of 
eicosanoids, such as thromboxanes, leukotrienes and prostacyclin. In female rabbit 
pulmonary arteries, there is a greater expression of 5- and 15-lipoxygenase which leads to 
an increased production of 5- and 15-HETE, respectively, which stimulates contraction of 
the pulmonary artery (Pfister, 2011). 
The expression of BMPR-2 is decreased by about 25% in human female cultured 
lymphocytes compared to males and 17β-E2 suppresses BMPR-2 expression in both 
cultured lymphocytes and human microvascular endothelial cells  (Austin et al., 2012). 
Under normoxic conditions in pulmonary endothelial cells, 17β-E2 can increase BMP 
signaling (phosphorylation of Smad1/5/8), whilst under hypoxic conditions, 17β-E2 
suppresses BMP signaling via estrogen receptor signaling and Hypoxia-inducible factor 1α 
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(HIF1α) (Ichimori et al., 2013). These divergent findings may be partly explained by the 
different anatomical locations of the endothelial cells studied (microvascular vs. large 
pulmonary arterial endothelial cells). In contrast, in hypoxic pulmonary microvascular 
endothelial cells, 17β-E2 reduces the phosphorylation of ERK, increases the expression of 
the cell cycle inhibitor, p27
kip1
 and decreases VEGF secretion and cell proliferation (Lahm 
et al., 2012). 
 Progesterone and pulmonary hypertension 1.8.2
Pregnenolone is converted to either DHEA or progesterone. Progesterone is the pre-curser 
to aldosterone. In both male and female rat coronary and pulmonary arteries, progesterone 
is a potent vasodilator (English et al., 2001). In this study, the vasodilatory properties of 
17β-E2, progesterone, testosterone and cortisol were compared in the different vascular 
beds. All steroids were associated with an acute vasodilatory response, although 
differences were noted between genders and the vascular bed studied. In the pulmonary 
arteries, progesterone was the most potent vasodilator, followed by testosterone, cortisol 
and then 17β-E2 (English et al., 2001). In rabbit pulmonary arteries, the vasodilatory 
properties of progesterone are endothelium-dependent and associated with elevations in 
NO and cGMP (Li et al., 2001). In rats deficient of gonadal estrogens by ovariectomy, 
progesterone has been shown to attenuate the development of MCT-induced PH, RVH and 
pulmonary vascular remodeling (Tofovic et al., 2009a). Progesterone receptors have been 
detected within the complex vascular lesions of a patient with PAH (Barberis et al., 1995), 
although this has never been repeated in a larger cohort of patients. Further studies are 
merited to understand the role of progesterone in PAH. 
However, the use of progesterone therapy in PAH should be approached with caution as it 
is the pre-curser to aldosterone. In patients with PAH, plasma aldosterone levels are 
increased (Maron et al., 2013). Aldosterone interacts with the mineralocorticoid receptor 
and its antagonist spironolactone prevents PASMC proliferation and attenuates 
experimental PH (Preston et al., 2013). This highlights a potential detrimental pathway that 
may be activated by progesterone therapy. 
 Androgens and pulmonary hypertension 1.8.3
Whilst the incidence of PAH is more common in women than in men, in patients older 
than 60 years of age, the estimated 2-year survival in male patients is significantly less 
compared to female patients (Shapiro et al., 2012). Young male patients (<45 years old) 
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with IPAH have been reported to have higher mean PAPs and pulmonary vascular 
resistance compared with females, whilst in older patients there were no differences in 
pulmonary haemodynamics (Ventetuolo et al., 2014). Interestingly, older patients (>45 
years) with IPAH, had significantly lower mean PAPs and pulmonary vascular resistance 
compared with younger patients, and this was observed in both sexes (Ventetuolo et al., 
2014). However, survival is worse in male patients (Shapiro et al., 2012). These sexual 
dimorphisms suggest that both estrogens and androgens may influence the pathogenesis of 
PAH. The levels of androgens and estrogens decline with age, with a dramatic reduction in 
estrogens in females after menopause. In PAH, the function of the right ventricle is a key 
determinant in the survival of patients (D'Alonzo et al., 1991;Sandoval et al., 1994). Thus 
is appears that both estrogens and androgens may adversely affect pulmonary 
haemodynamics in younger patients whilst promoting the function of the right ventricle. In 
contrast, in older patients, the reduction in estrogens and androgens may be associated with 
the lower mean PAPs and pulmonary vascular resistance compared with younger patients. 
Overall, these epidemiological differences in survival suggest that androgens may 
influence disease pathogenesis. 
Androgens are primarily synthesized within the gonads and the adrenal cortex. 
Testosterone is the primary androgenic steroid hormone that mediates its effects through 
the androgen receptor. Testosterone is metabolized to its potent, active metabolite 
dihydrotestosterone by 5α-reductase which can also activate the androgen receptor. As 
mentioned previously, right ventricular function is the most important prognostic factor in 
PAH (D'Alonzo et al., 1991). Androgen receptors have been identified in both the left and 
the right ventricle (Lizotte et al., 2009). Both aromatase and 5α-reductase expression are 
increased in cardiac hypertrophy which is associated with an enhanced production of 
dihydrotestosterone (Thum & Borlak, 2002). The contractile protein α-MHC has also been 
found to be reduced in cardiac hypertrophy and can be restored with administration of 
testosterone (Thum & Borlak, 2002). 
Testosterone is a potent vasodilator of the pulmonary vascular beds in both males and 
females (Rowell et al., 2009;Smith et al., 2005). In fact, it is a more potent vasodilator of 
the pulmonary arteries than 17β-E2 (English et al., 2001). These effects are rapid and have 
been shown to occur independently of the androgen receptor (Jones et al., 2002). The 
precise mechanism by which testosterone exerts these vasodilatory actions are 
incompletely understood. However, there is evidence to suggest that testosterone acts as a 
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calcium antagonist as the dilatation to testosterone is increased in vessels pre-constricted 
with agents that activate voltage-gated calcium channels (Jones et al., 2002). 
The relatively low levels of testosterone in females may provide rationale for the increased 
incidence of PAH amongst females. Studies examining the effects of testosterone on the 
pulmonary vasculature and right ventricle are limited. In mice, castration results in reduced 
RVH and myocyte diameter in response to pulmonary arterial banding, and testosterone 
successfully normalised these parameters (Hemnes et al., 2012). Pulmonary artery banding 
is a surgical technique that mimics right ventricular pressure overload by ligation of the 
pulmonary artery. Additionally, survival was improved in castrated mice that underwent 
pulmonary artery banding compared with pulmonary artery banding alone, despite 
testosterone having minimal effects on pulmonary haemodynamics (Hemnes et al., 2012). 
In a healthy cohort of patients, increased testosterone levels were associated with increased 
stroke volume and right ventricular mass and volume (Ventetuolo et al., 2011). In male 
patients, right ventricular ejection fractions worsen in males after initiating therapy, 
whereas it improves in females with IPAH, which may explain the sex differences in 
survival (Jacobs et al., 2013). 
DHEA is the pre-curser to androstenedione. The formation of testosterone from 
androstenedione is mediated by the activity of 17β-hydroxysteroid dehydrogenase 3 (17β-
HSD3). DHEA is synthesized primarily in the adrenal glands from cholesterol and is the 
most abundant adrenal steroid. In addition, the gonads also participate in DHEA synthesis. 
It commonly circulates in its sulfated form, DHEA-S, which acts as an internal reservoir 
for DHEA synthesis. DHEA-S is converted to DHEA by the activity of sulfotransferases 
within tissues. Men have higher levels of DHEA and DHEA-S than women (~50% more) 
and these decline with age (Parker, 1999). DHEA and DHEA-S are potent inhibitors of cell 
proliferation in several cell lines by halting cells in the G0/G1 phase (Jiang et al., 2005). In 
the hypoxic rat model of PAH, DHEA prevented the development of pulmonary arterial 
remodeling, RVH and PH (Bonnet et al., 2003). In vitro cellular studies in PASMCs have 
implicated that DHEA mediates its effects by reducing the levels of intracellular calcium 
and the activation of voltage gated potassium channels (Bonnet et al., 2003). In the SU-
Hypoxic model of PAH, DHEA treatment inhibited right ventricular apoptosis, fibrosis and 
oxidative stress by a reduction in NADPH levels (Alzoubi et al., 2013). Thus, DHEA 
mediates anti-oxidant effects by reducing the availability of NADPH to generate ROS. 
Furthermore, DHEA is a potent suppressor of induced-CYP1B1 expression in vivo 
(Ciolino et al., 2003). A clinical trial in patients with chronic obstructive pulmonary 
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disease associated PH has shown promising results for DHEA as a therapy by significantly 
increased 6-minuite walking tests and pulmonary haemodynamics (de La Roque et al., 
2012). 
 CYP1B1 and pulmonary hypertension 1.8.4
The fact that PAH is more common in women than in men has led to the hypothesis that 
estrogens, in particular 17β-E2, the main pre-menopausal hormone, may be facilitating the 
development and pathogenesis of PAH. One hypothesis is that estrogen metabolism is 
pathologically altered in disease. Increased CYP1B1 activity has been associated with the 
development of numerous cancers and cardiovascular diseases, as discussed previously. 
However, its contribution to the development and pathogenesis of PAH remains obscure. 
CYP1B1 expression is decreased by 10-fold in Epstein-Barr virus immortalized B 
lymphocytes harvested from patients with HPAH associated with a BMPR-2 mutation 
(West et al., 2008). In contrast, in female mice that over-express the human SERT gene 
and in hPASMCs derived from patients with IPAH, CYP1B1 expression is increased 
(White et al., 2011a). A genetic polymorphism in CYP1B1 (Asn453Ser; N453S), which 
is associated with an increased rate of degradation of CYP1B1 (Bandiera et al., 2005) is 
more common in patients with a BMPR-2 mutation without any evidence of PAH (Austin 
et al., 2009). This implicates that the activity of CYP1B1 is a requisite/second-hit factor 
for the development of PAH in patients harbouring a BMPR-2 mutation. Furthermore, in 
this cohort of patients the urinary 2-OHE1/16α-OHE1 ratio was lower compared to 
unaffected mutation carriers, suggesting that estrogen metabolism by this CYP1B1 
polymorphism yields increases in 16α-OHE1. Taken together, this suggests that CYP1B1 
may be a pathological mediator in PAH, yet the functional importance of CYP1B1 has 
never been critically evaluated. Despite paramount evidence that highlights a greater risk 
of PAH amongst females suggesting that a female component may be influencing disease 
pathogenesis, there is a paucity of investigation of estrogens and their metabolism in PAH. 
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  Aims 1.9
PAH is more common in women than in men (Badesch et al., 2010;Humbert et al., 
2006;Ling et al., 2012) and new insights suggest that estrogen metabolism may contribute 
to the pathogenesis of PAH. The principal aim of this research was therefore to investigate 
the role of estrogen metabolism, in particular by CYP1B1, on the development and 
pathogenesis of PAH. This was addressed by the following project aims: 
1. To functionally and molecularly characterise the impact of estrogen metabolism by 
CYP1B1 on the development of PH in vitro and in vivo 
2. To characterise the mechanisms that underlie CYP1B1 pathogenic activity in PH 
3. To develop a method to quantitatively measure estrogen metabolism in pulmonary 
vascular cells 
4. To determine the metabolic fate of 17β-E2 in hPASMCs from naïve cells and PAH-
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 Chemicals reagents and equipment 2.1
All chemical reagents were supplied by Sigma-Aldrich, Dorset, UK unless otherwise 
stated. All organic and aqueous solvents were supplied by Fisher Scientific Limited, 
Loughborough, UK. Materials for protein expression analysis and RNA expression were 
purchased from Invitrogen, Paisley, UK and Qiagen, UK, respectively unless otherwise 
stated. All materials used were of the highest grade obtainable. All cell culture plastics 
were provided by Corning (supplied by Fischer Scientific Limited, Loughborough, UK). 
 Animals 2.2
All experimental procedures were carried out in accordance with the United Kingdom 
Animal Procedures Act (1986) and with the "Guide for the Care and Use of Laboratory 
Animals" published by the US National Institutes of Health (NIH publication No. 85-23, 
revised 1996). All in vivo procedures were performed under the project license 60/4404 
(previously 60/3773) held by Professor Margaret MacLean at the University of Glasgow 
and under the personal license 60/12704 held by Anne Katrine Z. Johansen. All animals 
were maintained in the same environmental conditions and subject to a continuous 12 hour 
light/dark cycle and had access to fresh food and water ad libitum. Some animals were 
housed at the Central Research Facility at the University of Glasgow and others were 
housed in Professor Margaret MacLeans’ chamber suite. For genetically modified mice, 
tail samples were provided by the Central Research Facility for genotyping to confirm 
genetic background. 
 General experimental design 2.2.1
Where possible, animals were randomized into their respective study groups and studied 
blindly. Group identity was revealed after results had been analyzed. No mortalities were 
reported in any of the studies apart from the monocrotaline study, which have been 
summarized within the result section. 
 Cytochrome P450 1B1 knockout mice 2.2.2
Homozygote CYP1B1 knockout (CYP1B1-/-) mice were kindly provided by the National 
Institutes of Health/National Cancer Institute, Bethesda, USA. CYP1B1-/- mice were 
generated as described by Buters and colleagues (Buters et al., 1999). Briefly, a genomic 
clone of 10.5kb containing two of the three exons of murine CYP1B1 was generated using 
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a 1.7kb cassette. One of the exons was non-coding and the other two exons were targeted 
to disrupt the function of CYP1B1. The genomic clone was electroporated into embryonic 
stem cells, grown and transfected into blastocysts from C57BL/6 mice. These cells were 
then injected into psuedopregnant mice and bred with C57BL/6 to obtain CYP1B1-/- mice 
(Buters et al., 1999). Wild-type mice (C57BL/6) were purchased from Harlan Laboratories 
(Oxon, UK) and studied as controls. 
 Serotonin transporter overexpressing mice 2.2.3
Mice overexpressing the human serotonin transporter (SERT+ mice) were generated and 
kindly provided by Professor Tony Harmar from the University of Edinburgh. C57BL/6 x 
CBA wild-type mice were used to generate this mouse model. A 500kb yeast artificial 
chromosome (YAC35D8) was modified to contain the human SLC6A4 gene (encodes 
SERT) flanked by 150kb at the 5' and 300kb at the 3' region (Shen et al., 2000). A 
hemagglutinin epitope tag was incorporated into the yeast chromosome at the C-terminus 
of the SLC6A4 gene (Shen et al., 2000). The YAC clones were amplified and purified and 
injected into the pro-nuclei of fertilized eggs from C57BL/6 x CBA female mice to 
generate human SERT+ mice (Shen et al., 2000).  
 Models of pulmonary hypertension 2.3
Both the MCT and the hypoxic models of PH were studied. Whilst these “classical” animal 
models have and continue to contribute to our understanding of the molecular mechanisms 
that contribute to the pathobiology of the pulmonary hypertensive process, these models 
are generally no longer considered direct models of human PAH. Therefore, PH will be 
used when referring to animal models and PAH will be used when referring to human 
PAH. 
 Monocrotaline-induced pulmonary hypertension 2.3.1
10-16 male and female wistar rats (Harlan Laboratories, Oxon, UK) at 10-12 weeks old at 
termination procedure were studied per group. Where appropriate, rats were injected with 
the pneumotoxin, MCT pyrrole (Sigma-Aldrich, Dorset, UK). MCT was dissolved in 
1mol/L hydrogen chloride (HCl) at a concentration of 100 mg/mL, neutralized with 
1mol/L sodium hydroxide (NaOH), and diluted with sterile distilled water to 6 mg/mL. 
Rats were randomly subdivided to receive either vehicle or MCT at a dose of 60mg/kg by 
subcutaneous injection in the flank of the rat at day 0. All animals were weighed every day 
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and monitored for any signs of discomfort. Animals that were deemed unwell by the 
Central Research Facility staff were terminated by a schedule 1 procedure. 
2.3.1.1  2,3',4,5'-Tetramethoxystilbene study 
14 days post MCT injection animals were randomly allocated to receive either the highly 
potent and selective CYP1B1 inhibitor, TMS (Tocris, UK) at 3mg/kg/day or its vehicle 
(~4% (v/v) ethanol: distilled water) by intra-peritoneal injection for an additional 14 days. 
TMS was prepared freshly daily prior to use under sterile conditions. TMS was pre-
dissolved in 100% ethanol and diluted with distilled water to achieve 0.6mg per 1900µl 
solution. A 200g rat was injected with 1900µl of the drug solution and the volume was 
altered according to the weight of the animal to achieve a 3mg/kg dose. 
 Chronic hypobaric hypoxia 2.3.2
To study the effects of hypoxia on the cardiopulmonary unit, CYP1B1-/-, SERT+ and 
wild-type mice were exposed to 2 weeks of hypobaric hypoxia. On day 0, mice were 
placed into the hypobaric chamber and the pressure was gradually reduced to 750mbar 
(50mbar every 30 minutes) to allow for acclimatization. On day 1, the pressure was further 
reduced to 550mbar (50mbar every 30 minutes). This pressure is approximately equivalent 
to 10% oxygen, stimulating hypoxic pulmonary vasoconstriction in the lungs, which leads 
to the development of a moderate, yet consistent pulmonary hypertensive phenotype. 
Every 5 days, the chamber was brought back up to atmospheric pressure to replenish food 
and water and change caging (50mbar every 5 minutes). For dosing experiments, the 
chamber was brought to atmospheric pressure every day for a maximum of 30 minutes. 
Room temperature, humidity and the chamber pressure were monitored and recorded 
carefully throughout the entire study period. 
2.3.2.1 2,3',4,5'-Tetramethoxystilbene study in hypoxic pulmonary hypertension 
To assess the therapeutic viability of CYP1B1 in hypoxia-induced PH, 10-12 week old  
mice (Harlan Laboratories, Oxon, UK) were administered TMS (3mg/kg/day) or vehicle 
(~4% (v/v) ethanol: distilled water) via intra-peritoneal injection for the 14 day duration of 
chronic hypoxia exposure. All solutions were prepared fresh daily under sterile conditions. 
TMS was pre-dissolved in ethanol and diluted in distilled water to 0.06mg per 200µl. 
200µl was injected by intra-peritoneal injection to achieve a 3mg/kg dose in a 20g mouse 
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and adjusted accordingly. Mice maintained under normoxic conditions were studied as 
controls. 
2.3.2.2 2,3',4,5'-Tetramethoxystilbene study in SERT+ pulmonary hypertension 
Female SERT+ mice develop a robust PH phenotype at 5 months of age (MacLean et al., 
2004;White et al., 2011b). To assess the contribution of CYP1B1 to SERT+ PH, 5-6 
month old female SERT+ mice (normoxic and hypoxic) were administered TMS 
(1.5mg/kg/day) or vehicle (~4% (v/v) ethanol: distilled water) via intra-peritoneal injection 
for 14 days. This was studied in both normoxic and hypoxic conditions. All solutions were 
prepared fresh daily under sterile conditions. TMS was pre-dissolved in ethanol and diluted 
in distilled water to achieve a 0.03mg per 100µl solution. 100µl was injected by intra-
peritoneal injection to achieve a 1.5mg/kg dose in a 20g mouse and adjusted accordingly. 
2.3.2.3 Effect of CYP1B1 metabolites in pulmonary hypertension 
Female and male 10- to 12-week-old C57BL/6 littermate mice were administered 16α-
hydroxyestrone (16α-OHE1; Steraloids, US; 1.5 mg/kg/day) or vehicle (~4% ethanol v/v 
distilled H2O) daily via intraperitoneal injection for 28 days before the assessment of PH. 
In a separate study, female 10- to 12-week-old C57BL/6 littermate mice were administered 
4-hydroxyestradiol (4-OHE2; Steraloids, US; 1.5 mg/kg/day) or vehicle (~4% ethanol v/v 
distilled H2O) daily via intraperitoneal injection for 28 days before the assessment of PH 
 Assessment of pulmonary hypertension 2.4
 Anaesthesia 2.4.1
Mice were anaesthetised in an anaesthetic box with 3% (v/v) isoflurane (Abbot 
Laboratories, Berkshire, UK) supplemented with oxygen at a flow rate of 0.5L/min to 
assist in the flow of the anaesthetic gas. Mice were immediately weighed and transferred to 
a facemask continuously administering ~1.5% (v/v) isoflurane supplemented with oxygen 
at a flow rate of 0.5L/min. The required depth of anaesthesia was confirmed by the absence 
of a hind-limb or tail reflex. Throughout the procedure, anaesthesia was carefully 
monitored to ensure that the depth of anaesthesia neither became too shallow or too deep. 
This was monitored by continuous assessment of reflexes and observation of heart rate and 
breathing rates.  
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 Systemic arterial pressure 2.4.2
Once the required level of anaesthesia had been achieved, an incision was made in the skin 
at the ventral neck to expose the first layer of muscle which was carefully teased away to 
reveal the trachea. The left common carotid artery is located dorsal and slightly to the left 
of the trachea and is identifiable as a large bright red pulsating vessel. The artery was 
isolated from the vagus nerve which has a white appearance and runs alongside the vessel 
and cleaned up of any tissue by carefully manipulating the forceps alongside the vessel. 
Once isolated, surgical non-sterile nylon black monofilament suture size 5-0 (Harvard 
Apparatus, Massachusetts, USA) was placed underneath the artery and tied at the proximal 
end of the artery with a single knot, pulled back and taped down to expose an extended 
arterial length. A second piece of suture was placed underneath the artery and left untied. 
Thereafter, the right ventricular pressure (RVP; described below) was obtained. Once a 
steady reading of at least 5 minutes had been obtained for the RVSP, the systemic arterial 
pressure (SAP; Figure 2-1) was obtained. Using a microsurgical clip (Fine Science Tools, 
Heidelberg, Germany, FST#18055-04), the vessel was carefully clamped at the proximal 
end of the carotid artery. A small incision was made at the distal end of the artery just 
below where the suture had been tied. Using forceps, an opening was manipulated to allow 
a smooth insertion of a calibrated fluid-filled micro-cannula (Harvard Apparatus, 
Massachusetts, USA) which was advanced to the base of the clip. Using the second piece 
of suture, a knot was tied around the cannula and the artery. At this point, the three-way tap 
was turned on to allow the flow of heparinised saline (Heparin Sodium, Wockhardt, UK; 















Figure 2-1 Representative mean systemic arterial pressures 
Systemic arterial pressure (SAP; mmHg) taken from a 5-month old normoxic female wild-type 
mouse. 
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 Right ventricular pressure 2.4.3
2.4.3.1 In mice 
RVP were measured by diaphragmatic catheterisation in mice. It is technically challenging 
to accurately obtain PAP by this method, and therefore RVP were taken as an indirect 
assessment of the PAP. After isolating and tying off the left common carotid artery, an 
incision was made right above the sternum. Heparinised saline (20units/mL) was flushed 
through the line and the attached calibrated 25mm gauge needle to ensure that there were 
no air bubbles in the system that may obscure the result. The needle was then advanced 
underneath the sternum, a couple of mm to the right hand-side at approximately a 100° 
angle using a micromanipulator (Warner Instruments, Connecticut, USA). Pressure 
recordings were monitored carefully to estimate the location of the needle. Initially, a drop 
in pressure was observed as the needle advances through the diaphragm and into the 
abdominal cavity. The right heart was then catheterised with the needle which should 
produce a reading that has even oscillations, with diastolic values of near zero (Figure 2-2). 
Every few seconds, breathing artefacts will appear in the trace (these were not included in 
the analysis). An upward shift of the diastolic and systolic values is typically a pressure 
that is observed in the left ventricle. If the needle is resting against the septum of the heart, 
this can sometimes cause an ambiguous reading. Therefore, if such a pressure was 
obtained, the needle was first carefully moved slightly to the left. If this did not improve 
the pressure reading, it is a good indication that the needle had entered the left side of the 
heart as opposed to the right.  
2.4.3.2 In rats 
In rats, anaesthesia was maintained at ~2% (v/v) isoflurane supplemented with oxygen at a 
flow rate of 1L/min. To maintain a constant body temperature, rats were placed on a heat 
mat throughout the entire procedure and their temperature was monitored with a 
temperature probe. Systemic arterial pressures (SAP) were obtained by microcannulation 
of the left common carotid artery, as previously described prior to cannulation of the right 
ventricle. Due to the larger size of the artery surgical non-sterile nylon black monofilament 
suture size 4-0 (Harvard Apparatus, Massachusetts, USA) was used. RVP were obtained 
by catheterisation of the right ventricle via the right jugular vein using a fluid-filled 
cannula (with heparin; 20units/ml). 
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All pressure readings were obtained with Biopac Systems MP35 using a SS132 Blood 
pressure transducer (Biopac Systems Inc, California, USA). Blood pressure traces were 
analysed using BSL Pro 3.7 (Biopac Systems Inc, California, USA). 
 
Figure 2-2 Representative right ventricular pressure 
A representative trace of right ventricular pressure (RVP; mmHg) obtained by transdiaphragmatic 
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 Tissue harvest 2.4.4
Immediately following sacrifice, the heart and lungs were gently flushed with ice-cold 
Dulbecco’s phosphate buffered saline (DPBS) solution (Sigma-Aldrich, Dorset, UK) 
through the right ventricle. For molecular analysis, the lobes of the right lung were flash 
frozen in liquid nitrogen (polymerase chain reaction (PCR), protein and ELISA) and stored 
at -80ºC. For experiments where small vessel wire myography was performed, a lung lobe 
was retained for immunohistochemical analysis and the left lung was used for myography. 
For other experiments, the left lung was gently inflated with ~0.5ml (in mice) 10% (v/v) 
neutral buffered formalin (NBF; 90% (v/v) distilled water, 10% (v/v) formalin, 33mmol/L 
monosodium phosphate (NaH2PO4), 45mmol/L disodium phosphate (Na2HPO4)) and kept 
under gentle agitation in 10% NBF for a minimum of 4 hours prior to paraffin embedding 
(see section 2.6.1). Urine samples were collected by puncture of the bladder with BD 
Micro-Fine™ needle (BD, Oxford, UK) and immediately snap frozen. The uterus and 
ovaries were isolated and excised for assessment of dry weights and subsequently snap 
frozen. 
Other tissues were collected for the tissue repository (including kidneys, spleen and liver). 
Blood was collected in 100µL heparin sodium DPBS (10units of heparin). Cells were 
removed from the blood by centrifugation for 10 minutes at 2,000xg in a chilled centrifuge 
(4ºC) to obtain plasma. The plasma supernatant was pipetted into a chilled eppendorf and 
snap frozen. 
 16α-hydroxyestrone urinary analysis 2.4.5
16α-OHE1 concentration in urine samples was quantified by an enzyme linked 
immunosorbent assay (ELISA) (ESTRAMET 2/16, Demeditec Diagnostics, Germany) as 
per manufacturers’ instructions. Briefly, 16α-OHE1 was assayed with specific alkaline-
phosphatase–labelled conjugation, and quantification was determined by 405-nm 
spectrophotometry analysis (SpectraMax M2, Molecular Devices, US). 
 Right ventricular hypertrophy 2.4.6
RVH was assessed in all animal studies using Fultons’ Index (Fulton et al., 1952), by 
expressing the dry weight of the right ventricle over the dry weight of the left ventricle + 
septum (RV/LV+S). 
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 Small vessel wire myography 2.5
2.5.1.1 Isolation of the intra-pulmonary artery 
The main pulmonary artery branches into the left and right extra-pulmonary arteries from 
which the intra-pulmonary arteries descend (~200µm). The dorsal surface of the lung was 
carefully pinned down facing up. From this view, the hilum where the primary bronchi and 
pulmonary artery enter the lungs is visible. The pulmonary artery runs posterior to the 
bronchi along its length. The pulmonary artery was carefully excised from any peri-
adventitial tissue and cleaned up of parenchymal tissue. 
2.5.1.2 Vessel mounting onto a myograph 
The vessel bath chamber of each individual myograph unit (Multi Wire Myograph System 
– 610M; Danish Myo Technology A/S, Aarhus, Denmark) was filled with Krebs-Henseleit 
buffer (pH 7.4, mmol/L deionised water: 119 sodium chloride (NaCl),  4.7 potassium 
chloride (KCl), 1.2 magnesium sulphate (MgSO4), 25 sodium bicarbonate (NaHCO3), 1.2 
monopotassium phosphate (KH2PO4), 1.25 calcium chloride (CaCl2) and 11mM D-
glucose). Krebs-Henseleit solution was always prepared fresh on the day of isolation of 
vascular tissues. To obtain the optimal pH, the solution was oxygenated by a gas mixture 
containing 95% oxygen and 5% carbon dioxide. The myograph chamber was set to 37ºC 
and equilibrated and maintained with a constant gas flow of 16% oxygen, 5% carbon 
dioxide and 79% nitrogen. This gas composition was selected as it reflects the partial 
pressure of the lungs. Freshly isolated pulmonary arteries were maintained in Krebs-
Henseleit buffer and cut into ring segments of 2mm. The vessel was then cannulated with 
two pieces of 40μm diameter stainless steel wire (Danish Myo Technology A/S, Aarhus, 
Denmark) carefully to prevent damage to the endothelium. The vessel was mounted into 
the myograph chamber and secured in place and left to equilibrate in the buffer for 20 
minutes. 
2.5.1.3 Pressure Standardization 
Using the micrometer on the myograph, the pressure applied to the vessel was altered to 
mimic the transmural pressure present in vivo. All myography experiments performed were 
done in animals where RVSPs had been obtained and the pressure was set accordingly to 
this. To calculate the transmural pressure, P, the following equation was used (Mulvany & 
Halpern, 1977): 
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P = 2π x wall tension (t)/internal vessel circumference (L) 
t = force (f)/2x vessel length (v) 
L = (Xi– Xo) x 2 + 205.6; where Xi = applied tension; Xo=relaxed tension 
P/0.13333 =pressure in mmHg (0.1333kPa = 1mmHg) 
The internal circumference when the wires are touching is equal to 2 + π x 40µm (wire 
diameter size) = 205.6. 
Once the required transmural pressure had been achieved by gradual increments, the artery 
was left to stabilize for 30 minutes. The pulmonary arteries were contracted with 50nM 
KCl twice, with a wash step after the contraction had plateaued. Cumulative concentration 
response curves were then determined for serotonin (Sigma-Aldrich, Dorset, UK) at bath 
concentrations from 1nM to 100µM, incrementing in half log doses. The contraction to 
serotonin is represented as a % of the contractile response to the second KCl contractile 
response. 
All myography data was recorded and analysed using MyoDaq 20 (Danish Myo 
Technology A/S, Aarhus, Denmark). 




 Tissue Fixation and Paraffin Embedding  2.6.1
Tissue samples were immediately placed in NBF and placed on a shaker under gentle 
agitation for a minimum of 4 hours, depending on the size of the tissue. Formalin-fixed 
paraffin embedded tissue is optimum to help reduce background caused by expression of 
endogenous biotins. After fixation, tissue samples were dehydrated through a water-
histoclear gradient and then embedded in wax in a Citadel 1000 tissue processor (Thermo 
Scientific, UK), summarised in Table 2-1. Immediately prior to cutting for section-
mounting onto slides, tissue blocks were placed in -20˚C to help solidify the wax. Sections 
were cut at 3µm using a microtome (Leica RM2125, Leica Microsystems, Milton Keynes, 
UK), placed in water at 37˚C to gently melt the wax and then placed onto a polylysine-
coated slide (Sakura Finetek, Netherlands) to improve tissue adherence. For particularly 
sensitive antibodies, sections were cut, left to dry and then stored in the fridge and used 
within one week. For more commonly used antibodies, such as α-smooth muscle actin 
(αSMA), sections could be stored at room temperature for several months prior to staining. 
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Table 2-1 Process for paraffin-embedding small animal tissues 
Condition Small Tissue Samples  Larger Tissue Samples 
10% NBF 4 hours 8 hours 
70% Ethanol: Water 15 minutes 45 minutes 
80% Ethanol: Water 15 minutes 45 minutes 
95% Ethanol: Water 25 minutes 45 minutes 
95% Ethanol: Water 25 minutes 1 hour 
100% Ethanol: Water 15 minutes 1 hour 
100% Ethanol: Water 15 minutes 1 hour 
100% Ethanol: Water 15 minutes 1 hour 
Histoclear 30 minutes 1 hour 
Histoclear 30 minutes 1 hour 
Paraffin 30 minutes 1 hour 
Paraffin 30 minutes 1 hour 
Samples were maintained for a minimum of 4 hours in 10% neutral buffered formalin (NBF). 
Samples were however routinely maintained in NBF overnight. 
.




Sections were dewaxed in xylene for 30 minutes and rehydrated through an alcohol-water 
gradient (100% ethanol for 10 minutes, 100% ethanol for 5 minutes, 90% ethanol for 2 
minutes and 70% for 2 minutes). Sections were then washed in running water for 10 
minutes to ensure adequate rehydration. Antigen retrieval was performed using 10mM 
citric acid buffer (Citric acid monohydride dissolved in distilled water; Sigma-Aldrich, 
Dorset, UK), adjusted to pH 6.0 with 5M sodium hydroxide (NaOH), in a microwave for 4 
x 5 minutes and then left to cool at room temperature for 20 minutes. Formalin fixing of 
tissue can cause cross-linking of proteins which can mask the antigen site of interest and 
this step is therefore essential to prevent masking of proteins. The advantage of this type of 
fixing is that it preserves a good cellular morphology. Sections were then washed in 
running water for 10 minutes before blocking for 30 minutes in 3% (w/v) hydrogen 
peroxide solution (Sigma, Dorset, UK) to block endogenous peroxidase activity, which can 
be present at high levels in tissues and would yield a high background and non-specific 
staining. Sections were washed in running water before blocking with ready-to-use 2.5% 
(v/v) normal horse serum (ImmPRESS kit, Vector Labs, Peterborough, UK) for 1 hour at 
room temperature in a humidified chamber. Sections were then incubated with the relevant 
primary antibody overnight at 4ºC in a humidified chamber (see Table 2-2 for details on 
experimental conditions). The primary antibody diluent consisted of 1% (w/v) bovine 
serum albumin (BSA) in 10mM phosphate buffered saline (PBS) pH 7.4 (made using 
Sigma-Aldrich (Dorset, UK) tablets (2.7 mmol/L KCl, 137 mmol/L NaCl pH; 1 tablet 
dissolved in 200mL distilled water). The primary antibody was washed off in 3 x 10 
minute washes in tris-buffered saline (TBS) pH 8.4 (50mmol/L Tris, 150mmol/L NaCl) 
before incubation with an anti-rabbit Ig peroxidase polymer secondary antibody 
(ImmPRESS Kit, Vector Labs, Peterborough, UK) for 1 hour at room temperature. Excess 
secondary antibody was washed off in 3 x 10 minute washes with TBS. Positive 
immunolocalization was then visualised with a suitable chromagen for 2-15 minutes under 
the microscope (either 3,3’-diaminobenzidine (DAB) or Vector® VIP substrate kits, 
Vector Labs, Peterborough, UK). The reaction was terminated by immersion into running 
water once a positive signal had occurred with minimal background staining. Sections 
were then dehydrated through a water-ethanol gradient (70%, 90%, and 2 x 100% ethanol 
v/v) for 5 minutes in each solution, followed by 2 x 5 minutes in histo-clear (National 
Diagnostics, Georgia, USA) before mounting of slide sections on to cover slips using 
Tissue-Tek (Sakura Finetek, Netherlands). Staining was visualised and photographed using 
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a Zeiss Imager M.1 AX10 and axiovision Rel. 4.8 (Carl Zeiss Microscophy Ltd, 
Cambridge, UK). 
2.6.2.1 Haematoxylin and eosin counter-staining 
Rat sections were counter-stained with haematoxylin (nuclear stain) and eosin (cytoplasm 
and collagen) prior to dehydration and embedding. Sections were immersed in 
haematoxylin for 5 minutes and then rinsed in running water. Sections were differentiated 
in 1% acid-alcohol to remove excess stain. To enhance the blue stain, sections were placed 
into luke warm water followed by 3 minutes in eosin. Sections were rinsed in running tap 
water and then dehydrated through an ethanol gradient before mounting, as described 
above. 
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Table 2-2 Antibody manufacturers and optimal concentrations for immunohistochemistry 
Antibody Supplier Antibody Dilution 
CYP1B1 (rabbit pAb) Abcam-ab33586 1µg/mL 
α-SMA (rabbit pAb) Abcam-ab5694 0.4µg/mL 
vWF (rabbit pAb) Dako-A0082 3.1µg/mL 
To check for non-specific binding rabbit immunoglobulin G (IgG) were used at the same 
concentration as the primary antibody. All antibodies were polyclonal (pAb) and raised in rabbits. 
The secondary used for all immunohistochemistry experiments was therefore anti-rabbit. αSMA, α-
smooth muscle cell actin; vWF, von willebrand factor. 
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2.6.2.2 Quantitative Analysis of CYP1B1 Immunoreactivity 
Positive CYP1B1 immunoreactivity in murine and human pulmonary arteries was semi-
quantified by colorimetric analysis (MetaMorph, version 6.1, Molecular Devices, USA). 
The average pixel intensity of each image correlated to a greyscale range of 0 (black) to 
255 (white), with intermediate intensities being assigned an appropriate grey level.  
Preliminary studies were carried in randomly selected arteries to determine the pixel 
intensity range that corresponded with positive CYP1B1 staining. The colour threshold 
was selected to detect pixel intensity between 0 and 156 as representative of CYP1B1 
staining. Pulmonary arteries <80µm in mice and <200μm in human were selected and 
specifically analysed. The percentage threshold area detected was then expressed as the 
percentage of positive CYP1B1 immunoreactivity within the vessel wall. For both human 
and murine lung sections, a total of 15 pulmonary arteries from each lung were assessed. 
All immunoquantification was performed by Dr. Kirsty Mair. 
 Pulmonary vascular remodeling 2.6.3
Pulmonary vascular remodeling was assessed in 3µm sagittal lung sections stained with 
elastic picro-sirius red and pulmonary arteries <80µm external diameter was 
microscopically assessed for degree of muscularisation in a blinded fashion. The number 
of remodeled arteries was expressed over the total number of arteries present within the 
section and expressed as a percentage. To visualise the degree of muscularisation, 3µm 
sagittal lung sections were stained with α-SMA (Abcam, Cambridge, UK) as described 
above (see section 2.6.2).  
2.6.3.1 Elastic picro-sirius red staining 
Sections were dewaxed in histo-clear for 20 minutes and rehydrated through an alcohol-
water gradient (100% ethanol for 5 minutes, 100% ethanol for 5 minutes, 90% ethanol for 
minutes and 70% for 5 minutes). Sections were then washed in running water for 5 minutes 
to ensure adequate rehydration. The tissue section was then immersed into a 0.5% (w/v) 
potassium permanganate (KMNO4) solution for 5 minutes for oxidation to enhance 
staining. The sections were then rinsed in water and immersed into 1% (w/v) oxalic acid to 
decolorize the sections from the KMNO4 followed by an additional wash step. Sections 
were rinsed in 95% ethanol and then placed in Millers Elastin Stain (Thermo Scientific, 
UK) for 2 hours. Excess stain was removed by rinsing in 95% ethanol and then running tap 
water. Sections were counterstained with picro-sirius red for 3 minutes and then briefly 
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rinsed in water. Sections were dehydrated rapidly through a water-ethanol gradient (70% 
ethanol for 1 minute, 90% ethanol for 1 minute, 2 x 100% ethanol for 5 minutes each and 
then 2 x histo-clear for 5 minutes each. Sections were mounted onto cover slips as 
previously described. Staining was visualised using a Zeiss Imager M.1 AX10. The 
staining results in a black appearance of elastic fibres, a deep red colour in collagen and the 
cytoplasm, muscular cells, red blood cells and fibrin appear yellow.  
 Sodium dodecyl sulphate – polyacrylamide gel 2.7
electrophoresis 
 Protein solubilization 2.7.1
All tissue samples were homogenized in ice-cold 1% (v/v) lauryl maltoside (LM) buffer 
(Abcam, Cambridge, UK) in DPBS using a hand-held ultrasonic tissue homogenizer 
(Misonix XL-2000, Fisher Scientific, UK). Samples were kept on ice for 30 minutes to 
encourage protein solubilization, followed by ice-sonication. Samples were centrifuged to 
remove cellular debris at 10,000xg for 10 minutes at 4ºC and the supernatant was collected 
for protein estimation by a bicinchoninic acid (BCA) protein assay. 
 Bicinchoninic acid protein assay 2.7.2
Protein concentrations were determined using a BCA protein assay (Thermo Scientific, 
UK). The standard solutions ranged from 0-2mg/ml bovine serum albumin (BSA) solution, 
diluted in 1% (v/v) LM buffer in DPBS as required. In this reaction, copper in the reagent 
mix is reduced by the protein which reacts with the BCA to form a purple solution 
(greenpurple). Therefore, the more protein there is, the more intense the purple colour 
appears. Both the standards and the samples of interest were loaded onto a clear 96 well 
plate. Reagent A and Reagent B were mixed in the ratio 4.9ml to 0.1ml, respectively. 
200µl of this mixture was added to each well and left on a gentle shaker for 20-30mins. 
The plate was read at 562 nm using a POLARstar OPTIMA microplate reader (BMG 
Labtech, Germany). A representative standard curve is shown in Figure 2-3. 




Figure 2-3 A representative bicinchoninic acid protein assay standard curve 
A representative standard curve obtained for BSA solution (0-2mg/ml) using a bicinchoninic acid 
(BCA) protein assay. Samples performed in duplicate. 
 
Standard Curve
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 Western blotting 2.7.3
NuPAGE reducing agent was added to protein samples together with a sample buffer 
containing a blue dye for loading visualisation (NuPAGE lithium dodecyl sulfate sample 
buffer). Samples were heated for 15 minutes at 70°C in a heat block. This ensures adequate 
denaturing and reducing of protein disulphide bonds effectively exposing proteins to allow 
for efficient antibody binding. Samples were loaded onto Novex NuPAGE 4-12% 
polyacrylamide gels and separated according to protein size by a constant flow of an 
electrical current at 150volts in NuPAGE MOPS running buffer containing 1% (v/v) 
antioxidant using electrophoresis. See blue pre-stained protein standard was used as the 
protein ladder to determine approximate protein size. Once adequately separated, the 
proteins were transferred on to a polyvinylidene difluoride (PVDF) membrane (Millipore 
Corporation, Massachusetts, USA), which had been pre-activated by emersion in 100% 
methanol. This was performed using wet electroblotting in a transfer tank containing a 
transfer buffer consisting of 5% (v/v) NuPAGE transfer buffer, 20% (v/v) methanol, and 
1% (v/v) antioxidant prepared in distilled water. This was run at 30volts for 2 hours to 
allow for sufficient transfer of proteins onto the PVDF membrane. To check for transfer 
efficiency, blots were immersed in Ponseau S solution (0.1% (w/v) Ponseau S in 5% (v/v) 
acetic acid). This stains all proteins to allow for visualisation. This was subsequently 
washed off with water, reactivated with methanol and the membranes were transferred into 
a 5% (w/v) non-fat milk solution (marvel) in 0.1% (v/v) Tween 20 (Fisher Scientific, 
Loughborough, UK) in TBS (TBST: pH 7.6) to block the membrane to prevent non-
specific binding of the antibody for 1 hour at room temperature. Blots were rinsed in TBST 
and then incubated with the primary antibody overnight in either 5% (w/v) marvel in TBST 
or 5% BSA in TBST overnight at 4°C (See Table 2-3 for details). The unbound primary 
antibody was then washed off the blot by 3 consecutive washes in TBST each lasting 10 
minutes. The corresponding secondary antibody to which the first antibody was raised in 
(see Table 2-3 for details), linked with horseradish peroxidase (HRP) was then applied to 
the membrane at a 1:5000 dilution in 5% marvel TBST for 1 hour at room temperature 
with gentle rocking. The membrane was washed 3 times in TBST for ten minutes and 
antibody binding was detected by enhanced chemiluminescent (ECL) using Pierce ECL 
(Thermo Scientific, UK) or Immobilon western chemiluminescent HRP substrate (Merck 
Millipore, Massachusetts, USA) and developed onto film. The membranes were then 
washed and stripped using Restore western blot stripping buffer (Thermo Scientific, UK) 
and re-probed with a loading control (Glyceraldehyde 3-phosphate dehydrogenase, 
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GAPDH). For quantification, the densitometry was analysed using TotalLab 1D gel 
analysis (TotalLab, UK). 
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Table 2-3 Experimental details for antibodies used for protein analysis by western blotting 
Antibody Supplier  Antibody dilution human Detected band size 
CYP1B1 (rabbit pAb) Abcam-
ab33586 
0.2µg/mL in 5% non-fat milk 61kDa 
Aromatase (rabbit pAb) Abcam-
ab69653 
1µg/mL in 5% non-fat milk 58kDa 
COMT Sigma-
HPA001169 
1µg/mL in 5% non-fat milk 28kDa 
17β-HSD1 HPA021032 1µg/mL in 5% non-fat milk 35kDa 
GAPDH (mouse mAb) Abcam-
ab9484 
0.2µg/mL in 5% non-fat milk 40kDa 
Experimental details of antibodies used for protein analysis by western blotting. All antibodies were 
prepared in 5% non-fat milk in 0.1% tween tris buffered saline. A dilution factor is provided where 
the antibody concentration is not supplied by the manufacturer. Specified next to the primary 
antibody is the species that the antibody was raised in. pAb, polyclonal antibody; mAb, monoclonal 
antibody; GAPDH (loading control), glyceraldehyde-3-phosphate dehydrogenase. 
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 RNA analysis 2.8
 RNA extraction 2.8.1
To extract RNA from tissue samples, lysis was performed using QIAzol lysis reagent and 
extracted with the miRNEASY extraction kit according to manufacturer’s instructions. For 
both cell extractions and tissue extractions 700μl QIAzol was used. Where required, tissues 
were homogenised with a TissueLyser II using stainless steel beads for a total of 2 minutes, 
with 30 second intervals every 30 seconds (to prevent overheating of the samples risking 
RNA degradation). Samples were left at bench top for 5 minutes to promote dissociation of 
nucleoprotein complexes. To extract the RNA, 140μl of high grade chloroform was added 
and shaken vigorously. Samples were left for a further 3 minutes to encourage sample 
separation of RNA from DNA, proteins and lipids and then centrifuged at 12,000xg for 15 
minutes at 4ºC. The upper aqueous layer formed contains the RNA which was carefully 
transferred into a 1.5ml eppendorf and the remaining products were discarded. The RNA 
suspension is then precipitated with 1.5 x volumes of 100% high grade RNA-free ethanol 
and mixed by pipetting the mixture up and down. Half the sample is transferred into a spin 
column, which is provided in the extraction kit. The column contains a silica membrane 
that binds the RNA from the sample. The sample was centrifuged at 8,000xg for 15 
seconds at room temperature and the resulting elute was discarded and the process was 
repeated with the remaining sample. The captured RNA on the membrane is then washed 
with RWT buffer. To ensure adequate clean-up of contaminating DNA, DNase was added 
to the membrane and left at room temperature for 15 minutes. The sample was then washed 
again with RWT buffer followed by a wash with RPE buffer. All washes were removed by 
centrifugation at 8,000xg for 15 seconds at room temperature. The spin column was then 
transferred into a new 1.5ml eppendorf. 30µl of RNase free water was pipetted directly 
onto the RNA-enriched membrane and eluted by centrifugation for 1 minute at 8,000xg. 
The isolated samples were immediately transferred to ice. To determine RNA 
concentrations and purity, samples were analysed by a NanoDrop, ND-1000 
spectrophotometer (Thermo Scientific, UK) prior to storage in -80ºC. The NanoDrop 
measures the absorbance of a sample. RNA absorbs light at a wavelength of 260nm, whilst 
proteins absorb at a wavelength of 280nm. Thus the purity of the sample can be determined 
by expressing the absorbance at 260nm/280nm. All samples analysed had a 260/280 ratio 
of ~2. 
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 Reverse transcription 2.8.2
Extracted RNA samples were reverse transcribed with TaqMan® reverse transcription 
reagents (Life Technologies, Paisley, UK) as per manufacturers’ instructions. 1µg RNA 
was transcribed per sample in a cocktail of RT-buffer, 25mM magnesium chloride 
(MgCl2), deoxynucleotide triphosphates (dNTPs), random hexamers, RNase inhibitors and 
Multiscribe. Reverse transcription was performed using the Veriti® Thermal Cycler (Life 
Technologies, Paisley, UK) under the following cycling conditions: 10 minutes at 25ºC 
(maximised primer RNA template binding), 30 minutes at 48ºC for reverse transcription 
and 5 minutes at 95ºC to deactivate reverse transcription. 
 Quantitative real time-polymerase chain reactions 2.8.3
Gene expression was determined using TaqMan® mastermix and primers for mouse 
cyp1b1 (Mm00487229_m1) and normalised to β2-microglobulin (Mm00437762_m1). 
Samples were analysed using the ViiA7™ Real-Time PCR System (Life Technologies, 
Paisley, UK) with the following cycling conditions: 50ºC for 2 minutes to activate uracil N 
glycosylase (degrades DNA), 95ºC for 10 minutes to activate DNA polymerase followed 
by 50 cycles of 95ºC for 15 seconds for denaturation and 60ºC for annealing and extension. 
 Cell culture 2.9
 Human pulmonary arterial smooth muscle cells 2.9.1
HPASMCs were generated at the University of Cambridge and kindly provided by 
Professor Nicholas W. Morrell (University of Cambridge). HPASMCs were explanted 
from the distal pulmonary microvasculature (vessels with <1mm external diameter) from 
subjects with no reported presence of PH and patients with either HPAH or IPAH. Control 
samples were obtained from unused donor tissues. PAH hPASMCs were obtained at lung 
or heart-lung transplantations. Both male and female samples were used in these studies as 
specified within text. The smooth muscle cell phenotype was confirmed by positive α-
SMA staining by immunofluorescence. All tissue culture experiments were carried out 
under sterile conditions in a class II laminar flow hood. 
Distal hPASMCs were isolated as previously described by either microdissection or 
magnetic isolation (Wharton et al., 2000) and provided by Professor Nicholas Morrell 
(University of Cambridge). Samples were stored in liquid nitrogen facilities in 10% 
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dimethyl sulfoxide (DMSO) (v/v) in 10% (v/v) fetal bovine serum (FBS) Dulbecco’s 
modified eagle medium (DMEM). DMSO is a cryoprotectant that aids in reducing cell 
death during the slow-freezing process to liquid nitrogen (-196˚C). HPASMCs brought up 
from liquid nitrogen were kept on dry ice before rapidly defrosting the cells by dipping the 
bottom part of the vial into a 37˚C water bath. Once the contents in the vial had thawed, the 
exterior of the vial was wiped with 70% ethanol to prevent contamination. Even dispersion 
of the cells was ensured by pipetting the suspension up and down. To determine the 
number of viable cells present, 20µL of the cell suspension was diluted in an equal volume 
of Trypan Blue 0.4% solution (Sigma-Aldrich, Dorset, UK) and counted using a 
haemocytometer, counting each 16 squares in the four different corners to obtain an 
average. Trypan blue detects cell viability as viable cells do not absorb the dye, whilst dead 
cells are permeable to the dye and appear a dark blue colour. The haemocytometer is 
designed so that the number of cells in one set of 16 squares is equivalent to the number of 
cells x 10
4
/mL. Cells were diluted in 10% FBS (v/v; Sera Laboratories International, West 
Sussex, UK) 1% antibiotic antimycotic (AA) DMEM at the required cell density. Cells 
were plated at a density of 10,000 cells per cm
3
 in a T75 flask. Cells were then incubated at 
37˚C, 5% CO2, 95% air humidified cell culture incubator. Cells were left to adhere for a 
minimum of 24 hours and thereafter fed fresh media every 24 or 48 hours. DMEM 
contains phenol red, a pH indicator which progresses from a red colour to a yellow colour 
as the pH of the medium decreases which can be a result of a bacterial infection, cellular 
death or more commonly just a gradual reduction in pH in response to waste products 
released from the cells. All cell culture medium contained 1% (v/v) AA (10,000 unit’s 
penicillin, 10 mg streptomycin and 25μg amphotericin B per mL). Penicillin prevents 
bacterial cell growth by inhibiting cell wall synthesis. Streptomycin is a bacterial protein 
synthesis inhibitor and amphotericin B is an anti-fungal agent. 
2.9.1.1 Sub-culturing of human pulmonary arterial smooth muscle cells 
Cells were grown until near confluency and sub-cultured for further experiments and 
studied between passages 3 and passages 8. The cell culture medium was aspirated from 
the flasks and washed twice with sterile DPBS. 2mL of 0.25% trypsin/EDTA solution 
(0.1% (w/v) EDTA in PBS, Life Technologies, Paisley, UK) was added to the flask and 
swirled to distribute the solution over the entire surface of the flask. Trypsin cleaves 
proteins, thereby detaching them from the flask. The flask is returned to the cell culture 
incubator for approximately 3 minutes until all of the cells have developed a round 
morphology, whereby the flask is gently tapped to dislodge the cells. Immediately, 8mLs 
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of fresh 10% FBS DMEM was added to the flask to terminate the effects of trypsin. Cells 
were sub-cultured into 6 well plates at a density of 7,500 to 10,000 cells per cm
2
.The cell 
culture medium was replaced the following day and then every 24 or 48 hours after.  All 
cells were grown to the required level of confluency for subsequent experiments prior to 
cell-cycle synchronisation by serum deprivation in 0.2% charcoal-stripped (CS)-FBS in 
phenol-red free (PRF) DMEM for 24 hours. The cell culture medium was replenished after 
24 hours and the relevant agonists or antagonists were added to the wells for cell growth 
assays. 
 
Figure 2-4 Distal human pulmonary arterial smooth muscle cell morphology 
Microphotograph of distal female control human pulmonary arterial smooth muscle cells grown in a 
96 well culture dish. 
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 Charcoal-stripped fetal bovine serum  2.9.2
Endogenous estrogens present in FBS were removed by charcoal stripping. Dextran-
activated charcoal selectively removes non-polar components from serum including 
hormones. Dextran-coated charcoal (Sigma-Aldrich, Dorset, UK) was added to FBS at a 
concentration of 1g/100mL and left at 4ºC under gentle agitation. Samples were 
subsequently centrifuged at 1,811xg at 4ºC for 30 minutes. The stripped serum was 
decanted and filtered through a 0.22µm filter. This process was repeated and samples were 
aliquoted and frozen until use. Successful removal of 17β-E2 was determined by a 
competitive based immunoassay (Cayman Chemical, Michigan, USA; see section 2.12). 
This serum was used in all cell culture experiments. 
 
Figure 2-5 Removal of 17β-estradiol from foetal bovine serum 
17β-estradiol (17β-E2) was removed from foetal bovine serum (FBS) by charcoal stripping twice 
with dextran-coated charcoal. Samples were filtered to remove charcoal from samples with a 
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 Thymidine incorporation assay 2.10
To measure cellular proliferation, the incorporation of 
3
H-labelled thymidine into 
chromosomal strands of replicating DNA during mitosis was measured. HPASMCs were 
seeded in 24-well plates at a density of 7,500 cells per cm
2
. Cells were grown to ~60% 
confluency in 10% DMEM and then quiesced for 24 hours to arrest the cell cycle and 
synchronise the cells in 0.2% (v/v) CS-FBS, PRF-DMEM. Cell culture medium was 
replaced with 1% charcoal stripped PRF-DMEM and stimulated with agonists/antagonists 
for 72 hours. To investigate effects of antagonists, drugs were incubated with the cells for 
30 minutes prior to addition of an agonist. Drugs and media were replaced every 48 hours. 
3
H-Thymidine (Perkin Elmer, Cambridgeshire, UK) was added to the culture medium 
(0.1μCi) for the last 24 hours.  
To terminate the experiment, the medium was removed and the cell monolayer was washed 
twice with DPBS. Protein samples were purified by protein precipitation with 0.5mL 5% 
(w/v) tricholoacetic acid washes 3 times followed by cell lysis with 0.5ml 0.3M NaOH for 
a minimum of 30 minutes. The cell lysate was collected in 1mL Ecoscint A scintillation 
fluid (National Diagnostics, Georgia, USA), vortexed and left to settle for 2 hours. The 
total 
3
H thymidine was measured using a Tri-Carb 2800TR β-scintillation counter (Perkin 
Elmer, Cambridgeshire, UK). 
 CellTiter-Glo® luminescent cell viability assay 2.11
To determine the number of viable cells, the CellTiter-Glo® luminescence cell viability 
assay (Promega, Wisconsin, USA) was used, as described in the manufacturers’ protocol. 
This assay measures the amount of adenosine triphosphate (ATP) present in the cells using 
beetle luciferin, which undergoes oxidation by luciferase in the presence of ATP, 
magnesium and oxygen, emitting a luminescent signal. Therefore the amount of 
luminescence is directly proportional to the amount of ATP present in the cells which 
strongly correlates with cell number. 
Briefly, cells were plated in 96-well opaque walled clear-bottomed plates (Greiner Bio 
One, Stonehouse, UK) at a density of 7,500 cells per cm
2 
in 10% (v/v) FBS DMEM. At 
60% confluency, cells were quiesced in 0.2% (v/v) CS-FBS DMEM for 24 hours prior to 
addition of relevant agonists/antagonists, as described previously for thymidine 
incorporation assays (see section 2.10). The cell culture plates were removed from 
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controlled incubators and allowed to equilibrate to room temperature for about 30 minutes. 
An equal volume of the CellTiter Glo® reagent to the amount of media present in the wells 
was added to each well, alongside 3 blanks containing only cell culture medium (no cells 
for background luminescence). The plate was placed onto an orbital shaker to induce cell 
lysis and approximately 10 minutes was allowed for stabilisation of the luminescent signal. 
Luminescence was recorded using a luminometer (POLARStar OPTIMA, BMG Labtech, 
Germany). 
 17β-estradiol immunoassay 2.12
The levels of 17β-E2 were determined by competitive based immunoassay in whole lung 
samples from female wild-type and SERT+ mice and in hPASMCs from control and PAH 
patients. All tissue samples were homogenized in ice-cold 1% (v/v) LM buffer in DPBS 
using a hand-held ultrasonic tissue homogenizer (Misonix XL-2000, Fisher Scientific, 
UK). Samples were kept on ice for 30 minutes to encourage protein solubilization, 
followed by ice-sonication. Samples were centrifuged to remove cellular debris at 
10,000xg for 10 minutes at 4ºC and the supernatant was collected for protein estimation by 
a BCA protein assay (see section 2.7.2). 400µg of protein were loaded for mouse lung 
samples and 30µg of protein was loaded for hPASMCs samples. Each sample was 
performed in duplicate. 17β-E2 levels were determined by a 17β-E2 enzyme-linked 
immunosorbent assay kit as per manufacturer’s instructions (Cayman Chemical, Michigan, 
USA), which is summarized in Figure 2-6. Briefly, a constant amount of 17β-E2 
acetylcholinesterase conjugate (17β-E2 tracer) competes with 17β-E2 for binding with 
17β-E2 antiserum. Therefore, the amount of bound 17β-E2 tracer is inversely proportional 
to the concentration of 17β-E2 present in the sample. The plate supplied is pre-coated with 
a mouse monoclonal anti-rabbit IgG which binds free 17β-E2 antiserum. The plate was 
then washed with UltraPure Water (Cayman Chemical, Michigan, USA) five times to 
remove any unbound reagents. The activity of the acetylcholinesterase bound to the plate is 
measured by addition of Ellman’s reagent and read at a wavelength of 405nm for kinetic 
and end point measurements (SpectraMax M2 plate reader, Molecular Devices, California, 
USA).




Figure 2-6 Schematic of the 17β-estradiol immunoassay 
Image kindly provided by Cayman Chemical, Michigan, USA 
 
Plates are pre-coated with 
mouse monoclonal anti-
rabbit IgG and blocked with 
a proprietary formulation of 
proteins
Incubate with tracer, 
antiserum and either 
standard or sample
Wash to remove any 
unbound reagents
Develop the well with 
Ellman’s Reagent




Specific antiserum to 17β-E2
Free 17β-E2
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 17β-estradiol levels in extracellular medium 2.12.1
There is evidence that suggests that synthesis and metabolism of estrogens is increased in 
PAH. Thus, we investigated 17β-E2 uptake into cells by measuring the depletion from the 
extracellular medium as an indirect measurement of 17β-E2 metabolism in cells. Female 
hPASMCs derived from PAH patients and non-diseased controls were plated at a density 
of 10,000 cells per cm
2
 in 6-well plates and grown until near confluency. Cells were 
quiesced in 0.2% (v/v) CS-FBS PRF-DMEM for 24 hours and then stimulated with 1nM 
17β-E2 (544.76pg) for 10 minutes and 24 hours. At the termination of the experiment, cells 
were placed on ice and the spent medium was collected and the intact cells were lysed in 
1% (v/v) LM solution in DPBS for protein correction using a BCA protein assay. Levels of 
17β-E2 in the medium were determined using the 17β-E2 EIA, as previously described 
(see section 2.12). 
 High performance liquid chromatography 2.13
All aqueous and organic solvents were glass-distilled, high performance liquid 
chromatography high performance liquid chromatography (HPLC) grade. 
There is evidence that altered estrogen synthesis and metabolism may figure prominently 
in PAH. However, to date, limited knowledge is available on the dynamic regulation of 
estrogen metabolism in PAH. This is partly due to challenges in measuring steroid 
compounds and a lack of availability of immunoassays. To address this question, we 
developed a methodology to quantitatively measure estrogen metabolism in cell cultures 
using HPLC with ultraviolet (UV) and radiochemical detection. 
 Optimisation of separation of estrogen metabolites by high 2.13.1
performance liquid chromatography 
Fifteen estrogens and estrogen metabolites, including oestrone (E1), 17β-estradiol (17β-
E2), estriol/16α-hydroxyestradiol (16α-OHE2), 17α-estradiol (17α-E2), 16-epiestriol (16-
epi-E3), 17-epiestriol (17-epi-E3), 2-hydroxyestrone (2-OHE1), 2-hydroxyestradiol (2-
OHE2), 4-hydroxyestrone (4-OHE1), 4-hydroxyestradiol (4-OHE2), 2-methoxyestrone (2-
MeOHE1), 2-methoxyestradiol (2-MeOHE2), 4-methoxyestrone (4-MeOHE1), 4-
methoxyestradiol (4-MeOHE2), 16α-hydroxyestrone (16α-OHE1) were obtained from 
Steraloids, Inc. (Newport, USA). All steroids were dissolved in 0.1% ascorbic acid (w/v) 
methanol at a concentration of 0.25mg/ml. Ascorbic acid was added to the samples to 
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prevent non-specific oxidation. Samples were diluted in a mobile phase consisting of water 
(W), acetonitrile (A) and methanol (M) in the ratio 50-30-20, respectively (WAM) to 
10µg/mL. Initially, all steroids were separated by HPLC and detected by UV light. HPLC 
separation was carried out on a Sunfire C18 column (150mm x 4.6mm internal diameter 
column packed with 5µm C18 particles, Waters, Hertfordshire, UK), maintained at 25ºC. 
A total of 200μl of each steroid standard solution (equivalent to 2µg) was injected onto the 
HPLC column at a flow rate of 1ml per minute using a ASI-100 automated sample injector 
(Dionex, California, USA) and a P680 HPLC pump (Dionex, California, USA). Samples 
were initially analysed on a HPLC photo diode array detector (PDA) Dionex PDA-100 at 
wavelengths λ190nm to λ220nm (Dionex, California, USA) to determine the optimum UV 
that delivers the best spectral profile and maximal absorbance. 
Due to the structurally similarity of estrogen compounds, including structural isomers (for 
example, 17β-E2 and 17α-E2), to obtain a single chromatogram of all 15 estrogen 
metabolites, it was essential to use a gradient elution mode. This utilizes graded mobile 
phase compositions to improve the separation of the compounds. The interaction of the 
compounds with the column stationary phase and the mobile phase will determine its 
unique elution profile. All estrogen metabolites were successfully separated on gradient 
elution mode at 25ºC and detected at 200nm. The initial mobile phase consisted of 50-10-
40 WAM which was maintained for 1 minute. The mobile phase was altered to 55-40-4 
over a gradient from 1 to 8 minutes and maintained for 2 minutes under these conditions. 
The mobile phase was then switched to 50-30-20 in a ballistic gradient over 1 minute and 
maintained in these conditions for a subsequent 9 minutes. The mobile phase reverted back 
to the initial conditions for stabilisation of the UV signal for 10 minutes. 
 Optimization of estrogen metabolite extraction 2.13.2
Prior to HPLC analysis, estrogens were extracted from their biological matrix to remove 
interferences and maximise recoveries. Initially, we wished to assess the optimal extraction 
method for complete recovery of all the estrogen metabolites. We tested both solvent 
extractions and solid phase extraction (SPE) using Oasis® HLB Columns (Waters, 
Hertfordshire, UK).  
2.13.2.1 Solvent Extractions 
To assess the ability of solvent extractions to extract estrogen metabolites we used ethyl 
acetate, diethyl ether and dichloromethane in the ratios (aqueous: solvent) 1:1, 1:5 and 1:10 
 Chapter 2 - Methods 
98 
 
(except for dichloromethane where we were unable to separate the solvent from the 
biological matrix at the ratio 1:1). A mixture of all the standards (dissolved in 0.1% (w/v) 
ascorbic acid methanol) was added to 500μl of the biological matrix; 0.1% (w/v) ascorbic 
acid, 1% CS-FBS PRF-DMEM. Medium samples with an equal volume of 0.1% (w/v) 
ascorbic acid in methanol was also prepared for extraction. The former is known as pre-
spiking, where the standards are added into the biological matrix prior to the extraction. 
This can then be compared to the latter, where the standard solution is added to the sample 
after the extraction (post-spiking). This tests the efficiency of the extraction method. To 
each mixture, the relevant solvent was added and thoroughly vortexed and then allowed to 
separate on the bench top. Ethyl acetate and diethyl ether are less dense than the biological 
matrix and form the upper layer of the separation, which was carefully removed. In 
contrast, dichloromethane is denser and thus separates into the bottom layer. The mixture 
of estrogen standards was then added to the post-spiked samples. The samples were 
reduced to dryness under a gentle stream of oxygen free nitrogen gas at room temperature 
and reconstituted in the initial mobile phase (WAM 50-10-40).  
2.13.2.2 Oasis SPE Extraction 
A mixture of all the standards (dissolved in 0.1% (w/v) ascorbic acid methanol) was added 
to 10mL of the biological matrix; 0.1% (w/v) ascorbic acid, 1% CS-FBS PRF-DMEM. The 
Oasis® HLB reverse-phase cartridges 3 cubic centimetres 60 mg (Waters, Hertfordshire, 
UK) were placed onto a vacuum manifold to encourage flow (Waters extraction manifold, 
Waters, Hertfordshire, UK). The sorbent bed was preconditioned with 3mL methanol and 
3mL water prior to loading the sample (steroid standards in biological matrix and the 
biological matrix without any steroids), which was allowed to pass through the cartridge. 
The steroids were retained on the column which was subsequently re-equilibrated with 
3mL water followed by a 3mL wash with 5% (v/v) methanol in 95% water. All organic 
and aqueous solvents contained 0.1% (w/v) ascorbic acid. The steroids were then eluted 
through the cartridge with 0.1% (w/v) ascorbic acid in 100% methanol. The eluted samples 
were dried under a gentle stream of oxygen free nitrogen gas at room temperature and 
reconstituted in the initial mobile phase (50-10-40 WAM). This methodology is 
summarised in Table 2-4. 
Extraction recovery percentages for both solvent extractions and SPE were calculated by 
dividing the mean integrated peak areas from pre-spiked samples by the mean integrated 
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peak areas from post-spiked samples and control samples (no extraction) and multiplied by 
100. 
Table 2-4 Oasis® HLB extraction of Estrogen metabolites 
Solid phase extraction with Oasis® HLB 
Condition 3mL Methanol 
 3mL Water 
Loading Sample 
Re-equilibrate 3mL Water 
Wash 3mL 95% water in methanol 
Elution 3mL methanol 
 
2.13.2.3 High performance liquid chromatography 
100μl of sample was injected onto the HPLC column and run under a gradient elution 
mode, as previously described (See section 2.13.1).  
2.13.2.4 Extraction of radiolabelled 14C-17β-estradiol and optimisation of 
concentration required for optimum detection 
14
C-4C-17β-E2 (14C-17β-E2) specific activity, 55mCi/mmol; concentration, 0.1mCi/mL) 
was obtained from American Radiolabelled Chemicals, Inc. (Missouri, USA). 
14
C-17β-E2 
was selected as the suitable isotope as the deuterated form (
3
H-17β-E2) may lose 
deuteriums during CYP metabolism. The Oasis® HLB columns obtained the best 
recoveries of all estrogen metabolites (Chapter 5). The same methodology was therefore 
tested for the extraction of radiolabelled 17β-E2.  
To determine the optimal concentration of 17β-E2 to use for subsequent experiments, we 
required a concentration that provided maximal peak intensity in the radiolabelled detector 
without saturation of the signal (to allow greatest chance of detection of metabolite 
formation). The molar concentration of 
14
C-17β-E2 is calculated by dividing the 
radioactivity concentration by the specific activity (1.818mmol/L). The maximum peak 
intensity was obtained with 0.074µl of 
14
C-17β-E2. The optimal concentration was 50nM 
in 10mL (136.19ng), which was used for all subsequent experiments. This concentration 
allowed us to run the sample in replicate, a minimum of 3 times.   Radioactivity (counts 
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per minute) was determined by a radio HPLC detector (Berthold LP509, Berthold 
Technologies, Bad Wilbad, Germany).  
 Estrogen metabolism in cells 2.13.3
HPASMCs (passages 3-6) were seeded in 100mm tissue culture plates at a density of 
10,000 cells per cm
2
 and grown to near confluency. Cells were synchronised by serum 
deprivation for 24 hours in 0.2% CS-FBS, PRF-DMEM. After 24 hours, the cell culture 
media was replaced with 1% CS- FBS, PRF-DMEM to maintain adequate growth. To 
assess 17β-E2 metabolism, cells were exposed to 14C-17β-E2 at the pre-optimized 
concentration of 50nM (136.19ng) for various time-points (0, 10, 30 minutes, 1, 2, 4, 24, 
48 hours). At the end-point, cell culture plates were placed on ice; the spent, metabolite-
enriched medium was collected with 0.1% ascorbic acid to prevent oxidation of the 
extremely sensitive catechol estrogens and frozen at -20°C prior to SPE extraction (see 
section 2.13.2.2) and HPLC analysis. After SPE extraction, standards were added to the 
sample at a concentration of 10µg/mL for peak identification. The cell monolayer was 
washed twice with 10mL of ice cold DPBS, and lysed with a 1% LM (v/v) in DPBS. Cells 
were carefully scraped from the surface of the culture dish and placed in a pre-chilled 
eppendorf for 30 minutes. Cells were then further lysed by sonication in an ice bath (3 x 30 
seconds), centrifuged at 10,000xg for 10 minutes at 4ºC. The supernatant was removed and 
placed in a fresh, ice-chilled eppendorf and frozen at -20°C, prior to BCA analysis to 
determine the protein concentration for normalisation of results. 
2.13.3.1 High performance liquid chromatography 
100µl of the extracted product and steroids applied to the column was separated by HPLC 
and detected by a UV and radio-labelled detection system. The sample was separated using 
a Sunfire C18 column and maintained at 25ºC. To confirm peak identity, the samples were 
also separated with an Allure Biphenyl 5µm, 4.6 x 150mm column (Thames Restek, 
Buckinghamshire, UK) at 30ºC with reverse phase chromatography in isocratic mode using 
water and methanol in the mobile phase (32% water:78% methanol). All peak integrations 
for quantification were obtained from the sample run in the Allure Biphenyl column. 
All HPLC data analysis was performed with Chromeleon 6.5 chromatography data system 
(Dionex, California, USA). 
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 Statistical analysis and data handling 2.14
Data was processed and analyzed using GraphPad Prism 5 (California, USA). Data is 
represented as the groups mean ± the standard error of the mean (SEM). Data was analyzed 
by a student’s t test (where there were only two groups) or a Bonferroni’s Post Hoc test 





The Estrogen Metabolizing Enzyme Cytochrome 
P450 1B1 Influences the Development of 
Pulmonary Arterial Hypertension




Despite the complexity and multi-factorial pathology associated with PAH, the incidence 
of both IPAH and HPAH is more common in women than in men (Badesch et al., 
2010;Ling et al., 2012;Shapiro et al., 2012). This suggests that sex hormones may be 
mediating pathological effects in the presence and absence of genetic susceptibilities. This 
is supported by evidence that estrogens are important during lung development, normal 
physiology and pathophysiology (reviewed by Carey et al., 2007;Townsend et al., 2012). 
17β-E2, the main pre-menopausal hormone, is metabolised by various CYP enzymes to 
both pro- and anti-proliferative metabolites. Aberrant expression of CYP1B1, a major 
extra-hepatic estrogen-metabolizing enzyme, has been reported in both pre-clinical models 
of PAH (White et al., 2011a) and in human PAH (Austin et al., 2009). A genetic 
polymorphism in CYP1B1 (Asn453Ser; N453S), which is associated with an increased 
rate of degradation of CYP1B1 (Bandiera et al., 2005) is more common in patients with a 
BMPR-2 mutation without any evidence of PAH (Austin et al., 2009). This suggests that 
CYP1B1 activity is involved in the development of PAH in patients harbouring a BMPR-2 
mutation. Epidemiological evidence highlights a detrimental role for female gender in 
PAH, yet there is a paucity of understanding of the basis of this. Altered metabolism by 
aberrant CYP1B1 activity may underlie this, yet its contribution to PAH has so far been 
undetermined.  
In premenopausal women, the predominant circulating estrogen is 17β-E2. In women, 
circulating levels of 17β-E2 vary depending on the estrous cycle. In the follicular phase, 
circulating concentrations of 17β-E2 are about 100pg/mL (~0.37nM) and during ovulation 
these levels rise to about 600pg/mL (~2.20nM). After menopause, 17β-E2 levels are 
dramatically reduced up to 20-fold lower (Mendelsohn & Karas, 1999). Furthermore, 
vascular cells can modulate their own estrogenic milieu by the local conversion of 
testosterone or androstenedione to 17β-E2 and E1 respectively (Harada et al., 1999). 17β-
E2 and E1 can be interconverted to one another by the activity of 17β-HSD enzymes. In 
hPASMCs 17β-E2 at 1nM increases the expression of CYP1B1 and cellular proliferation 
(White et al., 2011a).  
CYP1B1 is a member of the CYP superfamily, which are monooxygenase enzymes that 
substitute a hydrogen atom to a hydroxyl group in the presence of oxygen and NADPH. 
CYP1B1 preferentially hydroxylates at the C4 position of the aromatic ring of 17β-E2 and 
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to a lesser extent, at the C2 and C16 positions (Badawi et al., 2001;Hanna et al., 2000;Lee 
et al., 2003). CYP metabolites can then undergo further metabolism by the activity of 
COMT to their methylated metabolites. Increased activity and expression of CYP1B1 has 
already been reported in many diseases including breast cancer (McKay et al., 1995), lung 
cancer (Murray et al., 1997), ovarian cancer (McFadyen et al., 2001), and systemic 
hypertension (Jennings et al., 2010). Yet, the contribution of CYP1B1 to the development 
of PAH remains uncertain.  
Here, we investigate the potential pathological contribution of CYP1B1 metabolism of 
17β-E2 on the development of PAH. We demonstrate increased CYP1B1 expression in 
both experimental and clinical PAH which may direct the intrinsically regulated 
metabolism of 17β-E2 towards the formation of pro-proliferative metabolites. Furthermore, 
we demonstrate an essential function of CYP1B1 on the development of experimental 
PAH supporting a putative pathological role of CYP1B1 metabolism in this highly 
prevalent disease in females. We provide evidence for gender differences in PAH, that 
suggests estrogen-related therapies, particularly through inhibition of pathological 
metabolism through CYP1B1, may be a promising therapeutic strategy in some patients.  
Aims of this chapter 
1. To functionally and molecularly characterise the impact of estrogen metabolism by 
CYP1B1 to the development of PAH in vivo 
  




 Hypoxia alters the estrogen metabolic axis in human 3.2.1
pulmonary arterial smooth muscle cells 
Hypoxia is a mediator in PAH pathogenesis and we therefore wished to investigate 
whether oxygen deprivation alters components of the estrogen-metabolic axis in 
hPASMCs. CYP1B1 transcription is predominantly mediated by translocation of the AhR 
to the nucleus where it associates with the ARNT and binds to DRE. HIF1α is a master 
regulator of hypoxia-induced gene expression. HIF1α mediates gene transcription in 
response to hypoxia by the AhR pathway by binding of the HIF1α-ARNT complex to 
hypoxia-response genes. There is therefore a close link between the AhR pathway, hypoxia 
and CYP1B1 and we were therefore interested to investigate the effect of hypoxia (1% 
oxygen) on CYP1B1 expression. Hypoxia increased the expression of CYP1B1 (Figure 
3-1a). 17β-HSD1 regulates internal reservoirs of E1 by converting them into 17β-E2. We 
report an increased expression of 17β-HSD1 following exposure to chronic hypoxia 
(Figure 3-1b), which suggests there is increased formation of 17β-E2 in response to 
hypoxia in these cells. This can then be further metabolised by increased CYP1B1 
expression. Activity of COMT methylates hydroxylated estrogens to their less active 
metabolites. Here, the expression of COMT was unchanged following hypoxic exposure 
(Figure 3-1c). 
 Pulmonary CYP1B1 expression is increased in 3.2.2
experimental and clinical PAH 
Chronic hypoxia and SU-hypoxia increased CYP1B1 mRNA and protein expression in 
murine pulmonary arteries compared to their normoxic counterparts (White et al., 2012). 
Immunohistochemistry analysis revealed that CYP1B1 was localised within all cells that 
comprise the vascular wall (Figure 3-2 - Figure 3-3). In human PAH, CYP1B1 protein and 
mRNA expression was increased in PASMCs compared to control (White et al., 2012). 
Similarly, CYP1B1 immunolocalisation and quantification revealed increased CYP1B1 
expression in the pulmonary arteries of patients with PAH compared to controls (Figure 
3-4). CYP1B1 was localised to all layers of the pulmonary arterial wall including α-SMA 
(smooth muscle cells) and von Willebrand positive cells (endothelial cells) (Figure 3-5). 
Patient characteristics are listed in Table 3-1. 
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Table 3-1 Patient characteristics of human lung sections 
Clinical data of patients with PAH including their sex, age, mean pulmonary arterial pressure 
(mPAP) and drug therapy that were used for Immunolocalisation and semi-quantification of 
CYP1B1 in the pulmonary arteries of lung sections.  
Sex Age Patient Information mPAP (mmHg) Drug Therapy 
F 26 HPAH 67 Nifedipine 
F 30 HPAH 46 Iloprost, sildenafil 
F 38 HPAH 56 Epoprostenol 
F 44 IPAH 44 Epoprostenol 
F 51 IPAH 49 Prostacyclin 
F 23 IPAH 57 Iloprost 
M 23 HPAH 54 Iloprost and sildenafil 
M 56 IPAH N/A N/A 




Figure 3-1 Effect of hypoxia on protein expression of CYP1B1, COMT and 17β-HSD1 in 
human pulmonary arterial smooth muscle cells (hPASMCs) 
Female control hPASMCs were quiesced for 24 hours and then exposed to either normoxic or 
hypoxic conditions (1% oxygen) for 24 hours. Cell homogenates were assayed for protein 
expression by western blotting for CYP1B1 (a), 17β-HSD1 (b) and COMT (c) and analysed by 
densitometric analysis. GAPDH was used as the internal loading control. Full western blots are 
shown in appendix 1. n=2 patients, repeated 2 times per condition, *P<0.05, **P<0.01, t-test, data 











































































































































Figure 3-2 Immunolocalisation of CYP1B1 in normoxic and hypoxic murine pulmonary 
arteries 
Female and male C57BL/6 mice were exposed to hypoxia (10% oxygen) or kept in room air for 2 
weeks. Representative immunohistochemistry for CYP1B1 in the small pulmonary arteries and 
quantification of the % positive CYP1B1 staining within the vessel wall. CYP1B1 expression is 
visualized by DAB staining (dark orange/brown stain). n=4 mice per group, ***P<0.001, One-way 
ANOVA with a Bonferroni’s post-hoc test. Data is expressed as the mean ± SEM. IgG control 
reveals no non-specific binding. Scale bar = 20µm. 













































Figure 3-3 Immunolocalisation of CYP1B1 in SU-hypoxic murine pulmonary hypertension 
Female and male (C57BL/6) mice were exposed to hypoxia (10% oxygen) or kept in room air for 3 
weeks and given SU5416 (20mg/kg) at 0, 7 and 14 days. Representative immunohistochemistry for 
CYP1B1 in the small pulmonary arteries and quantification of the % positive CYP1B1 staining 
within the vessel wall. CYP1B1 expression is visualized by DAB staining (dark orange/brown stain). 
n=5 mice per group, **P<0.01, One-way ANOVA with a Bonferroni’s post-hoc test. Data is 




























































Figure 3-4 Immunolocalisation of CYP1B1 in pulmonary arteries from patients with PAH 
CYP1B1 immunolocalisation and quantification of the % CYP1B1 staining in non-PAH, idiopathic 
PAH (IPAH) and heritable PAH (HPAH) pulmonary arteries. CYP1B1 expression is visualized by 
DAB staining (dark orange/brown stain). The IPAH artery is from a 56 year old male patient and the 
HPAH patient is a 26 year old female patient with a BMPR-2 mutation. Quantification was from n=4 
patients per group (see Table 3-1 for patient characteristics). **P<0.01, One-way ANOVA with a 
Bonferroni’s post-hoc test. Data is expressed as the mean ± SEM. IgG control revealed absence of 




Figure 3-5 Cellular localisation of CYP1B1 in human vascular lesions 
The expression of CYP1B1, α-SMA (smooth muscle cell marker) and vWF (endothelial cell marker) in 5μm consecutive human pulmonary arteries as visualized by the 
chromagen DAB which appears as a brown/orange stain. CYP1B1, α-SMA and vWF immunolocalisation in a complex vascular lesion from a 38 year old female 
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 Effect of chronic hypoxia in CYP1B1 deficient mice 3.2.3
To test the function of CYP1B1 in hypoxia-induced PAH, CYP1B1-/- mice were exposed 
to chronic hypobaric hypoxia for 14 days. Under basal conditions (normoxia), no 
differences in the ratio of RV/LV+S were observed between wild-type and CYP1B1-/- 
female mice. In contrast, male CYP1B1-/- mice had a reduced RV/LV+S ratio compared to 
wild-type mice. Following hypoxic exposure, both male and female wild-type mice 
develop increased RVH. In contrast, the degree of RVH induced by hypoxia was 
significantly less in male and female CYP1B1-/- mice compared to their wild-type controls 
(Figure 3-6). No baseline differences were observed in RVSPs between wild-type and 
CYP1B1-/- mice. Hypoxia induced increases in RVSP in wild-type mice and this effect 
was greater in male mice. CYP1B1-/- male mice exhibited an attenuated RVSP in response 
to hypoxia. No effect was observed in the female CYP1B1-/- mice (Figure 3-7). Hypoxia 
had no significant effects on the mean right ventricular pressure (mRVP) in female mice, 
whilst in male mice this was significantly increased (Table 3-2).  
Pulmonary arterial remodeling in the distal vasculature is a prominent feature of hypoxic-
induced PH and was therefore examined in lung sections obtained from these mice (Figure 
3-8 - Figure 3-9). Under normoxic conditions, no differences in vascular remodeling were 
observed in CYP1B1-/- mice compared to their wild-type controls. Hypoxia increased 
remodeling in the distal vasculature in both male and female wild-type mice. CYP1B1-/- 
female mice exhibited a similar degree of vascular remodeling as was observed in the wild-
type mice. In male CYP1B1-/- mice, the degree of vascular remodeling in response to 
hypoxia was significantly less than in the wild-type mice. 
mSAP, heart rate and body weights were monitored for any off-target effects of hypoxia or 
genetic ablation of CYP1B1 (Table 3-2). Exposure to hypoxia caused an increase in mSAP 
in male mice. This was not observed in any of the other groups studied. Female CYP1B1-/- 
mice had reduced heart rates compared to their wild-type counterparts under normoxic 
conditions. In male CYP1B1-/- mice, a reduced heart rate was reported following hypoxic 
exposure compared to wild-type mice. Female CYP1B1-/- mice were on average heavier 
than their respective wild-type mice under normoxic conditions. In contrast male CYP1B1-
/- mice weighed less than their wild-type controls under both normoxic and hypoxic 
conditions. 



























Figure 3-6 Right ventricular hypertrophy in chronically hypoxic CYP1B1-/- mice 
Female and male wild-type (C57BL/6) and CYP1B1-/- mice were exposed to hypoxia (10% 
oxygen) or kept in room air for 2 weeks. Right ventricular hypertrophy was assessed by expressing 
the dry weight of the right ventricle over the left ventricle and septum (RV/LV+S; Fultons index). 
n=8-12 per group, *P<0.05, **P<0.01, ***P<0.001, One-way ANOVA with a Bonferroni’s post-hoc 
test. Data is expressed as the mean ± SEM. 





























Figure 3-7 Right ventricular systolic pressures in chronically hypoxic CYP1B1-/- mice  
Female and male wild-type (C57BL/6) and CYP1B1-/- mice were exposed to hypoxia (10% 
oxygen) or kept in room air for 2 weeks. Right ventricular systolic pressures (RVSP) were 
measured by right heart catheterisation. n=7-11 per group, *P<0.05, **P<0.01, ***P<0.001, One-





Figure 3-8 Representative expression of α-smooth muscle actin positive cells in response to hypoxia in wild-type and CYP1B1-/- mice 
Female and male wild-type (C57BL/6) and CYP1B1-/- mice were exposed to hypoxia (10% oxygen) or kept in room air for 2 weeks. The degree of vascular 
muscularisation was visualized by α-smooth muscle actin (α-SMA) staining in the distal vasculature. α-SMA expression was visualised by DAB staining (dark 
orange/brown stain). Scale bar = 20µm 
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Figure 3-9 Pulmonary vascular remodeling in chronically hypoxic CYP1B1-/- mice 
Female and male wild-type (C57BL/6) and CYP1B1-/- mice were exposed to hypoxia (10% 
oxygen) or kept in room air for 2 weeks. The degree of pulmonary arterial remodeling was 
assessed by counting the number of remodeled and non-remodeled arteries in a lung section and 
expressed as the % of remodeled vessels over the total number of vessels. n=4-5 per group, 
*P<0.05, **P<0.01, One-way ANOVA with a Bonferroni’s post-hoc test. Data is expressed as the 
mean ± SEM. 
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 Intra-pulmonary arterial vasoconstriction in CYP1B1-/- Mice 3.2.4
Vasoconstriction of intra-pulmonary arteries is increased following hypoxic exposure. To 
investigate the contribution of CYP1B1 on the contractile response of the pulmonary 
artery, contractile responses to the potent vasoconstrictor serotonin were examined in 
arteries isolated from wild-type and CYP1B1-/- mice after normoxic and hypoxic 
exposure. In arteries from normoxic mice, there were no differences in pulmonary 
vasoconstriction across groups. (Figure 3-10a) Following hypoxic exposure, female wild-
type and CYP1B1-/- mice displayed similar contractile responses to serotonin. In contrast, 
male CYP1B1-/- mice had reduced serotonin-induced contractile responses compared to 
male wild-type mice (Figure 3-10b). 
 Effect of CYP1B1 on uterine + ovary weights 3.2.5
Given the prominent role of estrogen metabolism by CYP1B1, we were interested in 
assessing the effects of hypoxia (elevated CYP1B1 activity) and CYP1B1-/- (reduced 
CYP1B1 activity) on dry uterus and ovary weights. No changes were observed across the 
groups studied (Figure 3-11). 
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Figure 3-10 Vasoreactivity of the intrapulmonary arteries in chronically hypoxic CYP1B1-/- 
mice 
Female and male wild-type (C57BL/6) and CYP1B1-/- mice were exposed to hypoxia (10% 
oxygen) or kept in room air for 2 weeks. The intra-pulmonary arteries were isolated from mice at 
sacrifice and mounted in a myograph. The arteries were constricted twice by increasing 
extracellular concentrations to 50mM potassium chloride (KCl). The second response was used as 
a reference constriction to calculate the % vasoconstriction in response to serotonin. Following a 
wash-out and re-stabilization, cumulative concentration response curves to serotonin were 
constructed. Serotonin-induced pulmonary arterial vasoconstriction in mice maintained in normoxic 
conditions (a). Serotonin-induced pulmonary arterial vasoconstriction mice exposed to hypoxia (b); 
biological replicates are indicated above dose response curves in the legend; Bars are n=5-7, 





Table 3-2 Phenotypic data from wild-type and CYP1B1-/- mice 
Animal Group mSAP (mmHg) mRVP (mmHg) Heart rate (bpm) Body Weight (g) 
Female wild-type normoxic 91.37 ± 2.52 (7) 12.36 ± 0.47 (7) 489.3± 23.09 (6) 19.89 ± 0.17 (10) 
Female CYP1B1-/- normoxic 80.10 ± 1.82 (5) 12.22 ± 0.91 (5) 369.8 ± 21.54§ (6) 22.33 ± 0.34§ (10) 
Female wild-type hypoxic 98.98 ± 2.26 (9) 14.31 ± 0.53 (9) 416.6 ± 18.65 (9) 20.16 ± 0.36 (10) 
Female CYP1B1-/- hypoxic 93.18 ± 2.45 (7) 14.05 ± 0.48 (6) 357 ± 28.43 (8) 21.32 ± 0.48 (10) 
Male wild-type normoxic 88.99 ± 2.40 (8) 11.48 ± 0.8 (8) 472.8 ± 16.6 (8) 28.50 ± 0.60 (9) 
Male CYP1B1-/- normoxic 90.53 ± 2.70 (4) 9.86 ± 0.9 (9) 415.9 ± 20.74 (11) 25.82 ± 0.85§ (10) 
Male wild-type hypoxic 106.9 ± 2.03* (7) 15.23 ± 1.18* (8) 517 ± 15.37 (9) 28.66 ± 0.73 (8) 
Male CYP1B1-/- hypoxic 95.14 ± 7.52 (6) 12.88 ± 0.55 (10) 386 ± 16.00§§§ (9) 25.69 ± 0.34§§ (10) 
Female and male wild-type (C57BL/6) and CYP1B1-/- mice were exposed to hypoxia (10% oxygen) or kept in room air for 2 weeks. Mean systemic arterial pressures 
(mSAP) were measured by cannulation of the carotid artery. Mean right ventricular pressures (mRVP) were calculated from the right ventricular pressure obtained by 
right heart catheterisation. n numbers are indicated in brackets. *P<0.05, P<0.01 c.f. normoxic; §P<0.05, §§§P<0.01 c.f. wild-type, One-way ANOVA with a Bonferroni’s 
post-hoc test. Data is expressed as the mean ± SEM. 
 




Figure 3-11 The dry weights of the uterus and ovaries in chronically hypoxic female 
CYP1B1-/- mice 
Female and male wild-type (C57BL/6) and CYP1B1-/- mice were exposed to hypoxia (10% 
oxygen) or kept in room air for 2 weeks. The dry weight of the uterus and ovaries were expressed 
over the body weight. n=8-9, One-way ANOVA with a Bonferroni’s post-hoc test. Data is expressed 
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 Inhibition of CYP1B1 is protective on the development of 3.2.6
hypoxia-induced PAH 
Gene knockout may lead to compensatory mechanisms and as such, we wished to test the 
effect of CYP1B1 inhibition in mice. We therefore studied the effects of the highly potent 
and selective CYP1B1 inhibitor TMS in hypoxic-induced PH to determine the role of 
CYP1B1. The dosing procedures and the in vivo component (RVP, RVH, SAP) of this 
study were a joint collaborative effort with Ms. Emma Wallace, Ms. Annabel Campbell 
and Dr. Kevin White. TMS reduced the degree of RVSP, RVH and pulmonary vascular 
remodeling in both male and female mice exposed to chronic hypoxia (Figure 3-12 - 
Figure 3-15). Both hypoxia and TMS had no effects in mSAPs. Whilst no effects were 
observed on hypoxia on the average heart rates, TMS significantly increased the heart rate 
in female mice exposed to hypoxia, in comparison to their age-matched vehicle-control 
groups (Table 3-3).  















normoxic hypoxic normoxic hypoxic
female male








Figure 3-12 The CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS) attenuates the 
development of chronic hypoxia-induced right ventricular hypertrophy in mice 
Female and male wild-type mice were exposed to hypoxia (10% oxygen) or kept in room air for 2 
weeks. Mice were either injected with 3mg/kg/day TMS or vehicle (~5% ethanol in saline) during 
the 2 week study. Right ventricular hypertrophy (RVH) was assessed by expressing the dry weight 
of the right ventricle over the left ventricle and septum (RV/LV+S; Fultons index) in normoxic and 
chronically hypoxic vehicle- and TMS-treated female and male C57BL/6 mice. n=7-10, *P<0.05, 
**P<0.01, ***P<0.001, One-way ANOVA with a Bonferroni’s post-hoc test. Data is expressed as the 
mean ± SEM. 
 
































Figure 3-13 The CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS) attenuates the 
development of chronic hypoxia-induced right ventricular systolic pressures in mice 
Female and male wild-type mice were exposed to hypoxia (10% oxygen) or kept in room air for 2 
weeks. Mice were either injected with 3mg/kg/day TMS or vehicle (~5% ethanol in saline) during 
the 2 week study. Right ventricular systolic pressures (RVSP) were measured by right heart 
catheterization in normoxic and chronically hypoxic vehicle- and TMS-treated female and male 
C57BL/6 mice. n=7-10, *P<0.05, **P<0.01, ***P<0.001, One-way ANOVA with a Bonferroni’s post-





Figure 3-14 Representative α-smooth muscle actin–stained pulmonary arteries in normoxic and chronic hypoxic C57BL/6 mice dosed with vehicle- or the  
CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS) 
Female and male wild-type mice were exposed to hypoxia (10% oxygen) or kept in room air for 2 weeks. Mice were either injected with 3mg/kg/day TMS or vehicle 
(~5% ethanol in saline) during the 2 week. The degree of vascular muscularisation was visualized by α-smooth muscle actin (α-SMA) staining in the distal vasculature. 
α-SMA expression was visualized by DAB staining (dark orange/brown stain). Scale bar = 20µm. 
vehicle                        TMS                           vehicle                        TMS





























































Figure 3-15 The CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS) attenuates the 
development of chronic hypoxia-induced pulmonary vascular remodeling 
Female and male wild-type mice were exposed to hypoxia (10% oxygen) or kept in room air for 2 
weeks. Mice were either injected with 3mg/kg/day TMS or vehicle (~5% ethanol in saline) during 
the 2 week study. The degree of pulmonary arterial remodeling was assessed by counting the 
number of remodeled and non-remodeled arteries in a lung section and expressed as the % of 
remodeled vessels over the total number of vessels. n=4-7, *P<0.05, **P<0.01, ***P<0.001, One-




Table 3-3 Effect of CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS) in normoxic and hypoxic C57BL/6 mice on haemodynamics and phenotypes 
Animal Group mSAP (mmHg) mRVP (mmHg) Heart rate (bpm) Body Weight (g) 
Female Wild-type normoxic 91.07 ± 1.53 (9) 15.71 ± 0.49 (9) 428.2 ± 16.92 (9) 19.40 ± 0.20 (10) 
Female TMS normoxic 95.49 ± 1.63 (6) 12.47 ± 0.59 (10) 404.4 ± 14.70 (10) 18.30 ± 0.42 (10) 
Female wild-type hypoxic 98.59 ± 2.72 (8) 19.73 ± 1.13* (10) 366.0 ± 21.43 (9) 18.69 ± 0.31 (10) 
Female TMS hypoxic 100.70 ± 3.91 (6) 16.01 ± 1.06§ (10) 477.4 ± 21.30§§ (10) 15.66 ± 0.18§§§ (10) 
Male wild-type normoxic 100.90 ± 0.76 (8) 13.06 ± 0.89 (7) 441.8 ± 21.21 (8) 26.56 ± 0.51 (10) 
Male TMS normoxic 103.02 ± 4.00 (6) 13.00 ± 0.74 (6) 473.4 ± 14.15 (6) 26.31 ± 0.42 (10) 
Male wild-type hypoxic 100.50± 0.77 (5) 16.26 ± 1.103 (7) 485.5 ±33.59 (7) 26.14 ± 0.73 (10) 
Male TMS hypoxic 107.40 ± 2.10 (7) 14.20 ± 1.01 (6) 439.1 ± 26.09 (8) 24.57 ± 0.39 (10) 
Female and male wild-type mice were exposed to hypoxia (10% oxygen) or kept in room air for 2 weeks. Mice were either injected with 3mg/kg/day TMS or vehicle 
(~5% ethanol in saline) during the 2 week study. Mean systemic arterial pressures (mSAP) were measured by cannulation of the carotid artery. Mean right ventricular 
pressures (mRVP) were calculated from the right ventricular pressure obtained by right heart catheterisation. n numbers are indicated in brackets. *P<0.05, **P<0.01 
cf. normoxic; §P<0.05, §§§P<0.001 cf. vehicle, One-way ANOVA with a Bonferroni’s post-hoc test. Data is expressed as the mean ± SEM. 
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 Monocrotaline-induced PH is moderately altered by TMS 3.2.7
treatment in male but not female rats 
Having demonstrated CYP1B1 as an integrative mediator of hypoxia-induced PH, we 
wanted to assess its function in a severe inflammatory model of the disease, induced by the 
pneumotoxin MCT. Assistance was provided for the dosing procedures of this study and 
the majority of the female in vivo component (RVP, RVH and SAP) was carried out by 
Ms. Katie Hood, Dr. Ian Morecroft, Ms. Margaret Nilsen and Dr. Kirsty Mair. Both 
females and males develop RVH in response to MCT although this effect is more 
pronounced in the male rats. No effect was observed in response to TMS treatment in the 
female rats, yet male rats had a slight, yet non-significant reduction in RVH to a similar 
level to that observed in the female rats with TMS treatment (Figure 3-16). Here, we report 
that both female and male rats develop substantial increases in RVSP in response to MCT, 
and this effect was unaltered by CYP1B1 inhibition (Figure 3-17). 
Despite the severity of MCT-induced-PH, this occurs in the absence of the complex 
pulmonary arteriopathy that is a key feature in human PAH. However, vascular remodeling 
is present to a much greater extent than what is observed in hypoxic-induced-PH in mice 
with medial narrowing present. We therefore investigated the extent of pulmonary vascular 
remodeling in the distal vasculature of these animals. MCT induced substantial increases in 
arterial remodeling in both male and female rats (Figure 3-19). Although there were no 
significant effects observed by TMS treatment, the effect of MCT on arterial remodeling 
when comparing vehicle-TMS to MCT-TMS was non-significant in females, suggesting a 
moderate effect of TMS treatment in this group. Similarly, in male rats there was less 
significance when comparing vehicle-TMS with MCT-TMS as compared with vehicle-
vehicle to MCT-vehicle. When examining the degree of muscularisation in the distal 
vasculature, all rats developed neointimal lesions in response to MCT, yet these appeared 
much more pronounced in the vehicle group compared to TMS treated groups (Figure 
3-18). This may account for the improved survival in TMS treated rats (see below). 
To determine whether the effects of MCT and TMS were specific to the cardio-pulmonary 
unit, mSAP were monitored in all groups (Table 3-4). The mSAPs were increased in 
female rats in response to MCT whereas no effect was observed in male rats. This was 
unaffected by TMS treatment. MCT reduced the heart rate in male rats and this effect was 
improved by TMS treatment. No effect was observed in the female rats (Table 3-4). MCT 
and TMS had no effects on dry uterus + ovary weights (Figure 3-20). 
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Figure 3-16 Monocrotaline induces right ventricular hypertrophy and this is unaffected by 
the CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS) 
Female and male wistar rats were injected with a single injection of monocrotaline (MCT; 20mg/kg) 
or vehicle (see methods for a detailed description) on day 0. After 2 weeks, rats were injected with 
3mg/kg/day TMS or vehicle (~5% ethanol in saline) for a further 2 weeks. Right ventricular 
hypertrophy (RVH) was assessed by expressing the dry weight of the right ventricle over the left 
ventricle and septum (RV/LV+S; Fultons index). n=8-16, ***P<0.001, One-way ANOVA with a 
Bonferroni’s post-hoc test. Data is expressed as the mean ± SEM. 
  




Figure 3-17 Monocrotaline induces increases in right ventricular pressures and this is 
unaffected by unaffected by the CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS) 
Female and male wistar rats were injected with a single injection of monocrotaline (MCT; 20mg/kg) 
or vehicle (see methods for a detailed description) on day 0. After 2 weeks, rats were injected with 
3mg/kg/day TMS or vehicle (~5% ethanol in saline) for a further 2 weeks. Right ventricular systolic 
pressures (RVSP) were measured in rats by right heart catheterisation through the jugular vein. 
n=5-11, ***P<0.001, One-way ANOVA with a Bonferroni’s post-hoc test. Data is expressed as the 
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Figure 3-18 Representative α-smooth muscle actin–stained pulmonary arteries in monocrotaline (MCT) rats treated with vehicle- or the  CYP1B1 inhibitor 
2,3′,4,5′-tetramethoxystilbene (TMS) 
Female and male wistar rats were injected with a single injection of monocrotaline (MCT; 20mg/kg) or vehicle (see methods for a detailed description) on day 0. After 2 
weeks, rats were injected with 3mg/kg/day TMS or vehicle (~5% ethanol in saline) for a further 2 weeks. The degree of vascular muscularisation was visualized by α-
smooth muscle actin (α-SMA) staining in the distal vasculature. α-SMA expression was visualised by DAB staining (dark orange/brown stain). Sections have been 
counterstained with haematoxylin and eosin. Scale bar = 20µm 




Figure 3-19 Monocrotaline increases pulmonary vascular remodeling and this is unaffected 
by unaffected by the CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS) 
Female and male wistar rats were injected with a single injection of monocrotaline (MCT; 20mg/kg) 
or vehicle (see methods for a detailed description) on day 0. After 2 weeks, rats were injected with 
3mg/kg/day TMS or vehicle (~5% ethanol in saline) for a further 2 weeks. The degree of pulmonary 
arterial remodeling was assessed by counting the number of remodeled and non-remodeled 
arteries in a lung section and expressed as the % of remodeled vessels over the total number of 
vessels. n=6-7, **P<0.01, ***P<0.001, One-way ANOVA with a Bonferroni’s post-hoc test. Data is 
expressed as the mean ± SEM. 
 





































Table 3-4 Phenotypic data from monocrotaline wister rates treated with vehicle or the CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS) 
Animal Group mSAP (mmHg) mRVP (mmHg) Heart rate (bpm) Body Weight (g) 
Female vehicle-vehicle 103.6 ± 5.001 (8) 12.71 ± 1.247 (7) 406.9 ± 10.78 (8) 191.4 ± 4.63 (9) 
Female vehicle-TMS 109.6 ± 7.025 (6) 12.95 ± 1.149 (6) 402.6 ±14.19 (6) 195.3 ± 3.75 (9) 
Female MCT-vehicle 126.8 ± 10.15 (7) 27.52 ± 3.177** (8) 414.4 ± 6.46 (8) 209.3 ± 4.46 (12) 
Female MCT-TMS 122 ± 8.243 (7) 30.62 ± 3.661*** 
(11) 
393.7 ± 8.64 (12) 191.2 ± 4.40 (11) 
Male vehicle-vehicle 98.38 ± 2.548 (9) 11.52 ± 0.2759 (8) 397.2 ± 8.41 (9) 301.3 ± 9.74 (9) 
Male vehicle-TMS 106.6 ± 4.284 (9) 11.65 0.4779 (7) 398.2 ± 18.43 (9) 293.2 ± 9.72 (9) 
Male MCT-vehicle 83.86 ± 1.716 (5) 36.65 ± 1.143*** (5) 301.8 ± 14.06*** (7) 298.9 ± 10.71 (9) 
Male MCT-TMS 95.71 ± 5.047 (11) 31.83 ± 2.6*** (8) 360.1 ± 12.07§ (11) 280.0 ± 6.96 (12) 
Female and male wistar rats were injected with a single injection of monocrotaline (MCT; 20mg/kg) or vehicle (see methods for a detailed description) on day 0. After 2 
weeks, rats were injected with 3mg/kg/day TMS or vehicle (~5% ethanol in saline) for a further 2 weeks. Mean systemic arterial pressures (mSAP) were measured by 
cannulation of the carotid artery. Mean right ventricular pressures (mRVP) were calculated from the right ventricular pressure obtained by right heart catheterisation. n 
numbers are indicated in brackets. **P<0.01; ***P<0.001 c.f. vehicle control; §P<0.05 c.f. MCT-V, One-way ANOVA with a Bonferroni’s post-hoc test. Data is 
expressed as the mean ± SEM. 
  






























Figure 3-20 Monocrotaline and CYP1B1 inhibition with 2,3′,4,5′-tetramethoxystilbene (TMS) 
on uterus+ovary weights/body weights 
Female and male wistar rats were injected with a single injection of monocrotaline (MCT; 20mg/kg) 
or vehicle (see methods for a detailed description) on day 0. After 2 weeks, rats were injected with 
3mg/kg/day TMS or vehicle (~5% ethanol in saline) for a further 2 weeks. The dry weight of the 
uterus and ovaries were expressed over the body weight. n=5-9.  
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 Survival is improved in rats treated with TMS 3.2.8
Due to the severity of the MCT model, mortality rates increase substantially after about 20 
days post induction, from suspected right heart failure. Mortalities were reported in male 
rats treated with MCT after 23 days and after 26 days in female rats. TMS treatment 
delayed the onset of death in male rats and completely prevented this effect in female rats 
(Figure 3-21). 
 
Figure 3-21 CYP1B1 inhibition with 2,3′,4,5′-tetramethoxystilbene (TMS) improves survival in 
monocrotaline treated rats as assessed by Kaplan-Meier survival analysis 
Female and male wistar rats were injected with a single injection of monocrotaline (MCT; 20mg/kg) 
or vehicle (see methods for a detailed description) on day 0. After 2 weeks, rats were injected with 
3mg/kg/day TMS or vehicle (~5% ethanol in saline) for a further 2 weeks. Each group had 16 rats 
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 Estrogen synthesis and metabolism is dysregulated in 3.2.9
female SERT+ mice 
We have previously reported evidence for dysregulated estrogen metabolism in hypoxic-
associated PH and in human PAH (Chapter 3 and White et al., 2012). Here, we provide 
evidence that estrogen metabolism is dysregulated in female mice that overexpress the 
SERT. This model is unique in that it displays female susceptibility via the effects of 17β-
E2 (White et al., 2011b). Firstly, we demonstrated that the expression of the estrogen-
synthesizing enzyme, aromatase is increased in the lungs of female SERT+ mice compared 
to wild-type mice (Figure 4 1b). Based on this observation, we next determined the levels 
of endogenous 17β-E2 in the lungs of these mice. Despite increased protein expression of 
aromatase, whole lung levels of 17β-E2 were unchanged (Figure 4 1b) 
17β-E2 can undergo further metabolism via activity of CYP enzymes or may be 
interconverted to E1 by activity of 17β-HSD1. Previously we identified a critical role for 
CYP1B1 in PH pathogenesis (Chapter 3 and White et al., 2012). Furthermore the 
expression of CYP1B1 has been reported as increased in the proximal pulmonary arteries 
from female SERT+ mice at 2 months of age (when no PH phenotype is evident) (White et 
al., 2011a). As SERT+ mice do not develop the PH phenotype until 5 months of age, we 
wished to determine whether the expression of CYP1B1 was altered at this age. We 
studied the distal section of the lung as most of the key pathological changes associated 
with PH occur within the distal pulmonary arteries (Yuan & Rubin, 2005). CYP1B1 
mRNA and protein expression was increased in the lungs of female SERT+ mice (Figure 4 
2) 




























































Figure 3-22 Overexpression of SERT+ on aromatase expression and 17β-estradiol 
concentrations in whole lung homogenates 
5-6 month old female wild-type (C57BL/6 x CBA) and SERT+ mice lung homogenates were 
analyzed for aromatase expression and concentrations of 17β-estradiol (17β-E2). Western blot and 
densitometric analysis of aromatase expression. GAPDH was used as the internal loading control 
(a, c). Full western blots are shown in appendix 1. ELISA analysis of 17β-E2 concentrations in 
whole lung homogenates. 400µg of protein was loaded per well and assayed in duplicate. n=4-5, 
**P<0.01, t-test. Data is expressed as the mean ± SEM 
 










Figure 3-23 Lung CYP1B1 expression is increased in female SERT+ mice 
5-6 month old female wild-type (C57BL/6 x CBA) and SERT+ mice lung homogenates were 
analyzed for CYP1B1 expression. qRT-PCR for mRNA of CYP1B1 expression normalized to B2-
microglobulin (a). Western blot and densitometric analysis of CYP1B1 expression in whole lung 
samples from female wild-type and SERT+ mice. GAPDH was used as the internal loading control 
(b-c). Full western blots are shown in appendix 1. n=5-6, *P<0.05, t-test. Data is expressed as the 
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 Inhibition of CYP1B1 regresses pulmonary hypertension in 3.2.10
female SERT+ mice 
Female SERT+ mice exhibit an established PH phenotype at 5-6 months of age (White et 
al., 2011a). We have previously reported that CYP1B1 is involved in the development of 
both hypoxic and SU-hypoxic induced PH. Here, we provide evidence that CYP1B1 
influences the disease pathogenesis in a serotonin/estrogen-dependent model of PH.  
Female SERT+ mice have elevated RVSP compared to age-matched wild-type controls 
and this effect is exaggerated by exposure to chronic hypoxia. Inhibition of CYP1B1 in 
these mice reverses these elevated pressures under both normoxic and hypoxic conditions 
(Figure 3-24 -Figure 3-25). Despite elevated RVSP, female SERT+ mice do not develop 
RVH measured by RV/LV+S. However, on exposure to hypoxia, female SERT+ mice 
develop exaggerated RVH compared to wild-type mice. Inhibition of CYP1B1 with TMS 
(1.5mg/kg/day for 14 days) did not affect RVH in either normoxic or hypoxic conditions 
(Figure 3-26). Pulmonary vascular remodeling was increased in the distal vasculature in 
female SERT+ mice compared to wild-type mice in both normoxic and hypoxic 
conditions. This effect was completely reversed by CYP1B1 inhibition (Figure 3-28). In 
line with this, pulmonary arterial muscularisation was increased in female SERT+ mice 
and this was reduced by TMS treatment under both normoxic and hypoxic conditions 
(Figure 3-27) mSAP were unchanged by SERT overexpression, CYP1B1 inhibition and/or 
hypoxia (Table 3-5). Female SERT+ mice have a reduced heart rate, which is returned to 
rates similar to wild-type mice by TMS therapy. No other effects on heart rate were 
reported (Table 3-5). Interestingly, female SERT+ mice had dramatically lower body 













Figure 3-24 SERT mice have increased right ventricular systolic pressures which are 
exacerbated by hypoxia and reversed by CYP1B1 inhibition with 2,3',4,5'-
tetramethoxystilbene (TMS) 
Female wild-type C57BL/6 x CBA and SERT+ mice were exposed to hypoxia (10% oxygen) or kept 
in room air for 2 weeks. SERT+ mice were either injected with 1.5mg/kg/day TMS or vehicle (~5% 
ethanol in saline) during the 2 week study. Right ventricular systolic pressures (RVSP) were 
assessed by right heart catheterisation. n=7-10, *P<0.05; **P<0.01; ***P<0.001, One-way ANOVA 

















































































































Figure 3-25 Representative right ventricular pressure traces from wild-type, SERT+ and 
SERT+ mice treated with the CYP1B1 inhibitor 2,3',4,5'-tetramethoxystilbene (TMS) 
Representative right ventricular pressures from 5-6 month old female wild-type C57BL/6 x CBA, 
SERT+ mice and SERT+ mice treated with the CYP1B1 inhibitor TMS (1.5mg/kg/day) for 2 weeks. 
Traces were selected at random from each group.  
 




Figure 3-26 Right ventricular hypertrophy in female SERT+ mice in normoxic and hypoxic 
conditions and the effect of CYP1B1 inhibition with 2,3',4,5'-tetramethoxystilbene (TMS) 
Female wild-type C57BL/6 x CBA and SERT+ mice were exposed to hypoxia (10% oxygen) or kept 
in room air for 2 weeks. SERT+ mice were either injected with 1.5mg/kg/day TMS or vehicle (~5% 
ethanol in saline) during the 2 week study. Right ventricular hypertrophy (RVH) was assessed by 
expressing the dry weight of the right ventricle over the left ventricle and septum (RV/LV+S; 
Fultons index). n=9-11, ***P<0.001, One-way ANOVA with a Bonferroni’s post-hoc test. Data is 






















Figure 3-27 Representative α-smooth muscle actin–and von-Willebrand stained pulmonary arteries in wild-type and SERT+ mice treated with vehicle- or 
the  CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene (TMS) 
Female wild-type C57BL/6 x CBA and SERT+ mice were exposed to hypoxia (10% oxygen) or kept in room air for 2 weeks. SERT+ mice were either injected with 
1.5mg/kg/day TMS or vehicle (~5% ethanol in saline) during the 2 week study. Pulmonary arterial endothelial cells and smooth muscle cells are visualised by von 
Willebrand staining (DAB; dark brown colour) and α smooth muscle actin (α-SMA; VIP, pink/purple staining), respectively. V=vehicle. Scale bar = 20µm 






















Figure 3-28 SERT mice have increased pulmonary vascular remodeling and this is reversed 
by CYP1B1 inhibition with 2,3',4,5'-tetramethoxystilbene (TMS) 
Female wild-type C57BL/6 x CBA and SERT+ mice were exposed to hypoxia (10% oxygen) or kept 
in room air for 2 weeks. SERT+ mice were either injected with 1.5mg/kg/day TMS or vehicle (~5% 
ethanol in saline) during the 2 week study. The degree of pulmonary arterial remodeling was 
assessed by counting the number of remodeled and non-remodeled arteries in a lung section and 
expressed as the % of remodeled vessels over the total number of vessels. n=4-6, *P<0.05; 










































Table 3-5 Effect of SERT overexpression, hypoxia and TMS on mean systemic arterial pressures and heart rate 
Animal Group mSAP (mmHg) mRVP (mmHg) Heart rate (bpm) Body Weight (g) 
Wild-type vehicle normoxic 76.99 ± 2.64 (7) 11.84 ± 0.73 (8) 427.70 ± 6.79 (9) 26.31 ± 1.14 (9) 
SERT+ vehicle normoxic 85.16 ± 3.82 (10) 13.99 ± 0.56 (7) 322.80 ± 18.22§ (7) 20.23 ± 0.80§§§ (8) 
 
SERT+ TMS normoxic 90.49 ± 4.58 (9) 13.49 ± 0.62 (9) 395.30 ± 21.37 (9) 17.96 ± 0.98 (10) 
Wild-type vehicle normoxic 85.63 ± 2.35 (8) 18.10 ± 0.61*** (10) 415.60 ± 29.16 (10) 25.01 ± 0.82 (10) 
SERT+ vehicle hypoxic 92.13 ± 5.45 (6) 16.20 ± 0.73 (10) 405.40 ± 17.15 (9) 17.87 ± 0.53§§§ (10) 
SERT+ TMS hypoxic 85.98 ± 2.85 (6) 16.00 ± 0.43 (9) 395.00 ± 24.37 (10) 18.16 ± 0.48 (10) 
Female wild-type C57BL/6 x CBA and SERT+ mice were exposed to hypoxia (10% oxygen) or kept in room air for 2 weeks. SERT+ mice were either injected with 
1.5mg/kg/day TMS or vehicle (~5% ethanol in saline) during the 2 week study. Mean systemic arterial pressures (mSAP) were measured by cannulation of the carotid 
artery. Mean right ventricular pressures (mRVP) were calculated from the right ventricular pressure obtained by right heart catheterisation. n numbers are indicated in 
brackets. ***P<0.001 vs. normoxic control, §P<0.05, §§§P<0.001 vs wild-type control. 
 




The incidence of IPAH and HPAH is more common in women than in men suggesting that 
estrogens and/or their metabolites may be integrated in the pathogenesis of PAH. Whilst 
protective effects of 17β-E2 have been reported in both hypoxic and MCT-induced PH 
(Lahm et al., 2012;Umar et al., 2011;Xu et al., 2010), our present findings suggest that 
altered estrogen metabolism by up-regulation of CYP1B1 influences the development of 
PAH in both sexes. We show that CYP1B1 expression is increased in both experimental 
and clinical pulmonary vascular disease. Moreover, we provide the first unique evidence 
that estrogen metabolism by CYP1B1 is involved in the development of experimental PH. 
The increased cellular expression of CYP1B1 in the pulmonary arteries of patients with 
PAH suggests that its activity may be pertinent to disease pathogenesis and illustrates a 
potential attractive therapeutic target in this thus far un-curable cardiovascular disease. 
Hypoxia is a key mediator in PAH. Thus we wished to investigate the crude effects of 
oxygen deprivation on the estrogen-metabolic axis in healthy hPASMCs. Following a 24 
hour hypoxic exposure, 17β-HSD1 and CYP1B1 protein expression were increased, whilst 
no effects were observed in COMT expression (Figure 3-1). This suggests that elevated 
pathogenic metabolism of 17β-E2 via CYP1B1 may play a role in the development of 
PAH. Furthermore, increased expression of 17β-HSD1 suggests increased conversion of 
the less active E1 to the more active 17β-E2, which can then be further metabolised by 
CYP1B1.  
Given that hypoxia increased CYP1B1 expression in a homogenous population of 
hPASMCs, we next investigated the effects of chronic hypobaric hypoxia for 14 days on 
CYP1B1 expression in murine pulmonary arteries. Here, we show that CYP1B1 
expression was consistently up-regulated in both male and female mice by hypoxia (Figure 
3-2). In addition, combined VEGF-R inhibition with hypoxia for 21 days also increased 
CYP1B1 expression in the distal pulmonary arteries of both male and female mice (Figure 
3-3). Importantly, CYP1B1 expression was also increased in both male and female 
pulmonary arteries from patients with IPAH and HPAH (Figure 3-4 - Figure 3-5). CYP1B1 
expression was localised in both endothelial and smooth muscle cells (Figure 3-5). 
Furthermore, CYP1B1 protein and RNA expression is also increased in pre-clinical and 
human PAH (White et al., 2011a;White et al., 2012). 
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Given the profound vascular expression of CYP1B1, we next wished to investigate the role 
of CYP1B1 on the development of PAH in animal models of PAH. We assessed the 
development of hypoxia-induced PH in CYP1B1-/- mice (Figure 3-6 - Figure 3-10) and 
also examined the effect of chronic inhibition with the selective and potent CYP1B1 
inhibitor, TMS (Figure 3-12 - Figure 3-15). Hypoxia-induced increases in RVSP, RVH, 
pulmonary vascular remodeling and pulmonary intra-arterial vasoconstriction were 
attenuated in male CYP1B1-/- mice. In contrast, RVH was the only PAH parameter that 
was attenuated in female CYP1B1-/- mice in response to chronic hypoxia. CYP1B1 is 
expressed during embryonic development and is constitutively expressed in several adult 
tissues (Choudhary et al., 2003). This highlights a critical role of this enzyme and suggests 
that genetic deletion of CYP1B1 may result in compensatory effects, which may be 
necessary considering the importance of this enzyme in xenobiotic metabolism. We 
therefore wished to investigate the effects of the selective and potent CYP1B1 inhibitor, 
TMS in the hypoxic model of PH to determine if the effects of selective CYP1B1 
inhibition were different from CYP1B1 gene knockout.  Additionally, we wanted to assess 
the therapeutic potential of TMS therapy in PAH. We demonstrated that inhibition of TMS 
attenuated the development of hypoxia-induced PH in both male and female mice, as 
assessed by RVSP, RVH and pulmonary vascular remodeling. 
Although, hypoxia-induced PH is a useful pre-clinical model of PAH, it fails to 
recapitulate the complex arteriopathy that is seen in human PAH. In collaboration with 
Novartis Pharmaceuticals in Horsham, we investigated the role of CYP1B1 in SU-hypoxia 
induced-PAH (White et al., 2012) which is associated with the formation of occluded 
vascular lesions (Ciuclan et al., 2011), which are absent in the classic hypoxic model of 
PH. TMS attenuated the development of SU-hypoxic induced increases in RVSP, RVH, 
pulmonary vascular remodeling and the formation of occluded vascular lesions, further 
supporting a pathogenic effect of CYP1B1 activity in vivo (White et al., 2012). 
Inflammation is a well-documented component associated with the disease pathology of 
PAH (reviewed by Price et al., 2012). MCT is a plant-derived alkaloid that targets and 
disrupts the vascular endothelium which elicits an inflammatory response. It therefore 
drives a distinct disease pathology compared to the hypoxic and SU-hypoxic models of 
PAH. To assess the function of CYP1B1 activity on the progression of PH, we investigated 
the ability of CYP1B1 inhibition on reversal of established PH in the MCT model of PH 
(Figure 3-16 - Figure 3-19). Despite large increases in RVSP and RVH in both males and 
females, there was no development of the complex arteriopathy that is observed in end-
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stage human disease, albeit neointimal lesions were present. The results presented here 
suggest that CYP1B1 inhibition for 2 weeks did not improve pulmonary haemodynamics. 
No effects were observed in response to TMS on reversal of RVH in females, yet moderate 
effects were reported in male rats. Although CYP1B1 inhibition did not significantly 
reverse pulmonary vascular remodeling, there appeared to be a trend towards an 
improvement, that may have been uncovered had treatment been prolonged. From a 
histological perspective, luminal narrowing observed in response to MCT appeared 
reduced in rats treated with TMS (Figure 3-18). Inhibition of CYP1B1 reduced mortality 
rates in male rats treated with MCT and completely prevented mortalities in female rats 
(Figure 3-21). Perhaps, it is not surprising that CYP1B1 inhibition was unable to 
successfully reverse RVH and RVSP in a two-week dosing regimen, given the severity of 
the induced phenotype, especially when the manifested disease is already far advanced. 
However, this is challenged by numerous reports that have shown successful attenuation of 
MCT-PH with various estrogenic drugs, including geinstein (a soy phytoestrogen) (Matori 
et al., 2012) and 17β-E2 (Umar et al., 2011). However, the applicability of this model as a 
pre-clinical model of PAH has been challenged by the lack of similarity with the 
arteriopathy that is the hallmark human PAH, even at the end-stages of MCT-PH 
(reviewed by Gomez-Arroyo et al., 2012a). 
Numerous studies have highlighted beneficial effects of circulating 17β-E2 in the hypoxic 
and MCT models of PAH (Lahm et al., 2012;Umar et al., 2011;White et al., 2011b;Xu et 
al., 2010;Yuan et al., 2013). In contrast, in models that display heightened activity of the 
SERT, circulating 17β-E2 exacerbates disease phenotypes (White et al., 2011b;Dempsie et 
al., 2011). This suggests that SERT may mediate the pathogenic effects of 17β-E2. One 
hypothesis is that SERT mediates the damaging effects of 17β-E2 by up-regulating the 
expression of CYP1B1, thereby altering estrogen metabolism towards the formation of 
pathogenic metabolites (White et al., 2011a). We therefore next investigated the effects of 
CYP1B1 inhibition with TMS in the female susceptible SERT+ model of PH. In this study, 
we provide evidence that the estrogen metabolic axis is dysregulated in female SERT+ 
mice at 5-6 months of age by increased expression of aromatase and CYP1B1 (Figure 3-22 
- Figure 3-23). At 5-6 months of age female SERT+ mice present with a PH phenotype - 
increased PAPs and pulmonary vascular remodeling compared to wild-type mice. 
Inhibition of CYP1B1 with TMS reverses both the increased PAPs and pulmonary vascular 
remodeling to pressures akin to wild-type mice, suggesting that the SERT is mediating its 
effects via increasing CYP1B1 activity (Figure 3-24 - Figure 3-25, Figure 3-27 - Figure 
3-28).  Despite elevated RVSP and pulmonary vascular remodeling, female SERT+ mice 
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do not develop compensatory RVH. This supports previous findings where a dissociate 
mechanism appears to contribute to ventricular remodeling and vascular pressures in this 
model of PAH (White et al., 2011b). In ovariectomized SERT+ mice, exogenous 17β-E2 
reduces RVH (White et al., 2011b) suggesting that 17β-E2 mediates cardioprotective 
effects in this model, despite exerting pathogenic effects within the pulmonary vasculature. 
Thus we propose that the underlying genetic transformations occurring specifically in the 
lung may contribute to vascular remodeling and increased pressures. RVH is an adaptive 
response to increased PAP, which appears absent in mice with a global over-expression of 
the SERT, suggesting that SERT may be mediating direct effects in the heart. This is 
supported by studies that have reported the development of RVH in mice that that 
overexpress SERT specifically in smooth muscle cells driven by the SM22 promoter 
(Guignabert et al., 2006). To challenge this, it would be of interest to investigate the effects 
of pulmonary artery banding on RVH in female SERT+ mice. Pulmonary artery banding is 
a surgical technique that mimics right ventricular pressure overload by ligation of the 
pulmonary artery. Despite the absence of RVH under normoxic conditions, when exposed 
to hypoxia, female SERT+ mice develop exaggerated RVH in comparison to wild-type 
mice exposed to hypoxia, as previously reported (White et al., 2011b). CYP1B1 inhibition 
failed to attenuate the development of hypoxia-induced RVH in these mice, which 
contradicts the beneficial effects of CYP1B1 inhibition on reducing RVH in the hypoxic 
murine models of PH. Thus the absence of a therapeutic effect of CYP1B1 inhibition on 
hypoxia-induced RVH in female SERT+ may be attributable to an effect mediated directly 
by SERT over-expression in the right ventricle. 
Our present in vivo findings highlight a critical role for CYP1B1 in the development and 
pathogenesis of PAH. CYP1B1 is an extra-hepatic estrogen, xenobiotic and fatty acid 
metabolizing enzyme. CYP1B1 metabolizes estrogens (17β-E2 and E1) by hydroxylation 
at the C2, C4 and C16 positions within the carbon ring structure resulting in the formation 
of 2-, 4, 16-hydroxylated estrogens. The biological effects of estrogens will depend on the 
profile of metabolites formed within a target tissue. Increased activity of CYP1B1 will 
therefore alter estrogen metabolism. Proliferative screens of CYP1B1 estrogen metabolites 
suggest that the 16α-hydroxylated estrogens are potent inducers of cellular proliferation in 
hPASMCs (White et al., 2012). Recent evidence has suggested that altered estrogen 
metabolism by CYP1B1 may underlie the development of PAH in patients with BMPR-2 
mutations (Austin et al., 2009). Females harboring a BMPR-2 mutation without any 
evidence of PAH were more likely to present with a polymorphism in CYP1B1 associated 
with an increased degradation of CYP1B1. In PAH patients with a BMPR-2 mutation and 
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the wild-type CYP1B1, the 2-OHE/16α-OHE1 ratio was 2.3 fold lower compared to 
unaffected mutation carriers (Austin et al., 2009), suggesting that CYP1B1 activity is 
associated with the formation of 16α-OHE1. It is therefore likely that the beneficial effects 
of CYP1B1 inhibition observed in our studies are related to a reduction in the metabolism 
of 17β-E2 and E1 towards the formation of 16α-OHE1 (17β-E2 can be converted to E1 
which can then be metabolized to 16α-OHE1 or 16α-OHE2 can be converted to 16α-OHE1 
by the activity of HSD enzymes). However, the 4-hydroxylation of estrogens is recognized 
as the predominant metabolic pathway mediated by CYP1B1 activity (Badawi et al., 
2001;Hanna et al., 2000;Lee et al., 2003). In addition, in the murine lung, normal CYP1B1 
activity is associated with the formation of 4-OHE1 (Peng et al., 2013). The metabolic 
conversion of 17β-E2 by the 4-hydroxylation pathway is recognized to contribute to DNA 
damage by superoxide production (Acharya et al., 2010). We have recently provided 
evidence that 4-hydroxylation induces profound superoxide production in hPASMCs (up to 
6 fold higher after incubations for 5 minutes compared to control) (unpublished data). 
Thus, CYP1B1 may be inducing its pathogenic effects via increased superoxide 
production. 
The beneficial effects of CYP1B1 inhibition in vivo may also be attributable to subsequent 
increases in estrogens available to mediate effects via estrogen receptors through genomic 
and non-genomic signaling or other metabolic pathways. Numerous studies have provided 
evidence that estrogens mediate protective effects in both acute and chronic vascular 
injury.  17β-E2 increases eNOS expression and NO synthesis in pulmonary vascular cells 
via genomic and non-genomic mechanisms through ERα and ERβ (Austin et al., 2013). 
Both endogenous and exogenous estrogens mediate rapid vasodilatory effects of isolated 
pulmonary arterial rings by non-genomic mechanisms (Lahm et al., 2008a). In vivo, 
exogenous 17β-E2 can prevent the onset of hypoxia-induced PH (Lahm et al., 2012) and 
reverse severe PH in the MCT model (Umar et al., 2011). In contrast, in models that 
display female susceptibility, including the SERT+ model, the mts100/A4 overexpressing 
mouse and dexfenfluramine-treated mice, where a PH phenotype is only evident in female 
mice, 17β-E2 is a critical disease mediator (Dempsie et al., 2011;Dempsie et al., 
2013;White et al., 2011b). More recently, we have provided evidence that locally produced 
estrogens via activity of aromatase are associated with the development and progression of 
both hypoxia and SU-hypoxia induced PH (Mair et al., 2013). These conflicting results 
may be attributable to altered estrogen receptor profiles or metabolic enzymes in the 
different models studied.  
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CYP1B1 is also an important enzyme in the metabolism of arachidonic acid into EETs and 
HETEs (Choudhary et al., 2004). Arachidonic acid metabolism results in the formation of 
eicosanoids which have been implicated in both cancers and cardiovascular diseases 
(Capdevila & Falck, 2001). In systemic vascular smooth muscle cells, Ang II and 
arachidonic acid cause migration, proliferation and hypertrophy which is attenuated by 
CYP1B1 inhibition with TMS (Yaghini et al., 2010). This is associated with a reduced 
formation of ROS and its downstream signaling molecules ERK1/2 and p38MAPK 
(Yaghini et al., 2010). In the rabbit pulmonary arteries, arachidonic acid stimulates 
endothelium-dependent vasoconstriction and these effects are greater in female pulmonary 
arteries compared to male pulmonary arteries (Pfister, 2011). 15-HETE is a metabolite 
formed by the metabolism of arachidonic acid by CYP1B1 and 15-lipoxygenase. 15-
lipoxygenase expression and 15-HETE synthesis is greater in female rabbit pulmonary 
arteries compared with males and stimulates vasoconstriction (Pfister, 2011). Taken 
together, the therapeutic effects observed with CYP1B1 inhibition may be via a reduced 
formation of the pulmonary vasoconstrictors, EETs and HETEs. 
Arachidonic acid is also the precursor to prostaglandins by the COX pathway. Prostacyclin 
is a member of the prostanoid family and is a potent vasodilator, with anti-inflammatory 
and anti-mitogenic properties. PAH is associated with increased pulmonary 
vasoconstriction, inflammation and remodeling and prostacyclin analogues are therefore 
used in the management of PAH. Prostacyclin is the principle arachidonic acid metabolite 
(Alhencgelas et al., 1982) and prostacyclin synthase levels are decreased in PAH (Tuder et 
al., 1999). CYP1B1 inhibition may therefore also increase the availability of arachidonic 
acid for subsequent prostacyclin synthesis. 
Arachidonic acid and estrogen metabolism by CYP1B1 are associated with increased ROS 
formation (Yaghini et al., 2010;Chen et al., 2004), which is associated with the 
pathogenesis of PAH (Bowers et al., 2004;Fessel et al., 2013b;Hemnes et al., 2011). Thus 
multiple pathways may interplay to cause injurious ROS production and cellular 
proliferation via CYP1B1 activity, resulting in a pathogenic environment in the pulmonary 
vasculature that can be reversed by CYP1B1 inhibition. The benefits of CYP1B1 inhibition 
may therefore be pertinent to a greater cohort of patients and have further beneficial effects 
that target several conjoined pathways that are associated with the pathology of PAH. 
CYP1B1 expression is increased in hPASMCs by 17β-E2 (White et al., 2011b). Increased 
aromatase activity is associated with the pathogenesis of PAH (Mair et al., 2013) 
suggesting that increased production of estrogens within the pulmonary vasculature may 
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increase CYP1B1 expression therefore driving pathological estrogen and arachidonic acid 
metabolism whilst reducing levels of estrogens and prostacyclins. 
CYP1B1 is a putative pro-carcinogen marker and the results presented here support a role 
for CYP1B1 in PAH. Inhibition of CYP1B1 is currently under phase II clinical trials for 
the treatment of cancer (Luby, 2008) and our data indicates that CYP1B1 inhibition may 
be a promising therapeutic target to restore dysfunctional estrogenic metabolism in PAH. 
Comprehensive analyses of the estrogen metabolic pathway in PAH are merited to provide 
a better understanding of estrogen metabolism in PAH. It is imperative that estrogen-
related therapies are considered in the management of PAH, given the drastic gender 
disparity that is observed in clinic. Perhaps we can learn from our colleagues in oncology, 
whom now effectively treat cancers depending on estrogen status. 
 




Dynamic Alterations in the Estrogen Metabolic 
Axis in Pulmonary Hypertension 




Estrogen and its metabolites are emerging as highly pathogenic mediators in various 
diseases. Among these, the debilitating and fatal cardiovascular disease PH appears to be 
affected by abnormal activity of the estrogen pathway to adversely affect pulmonary 
vascular cell survival and function. PAH is the most fatal subtype of PH and 
predominantly affects women. For example, in the largest PH registry in the World, the 
Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL), more 
than 80% of patients diagnosed were females (Badesch et al., 2010). Altered estrogen 
synthesis (Mair et al., 2013) and metabolism (Chapter 3 and White et al., 2012) contributes 
to the pathogenesis of PAH. We have recently provided evidence that the estrogen 
metabolic axis is dysregulated in PAH in part via the activity of the putatively pathogenic 
CYP enzyme CYP1B1 (Chapter 3 and White et al., 2012). PAH is characterised by 
obstructive vascular lesions in the distal vasculature by excessive PASMC proliferation 
(Archer et al., 2010;Schermuly et al., 2011), suggesting that anti-proliferative therapies are 
needed. Estrogen and its metabolites elicit potent biological effects within target cells (Zhu 
& Conney, 1998), yet the dynamic regulation of estrogen metabolism in PAH remains 
obscure. We hypothesized that estrogen metabolism is pathologically altered in PAH 
towards the formation of pro-proliferative estrogen metabolites. Modulation of the 
estrogen metabolic pathway that favours the formation of anti-proliferative metabolites 
over pro-proliferative metabolites may represent a novel therapeutic strategy in this highly-
gender selective disease. 
The circulating C19 precursor’s testosterone and androstenedione are converted to 17β-E2 
and E1 respectively by the activity of CYP19A1 (aromatase). Recent evidence highlights a 
potential for locally synthesized estrogens (17β-E2 and E1) in the distal pulmonary arteries 
through expression of aromatase (Mair et al., 2013). Tissues can also regulate their own 
estrogenic milieu through the 17β-HSD enzymes. 17β-HSD1 converts E1 into 17β-E2, 
whereas 17β-HSD2 converts 17β-E2 into E1. 17β-E2 and E1 undergo oxidative 
metabolism by the catalytic activity of CYP enzymes in the presence of NADPH to yield 
the 2-, 4- and 16-hydroxylated estrogens (Figure 4-1). The catechol estrogens (the 2- and 
4-hydroxylated estrogens) formed by this transformation can then undergo rapid 
methylation by the activity of COMT to their less estrogenic methoxyestrogens. 
Alternatively, CYP enzymes can also further oxidise catechol estrogens, specifically the 4-
hydroxyestrogens to quinones and semiquinones that can enter redox cycling and interact 
with DNA to form DNA adducts, which can generate apurinic sites resulting in DNA 
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damage. Recently, DNA damage has been shown to be an important mediator in the 
pathogenesis of PAH and provides a novel therapeutic target (Meloche et al., 2013). 
 
Figure 4-1 Summary of the hydroxylation of estrone and 17β-estradiol by human 
cytochrome P450 isoforms 
CYP enzymes that are highlighted in bold have a high activity for the hydroxylation at that specific 
carbon position. Diagram modified and reproduced with permission from Professor Bao-Ting Zhu 
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Both herein (Chapter 3) and previously (White et al., 2012) we present extensive evidence 
that estrogen strongly drives PAH onset specifically through pathologic induction of the 
putative cancer-causing enzyme (Murray et al., 1997) CYP1B1. In effect, this is thought to 
potently shift estrogen metabolism towards the formation of pathogenic metabolites. 16-
hydroxylation and 4-hydroxylation of 17β-E2 represent a pathogenic pathway that may be 
activated by increased CYP1B1 activity (Chapter 3 and White et al., 2012). 16-
hydroxylated estrogens robustly induce proliferation of hPASMCs (Chapter 3 and White et 
al., 2012). The 4-hydroxylated estrogen metabolites are highly associated with 
tumorigenesis via the formation of ROS that can generate apurinic sites leading to DNA 
damage (Acharya et al., 2010). 
The lung hosts a substantial number of CYP enzymes. The most prominent are CYP1A1, 
CYP1B1 and CYP2B6 under normal physiological conditions (Bieche et al., 2007) which 
are predominantly extra-hepatic enzymes. CYP1B1 is also highly expressed in the trachea 
and to a lesser extent in the bone marrow, kidney, heart, mammary gland, prostate, spleen, 
thyroid and uterus (Bieche et al., 2007). CYP1A1 is most highly expressed in the lung but 
is also present within other tissues including the kidney, trachea, liver and mammary gland 
(Bieche et al., 2007). In contrast, CYP2B6 is less abundantly expressed with similar levels 
in the liver compared with the lungs as well as the kidney and trachea (Bieche et al., 2007). 
To date, a comprehensive analysis of estrogen metabolism in PAH has been hampered by 
challenges in measuring estrogens and its metabolites due to their relatively low 
abundance, structural similarities and a required high level of expertise in ‘omics analysis. 
Currently, the most commonly used methodologies include immunoassays, gas 
chromatography mass spectrometry (GC-MS) and liquid chromatography mass 
spectrometry (LC-MS) (Gaikwad, 2013). There is a lack of available immunoassays to 
measure all estrogens of interest and it is impossible to analyse multiple steroids in one 
single assay. GC-MS and LC-MS are considered the gold standard techniques in steroid 
analysis yet they carry selective bias and extensive sample preparation for measurement of 
estrogens. To date, estrogen metabolites have only been preliminarily measured in serum 
from patients with severe PAH (Chhatwani et al., 2010). Aromatase (Mair et al., 2013) and 
CYP1B1 (Chapter 3 and White et al., 2012) are expressed within smooth muscle cells of 
the distal pulmonary vasculature indicating local synthesis and metabolism of estrogens 
potentially creating a potent estrogenic milieu. It was therefore of importance to examine 
and quantitatively measure the dynamic profile of estrogen metabolism in a homogenous 
PASMC culture given that an altered estrogen metabolic profile may figure prominently in 
PAH. Pulmonary vascular smooth muscle cell proliferation is a well-established and 
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dominant feature of PAH (Archer et al., 2010;Schermuly et al., 2011), suggesting that anti-
proliferative therapies are necessary to reverse the extensive vascular obliteration. Thus, 
we developed a methodology adapting a HPLC approach to quantitatively fate map 
estrogen metabolism in a homogenous hPASMC population to determine the dynamic 
regulation of estrogen metabolism in PAH and precisely uncover underlying molecular 
events that contribute to PAH pathogenesis via a dysregulated estrogen metabolic axis. 
In this chapter, we investigated the effects of estrogen metabolites on the pulmonary 
circulation and investigated the metabolism of 17β-E2 in hPASMCs providing the first 
direct evidence that estrogen is metabolized by hPASMCs. We provide evidence that 16α-
OHE1 is a disease-modifying metabolite in female mice only. We demonstrate key 
differences in estrogen metabolism in control and PAH hPASMCs. We provide evidence 
for prominent, yet variable activity of 17β-HSD2 in hPASMCs by the formation of E1, 
considered an inactive reservoir for 17β-E2 synthesis. Importantly, we demonstrate that 
estrogen metabolism is pathologically altered in PAH and highlights a novel treatment 
paradigm in this highly female-selective disease. 
Aims of this chapter: 
1. To assess the contribution of estrogen metabolites on pulmonary haemodynamics 
and cellular function 
2. To develop a method to quantitatively measure estrogen metabolism in pulmonary 
vascular cells 
3. To determine the metabolic fate of 17β-E2 in hPASMCs from naïve cells and PAH-
PASMCs in both males and females 
 




 The CYP1B1 metabolite 16α-hydroxyestrone is increased 4.2.1
by hypoxia 
We have shown that CYP1B1 expression is increased in human PAH and in murine 
experimental models of PH (Chapter 3 and White et al., 2012). Furthermore, genetic 
ablation of CYP1B1 and inhibition of CYP1B1 attenuated the development of hypoxic-
induced-PH. We next wished to identify a mechanistic pathway that mediates CYP1B1 
pathogenesis. Cellular proliferation screening revealed that 16α-OHE1 is the predominant 
CYP1B1 metabolite found to cause significant proliferation in control hPASMCs (White et 
al., 2012). As an indicative measure of CYP1B1 activity in murine PH, we assessed 
urinary concentrations of 16α-OHE1 in response to chronic hypoxia exposure. Urinary 
concentrations of 16α-OHE1 were increased in both male and female mice following 
exposure to chronic hypoxia (Figure 4-2).  
 16α-hydroxyestrone inflicts a pulmonary hypertensive 4.2.2
phenotype in female mice only 
To determine whether 16α-OHE1 is a pulmonary vascular insult that can directly cause a 
PH phenotype in vivo, mice were administered 16α-OHE1 for 28 days (Figure 4-4). Dr. 
Kevin White and Ms. Leigh Paton performed the entire female dosing, in vivo procedures, 
pulmonary vascular remodeling and α-SMA analysis of this study. In female mice, 16α-
OHE1 resulted in increased RVSP, RVH and pulmonary vascular remodeling. In contrast, 
no effects were observed in male mice in any of the parameters measured. The effects 
observed were specific to the cardio-pulmonary unit in female mice, as no changes were 
measured in mSAP. In contrast, 16α-OHE1 significantly reduced mSAP in male mice 
(Table 4-1). 
 



































Figure 4-2 Urinary levels of the 16α-hydroxyestrone is increased by chronic hypoxia in male 
and female mice 
Urinary levels of 16α-hydroxyestrone (16α-OHE1) were assessed in the urine of mice kept at 
normoxic conditions or after exposure to 2 weeks hypoxia (10% oxygen) by a competitive 
immunoassay (ESTRAMET 2/16). n=5, *P<0.05, t-test, data is expressed as the mean ± SEM.  
 




Figure 4-3 16α-hydroxyestrone (16α-OHE1) induces right ventricular hypertrophy in female 
mice only 
Female and male C57BL/6 mice were dosed with 16α-OHE1 1.5mg/kg/day or vehicle (~5% ethanol 
in saline) for 28 days. Right ventricular hypertrophy was assessed by expressing the dry weight of 
the right ventricle over the left ventricle and septum (RV/LV+S; Fultons index). n=7-10 per group, 




















Figure 4-4 16α-hydroxyestrone (16α-OHE1) increases right ventricular systolic pressures in 
female mice only 
Female and male C57BL/6 mice were dosed with 16α-OHE1 1.5mg/kg/day or vehicle (~5% ethanol 
in saline) for 28 days. Right ventricular systolic pressures (RVSP) were measured by right heart 
catheterisation. n=7-8 per group, **P<0.01 One-way ANOVA with a Bonferroni’s post-hoc test. 

























Figure 4-5 Representative α-smooth muscle actin–stained pulmonary arteries in 16α-
hydroxyestrone (16α-OHE1) or vehicle treated C57BL/6 male and female mice 
Female and male C57BL/6 mice were treated with16α-hydroxyestrone (16α-OHE1, 1.5mg/kg/day) 
or vehicle (~5% ethanol in saline) for 28 days. Muscularisation is visualised by α-smooth muscle 


















Figure 4-6 16α-hydroxyestrone (16αOHE1) increases pulmonary arterial remodeling in 
female mice only 
Female and male C57BL/6 mice were treated with16α-hydroxyestrone (16α-OHE1, 1.5mg/kg/day) 
or vehicle (~5% ethanol in saline) for 28 days. The degree of pulmonary arterial remodeling was 
assessed by counting the number of remodeled and non-remodeled arteries in a lung section and 
expressed as the % of remodeled vessels over the total number of vessels. n=4-6 per group, 





























Table 4-1 Phenotypic data from 16α-hydroxyestrone treated mice 
Animal Group mSAP (mmHg) mRVP (mmHg) Heart Rate (bpm) Body Weight (g) 
Female Vehicle 76.68 ±1.97 (5) 12.34 ± 0.45 (9) 437.1 ± 19.87 (9) 23.16 ± 0.56 (10) 
Female 16α-OHE1 86.39 ± 3.10 (6) 14.95 ± 0.72* (9) 487.8 ± 22.40 (9) 23.63 ± 1.05 (10) 
Male Vehicle 91.14 ± 2.20 (7) 13.58 ± 0.40 (10) 407.6 ± 11.72 (10) 23.92 ± 0.43 (10) 
Male 16α-OHE1 76.87 ± 2.39** (9) 14.55 ± 0.89 (8) 434.5 ± 11.66 (9) 24.01 ± 0.48 (10) 
Female and male C57BL/6 mice were treated with16α-hydroxyestrone (16α-OHE1, 1.5mg/kg/day) or vehicle (~5% ethanol in saline) for 28 days. Mean systemic 
arterial pressures (mSAP) were measured by cannulation of the carotid artery. Mean right ventricular pressures (mRVP) were calculated from the right ventricular 
pressure obtained by right heart catheterisation. n numbers are indicated in brackets. *P<0.05, **P<0.001  
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 16α-hydroxyestrone-induced proliferation is inhibited by a 4.2.3
reactive oxygen species scavenger and an inhibitor of 
extracellular regulated kinase 1/2 
We have shown that 16α-OHE1 induces a PH phenotype in female mice only and that it is 
a potent induced of hPASMCs proliferation (White et al., 2012). We were therefore 
interested in investigating potential mechanisms related to this accelerated rate of 
proliferation. CYP1B1 is recognised to facilitate production of ROS which mediates 
phosphorylation of the target gene ERK1/2 (Jennings et al., 2010;Jennings et al., 2012). It 
was therefore of interest to investigate the effects of a ROS scavenger (tempol) and an 
inhibitor of ERK1/2 inhibitor (UO126) on 16α-OHE1-induced proliferation. hPASMCs did 
not proliferate to 16α-OHE1 in the presence of either tempol or UO126, providing 





































































Figure 4-7 16α-hydroxyestrone (16α-OHE1)-induced proliferation in human pulmonary 
arterial smooth muscle cells (hPASMCs) is mediated by the formation of reactive oxygen 
species (ROS) 
Female PAH hPASMCs were quiesced for 24 hours in 0.2% charcoal-stripped FBS (estrogen free) 
phenol red free DMEM. HPASMCs were then pre-incubated with a vehicle (water), an ERK inhibitor 
(UO126, 1μM) or tempol (ROS scavenger, 1mM) for 45 minutes prior to addition of 16α-OHE1 
(1nM) in the presence of 2.5% charcoal-stripped FBS phenol red free DMEM. Thymidine was 
added for the last 24 hours (0.1μCi) and thymidine incorporation was assessed after 72 hours. The 
effect of inhibitors alone is included in appendix 1. n=1, repeated 4 times, **P<0.01, One-way 
ANOVA with a Bonferroni’s post-hoc test. Data is expressed as the mean ± SEM. 
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 4-hydroxyestradiol attenuates serotonin-induced 4.2.4
vasoconstriction in the pulmonary arteries 
16α-OHE1 and 16αOHE2 were the only CYP1B1 metabolite to induce proliferation of 
hPASMCs (White et al., 2012). However, other pathogenic effects beyond smooth muscle 
cell proliferation may be present. We could therefore not conclude that all effects of 
CYP1B1 were mediated via formation of 16α-OHE1. 4-hydroxylation of 17β-E2 is the 
predominant metabolic pathway of CYP1B1 activity. We therefore wished to determine 
the effects of 4-OHE2 in vivo. No effect was observed in RVSP, RVH (Figure 4-8) or 
mSAP (Table 4-2). Body weights were significantly reduced in mice dosed with 4-OHE2 
(Table 4-2) 
Surprisingly, serotonin-induced pulmonary arterial vasoconstriction was significantly 
reduced in mice that had been treated with 4-OHE2 compared to their vehicle controls 
Figure 4-10. Given the high estrogenic activity of 4-OHE2 we also monitored potential 
hypertrophic/growth effects of the reproductive organs. 4-OHE2 significantly increased the 
dry weight of the uterus and ovaries combined compared to the control-vehicle group 
(Figure 4-11). Furthermore, this was accompanied by a fluid-filled uterus indicating 
hydrometrocolpolis. 
 




Figure 4-8 4-hydroxyestradiol (4-OHE2) has no effects on right ventricular hypertrophy or 
right ventricular systolic pressures 
Female C57BL/6 mice were dosed with 4-OHE2 (1.5mg/kg/day) or vehicle (~5% ethanol in saline) 
for 28 days. Right ventricular hypertrophy was assessed by expressing the dry weight of the right 
ventricle over the left ventricle and septum (RV/LV+S; Fultons index (a). Right ventricular systolic 
pressures (RVSP) were measured by right heart catheterisation (b). n=6-10. One-way ANOVA with 
















































Figure 4-9 4-hydroxyestradiol had no effects on pulmonary vascular remodeling 
Female C57BL/6 mice were dosed with 4-OHE2 (1.5mg/kg/day) or vehicle (~5% ethanol in saline) 
for 28 days. Representative α-smooth muscle actin–stained pulmonary arteries in 4-OHE2 or 
vehicle treated C57BL/6 female mice and percentage of remodeled pulmonary arteries. The degree 
of pulmonary arterial remodeling was assessed by counting the number of remodeled and non-
remodeled arteries in a lung section and expressed as the % of remodeled vessels over the total 
number of vessels. n=5-6, One-way ANOVA with a Bonferroni’s post-hoc test. Data is expressed 
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Figure 4-10 4-hydroxyestradiol reduces serotonin-induced vasoconstriction 
Female C57BL/6 mice were dosed with 4-OHE2 (1.5mg/kg/day) or vehicle (~5% ethanol in saline) 
for 28 days. The intra-pulmonary arteries were isolated from mice at sacrifice and mounted in a 
myograph. The arteries were constricted twice by increasing extracellular concentrations to 50mM 
potassium chloride (KCl). The second response was used as a reference constriction to calculate 
the % vasoconstriction in response to serotonin. Following a wash-out and re-stabilization, 
cumulative concentration response curves to serotonin were constructed. Cumulative concentration 
response curves to serotonin (a). Area under the curve analysis (b). n=6-7, *P<0.05, t-test. Data is 
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Table 4-2 Phenotypic data from 4-hydroxyestradiol treated mice 
Animal Group mSAP (mmHg) mRVP (mmHg) Heart Rate (bpm) Body Weight (g) 
Female Vehicle 84.22 ± 1.51 (4) 11.45 ± 0.42 (6) 366.0 ± 24.20 (6) 18.75 ± 0.56 (6) 
Female 4-OHE2 83.31 ± 5.76 (8) 12.60 ±0.63 (9) 375.6 ± 12.19 (9) 17.61 ± 0.17** (10) 
Female C57BL/6 mice were dosed with 4-OHE2 (1.5mg/kg/day) or vehicle (~5% ethanol in saline) 
for 28 days. Mean systemic arterial pressures (mSAP) were measured by cannulation of the carotid 
artery. Mean right ventricular pressures (mRVP) were calculated from the right ventricular pressure 
obtained by right heart catheterisation. n numbers are indicated in brackets **P<0.01. 
 
Figure 4-11 Effect of 4-hydroxyestradiol on uterus + ovary weights 
Female C57BL/6 mice were dosed with 4-OHE2 (1.5mg/kg/day) or vehicle (~5% ethanol in saline) 
for 28 days. The dry weight of the uterus and ovaries were expressed over the body weight, n=5-
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 Effect of estrogen metabolism by CYP1B1 on cellular 4.2.5
function 
Recent evidence has highlighted that the predominant CYP1B1 metabolite in the lungs of 
mice is 4-OHE1 (Peng et al., 2013). Thus, we assessed the functional consequences of 
increased CYP1B1 activity in hPASMCs from female control patients by exposure to 4-
OHE1 (Figure 4-12 - Figure 4-15). 4-OHE1 had no effect on cell viability as assessed by 
quantification for ATP after 3 and 5 days incubation. In contrast, 4-OHE1 dramatically 
reduced DNA replication as assessed by a reduction in thymidine incorporation at 3 days 
(Figure 4-12). Following a 5-day incubation with 4-OHE1, this effect was no longer 
observed (Figure 4-13).  
CYP1B1-/- mouse lungs have a higher concentration of 2-MeOHE2 (Peng et al., 2013) 
suggesting that this is negatively regulated by CYP1B1 activity. We were therefore 
interested in determining the effects of 2-MeOHE2 on cellular viability and proliferation 
(Figure 4-12 - Figure 4-15). 2-MeOHE2 caused a dramatic reduction in cell viability and 
proliferation as assessed by ATP and thymidine incorporation assays, respectively, 
following incubations for both 3 and 5 days.  
 




































































































































Figure 4-12 Effect of 4-hydroxyestrone (4-OHE1) and 2-methoxyestradiol (2-MeOHE2) on 
human pulmonary arterial smooth muscle cell (hPASMC) viability and proliferation for 3 
days 
Female control hPASMCs were quiesced for 24 hours in 0.2% charcoal-stripped FBS (estrogen 
free) phenol red free DMEM. hPASMCs were then incubated with either 4-OHE1 (1μM), 2-
MeOHE2 (1μM) or vehicle (0.01% ethanol) for 3 days in 1% or 3% charcoal-stripped FBS phenol 
red free DMEM and assessed for cell viability with the CellTiter-Glow® luminescence assay (a) and 
cell proliferation by the thymidine incorporation assay (b) n=1-2, repeated 4 times per cell line. 
**P<0.01, ***P<0.001. One-way ANOVA with a Bonferroni’s post-hoc test. Data is expressed as the 
mean ± SEM. 


































































































































Figure 4-13 Effect of 4-hydroxyestrone (4-OHE1) and 2-methoxyestradiol (2-MeOHE2) on 
human pulmonary arterial smooth muscle cell (hPASMC) viability and proliferation for 3 
days 
Female control hPASMCs were quiesced for 24 hours in 0.2% charcoal-stripped FBS (estrogen 
free) phenol red free DMEM. hPASMCs were then incubated with either 4-OHE1 (1μM), 2-
MeOHE2 (1μM) or vehicle (0.01% ethanol) for 5 days in 1% or 3% charcoal-stripped FBS phenol 
red free DMEM and assessed for cell viability with the CellTiter-Glow® luminescence assay (a) and 
cell proliferation by the thymidine incorporation assay (b) n=2, repeated 4 times per cell line. 
**P<0.01, ***P<0.001. One-way ANOVA with a Bonferroni’s post-hoc test. Data is expressed as the 
mean ± SEM. 




Figure 4-14 Representative microphotographs of human pulmonary arterial smooth muscle 
cells (hPASMCs) following incubations with 4-hydroxyestrone (4-OHE1) and 2-
methoxyestradiol (2-MeOHE2) for 3 days 
Female control hPASMCs were quiesced for 24 hours in 0.2% charcoal-stripped FBS (estrogen 
free) phenol red free DMEM. HPASMCs were then incubated with 4-OHE1 (1μM), 2-MeOHE2 
(1μM) or vehicle (0.01% ethanol) for 3 days in 1% or 3% charcoal-stripped FBS phenol red free 
DMEM. Representative images of each condition are shown. 
 
Figure 4-15 Representative microphotographs of human pulmonary arterial smooth muscle 
cells (hPASMCs) following incubations with 4-hydroxyestrone (4-OHE1) and 2-
methoxyestradiol (2-MeOHE2) for 5 days 
Female control hPASMCs were quiesced for 24 hours in 0.2% charcoal-stripped FBS (estrogen 
free) phenol red free DMEM. HPASMCs were then incubated with 4-OHE1 (1μM), 2-MeOHE2 
(1μM) or vehicle (0.01% ethanol) for 5 days in 1% or 3% charcoal-stripped FBS phenol red free 
DMEM. Representative images of each condition are shown. 
 
1% Serum          +4-OHE1 (1μM)      +2-MeOHE2 (1μM)              3%                 +4-OHE1 (1μM)    +2-MeOHE2 (1μM) 
1% Serum          +4-OHE1 (1μM)      +2-MeOHE2 (1μM)              3%                 +4-OHE1 (1μM)    +2-MeOHE2 (1μM) 
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 17β-estradiol intracellular levels in human pulmonary 4.2.6
arterial smooth muscle cells 
Aromatase is expressed in both murine and human pulmonary arteries, providing evidence 
for local synthesis of estrogens (Mair et al., 2013). Here, we provide evidence that 17β-E2 
is present in abundance in hPASMCs (Figure 4-16). No differences in 17β-E2 levels were 
observed in patients with PAH compared to control samples. There were also no gender 
differences. We have recently provided evidence for interactions of the estrogen and 
serotonin pathways (White et al., 2011b). We were therefore interested in investigating the 
effects of serotonin on intracellular 17β-E2 concentrations. Serotonin had no effects in any 
of the groups studied. 
 Depletion of 17β-estradiol from the extracellular medium in 4.2.7
human pulmonary arterial smooth muscle cells 
To directly measure intracellular flux of 17β-E2 in hPASMCs, female control and PAH-
hPASMCs were incubated with 17β-E2 and the extracellular medium was collected to 
analyse the depletion of 17β-E2 at various time-points (Figure 4-17). After ten minutes, 
there were no differences in the control hPASMCs and the PAH-hPASMCs. After 24 
hours, there was substantially less 17β-E2 in the extracellular medium in the PAH 
hPASMCs in comparison to the control hPASMCs. 
 Patient characteristics 4.2.8
Intracellular levels of 17β-E2 was analysed in hPASMCs homogenates from both male and 
female control and PAH samples. The patients used for these studies are listed in the tables 
below. We have provided evidence that estrogen metabolism is dysregulated in PH/PAH 
by increased expression of CYP1B1. We were therefore interested to develop a 
methodology to quantitatively determine estrogen metabolism in pulmonary vascular cells. 
Due to the valuable nature of this cell type and time constraints of this project, each 
experiment was performed in one patient, in duplicate over two separate passages. For 
clarification, the female control used for this study was a 59 year old female, the male 
control was a 62 year old male with emphysema, the female PAH patient was a 24 year-old 
female with IPAH and the male PAH patient was a 43 year-old male with APAH 
(Eisenmengers syndrome). See Table 4-3 and Table 4-4 for patient characteristics. 
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Table 4-3 Patient characteristics of control human pulmonary arterial smooth muscle cells 
Sex Age Patient Information Drug Therapy 
F 64 N/A aspirin 
F 58 Mild emphysema N/A 
F 59 N/A Aspirin, simvastatin, bisoprolol, ramipril, metalazine, wuinine 
sulphate, loperamide 
F N/A N/A N/A 
M 72 N/A N/A 
M 62 N/A N/A 
M 76 N/A N/A 
M N/A N/A N/A 
 
Table 4-4 Patient characteristics of pulmonary arterial hypertension human pulmonary 
arterial smooth muscle cells 
Sex Age Patient Information mPAP (mmHg) Drug Therapy 
F 24 IPAH N/A N/A 
F 30 HPAH (R899X 
mutation) 
46 IV prostanoids, warfarin, zopliclone, 
mebeverine, frusimide 
F 33 IPAH 33 IV prostanoids, bosentan, frusemide, 
adizem 
M 43 APAH (Eisenmengers 
syndrome) 
N/A N/A 
M 17 HPAH (W9X mutation) 72 IV prostanoids, warfarin, iloprost 
 
 







control      PAH      control      PAH























Figure 4-16 Intracellular 17β-estradiol (17β-E2) concentrations in pulmonary arterial smooth 
muscle cells (hPASMCs): effect of serotonin 
17β-E2 levels were measured in hPASMCs by ELISA. HPASMCs were grown to 70% confluency 
and then serum starved in 0.2% charcoal-stripped (estrogen free) DMEM for 24 hours to 
synchronise the cells. The medium was then changed to 10% charcoal stripped DMEM and 
maintained under these conditions for 48 hours. The cells were lysed with 1% lauryl maltoside 
buffer and assayed by ELISA. 50μg of protein was loaded per well. n=2-4 patients per group, 
assayed in duplicate. One-way ANOVA with a Bonferroni’s post-hoc test. Data is expressed as the 
mean ± SEM.  
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Figure 4-17 Depletion of 17β-estradiol from the extracellular medium in human pulmonary 
arterial smooth muscle cells (hPASMCs) 
HPASMCs from a control and PAH patient were incubated with 17β-estradiol (17βE2; 
272.38pg/mL) for 10 minutes and 24 hours. Extracellular (medium) levels of 17β-E2 were assayed 
by ELISA. Basal levels of 17β-E2 in the medium used were almost undetected. The media used for 
these studies was twice charcoal-stripped (steroid free) phenol-red free DMEM. n=1 patient per 
group, assayed in duplicate, **P<0.01 t-test comparing the mean ±SEM. 
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 Absorption profiles of estrogen metabolites by high 4.2.9
performance liquid chromatography 
Initially, we identified the unique absorption profiles of the 15 (of the 49 authentic 
estrogen metabolites of 17β-E2 and E1 (Lee et al., 2003)) most prominent estrogen 
metabolites using an isocratic mobile phase constituted of water (50%), acetonitrile (30%) 
and methanol (20%) at a flow rate of 1mL per minute at 25°C. Metabolites were separated 
with a Sunfire C18 5µm, 4.6 x 150mm column (Waters, UK). 100µL of each metabolite at 
a concentration of 1μg/ml was injected into the HPLC and detected by UV light. Under 
these conditions, all metabolites were identified within the first 20 minutes (Figure 4-18 - 
Figure 4-21).  
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Figure 4-18 Chromatograms of 17β-estradiol, estrone and 17α-estradiol 
Chromatograms of estrogens following high performance liquid chromatography with 
ultraviolet absorption (λ200nm). 100μL of 17β-estradiol, estrone and 17α-estradiol 
standards at a concentration of 1μg/mL was injected onto the Sunfire C18 5µm, 4.6 x 
150mm column and run under isocratic conditions in a mobile phase consisting of water, 
acetonitrile and methanol in the ratio 50-30-20 at a flow rate of 1mL/min at 25ºC. mAu, 
milli absorbance unit. 




Figure 4-19 Chromatograms of 16α-hydroxyestrone, 16α-hydroxyestradiol, 16 epiestriol and 
17 epiestriol 
Chromatograms of estrogens following high performance liquid chromatography with 
ultraviolet absorption (λ200nm). 100μL of 16α-hydroxyestrone, 16α-hydroxyestradiol, 16 
epiestriol and 17 epiestriol standards at a concentration of 1μg/mL was injected onto the 
Sunfire C18 5µm, 4.6 x 150mm column and run under isocratic conditions in a mobile 
phase consisting of water, acetonitrile and methanol in the ratio 50-30-20 at a flow rate of 
1mL/min at 25ºC. mAu, milli absorbance unit. 
























































Figure 4-20 Chromatograms of 2-hydroxyestrone, 2-hydroxyestradiol, 4-hydroxyestrone and 
4-hydroxyestradiol 
Chromatograms of estrogens following high performance liquid chromatography with 
ultraviolet absorption (λ200nm). 100μL 2-hydroxyestrone, 2-hydroxyestradiol, 4-
hydroxyestrone and 4-hydroxyestradiol standards at a concentration of 1μg/mL was 
injected onto the Sunfire C18 5µm, 4.6 x 150mm column and run under isocratic 
conditions in a mobile phase consisting of water, acetonitrile and methanol in the ratio 50-
30-20 at a flow rate of 1mL/min at 25ºC. mAu, milli absorbance unit. 
 
 
























































Figure 4-21 Chromatograms of 2-methoxyestrone, 2-methoxyestradiol, 4-methoxyestrone 
and 4-methoxyestradiol 
Chromatograms of estrogens following high performance liquid chromatography with 
ultraviolet absorption (λ200nm). 100μL of 2-methoxyestrone, 2-methoxyestradiol, 4-
methoxyestrone and 4-methoxyestradiol standards at a concentration of 1μg/mL was 
injected onto the Sunfire C18 5µm, 4.6 x 150mm column and run under isocratic 
conditions in a mobile phase consisting of water, acetonitrile and methanol in the ratio 50-
30-20 at a flow rate of 1mL/min at 25ºC. mAu, milli absorbance unit. 
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 Combined chromatogram of estrogen metabolites 4.2.10
Our goal was to separate all 15 estrogen metabolites in a single chromatographic run to 
enable comparative analysis. To achieve this, we applied a gradient elution mode 
(alteration of the mobile phase during the run), which allows for further separation 
depending on the interaction of the estrogen metabolites with the stationary and mobile 
phases. This was essential due to the structural similarity of all metabolites. 
All estrogen metabolites were successfully separated on gradient elution mode at λ200nm 
at 25ºC (Figure 4-22). The mobile phase consisted of water, acetonitrile and methanol. The 
initial mobile phase consisted of 50-10-40 WAM for 1 minute and switched to 55-40-5 
over 8 minutes and maintained for 2 minutes in this mobile phase composition. This was 
changed to 50-30-20 over 1 minute and maintained for 9 minutes. The mobile phase was 
the reverted back to the initial mobile phase for stabilisation of the UV signal for 10 
minutes. 
This column allowed for efficient separation for the estrogens with simultaneous detection 
by the UV system. The programme was initially extremely useful to identify the section of 
the chromatographic profile where our metabolite peaks formed. However, the widths of 
the peaks on the radio-labelled HPLC resulted in some difficulties in peak assignment 
between closely eluting peaks. It was therefore essential to do further method development 
to suit the different metabolite formation. The samples were therefore also separated with 
an Allure Biphenyl 5µm, 4.6 x 150mm column (Restek, UK) at 30ºC with reverse phase 
chromatography in isocratic mode using water and methanol in the mobile phase (32% 
water:78% methanol). All peak integrations for quantification were obtained from the 
sample run in the Allure Biphenyl column. Peak identification was confirmed using the 




Figure 4-22 Ultraviolet absorption profiles of the 15 estrogen metabolites with the Sunfire C18 column 
The 15 most prominent estrogen metabolites were separated by high performance liquid chromatography and detected by ultraviolet (UV) absorption in gradient elution 
mode (the baseline alters due to the variations in absorption during the solvent gradient and was reset at 9 and 12 minutes). The mobile phase consisted of water, 
acetonitrile and methanol (WAM). The mobile phase was altered to 55-40-4 over a gradient from 1 to 8 minutes and maintained for 2 minutes under these conditions. 
The mobile phase was then switched to 50-30-20 in a ballistic gradient over 1 minute and maintained in these conditions for a subsequent 9 minutes. The mobile 
phase was then returned to the initial mobile phase for stabilisation of the UV signal for 10 minutes. (See Table 4-5 for individual peak identification). 
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Table 4-5 Estrogen compound retention times on the Sunfire C18 Column 
Peak Estrogen Compound Abbreviation Retention Time (Mins) 
1 16α-Hydroxyestradiol 16α-OHE2 5.2 
2 16α-Hydroxyestrone 16α-OHE1 7.2 
3 16-Epiestriol 16-epi-E3 8.0 
4 17-Epiestriol 17-epi-E3 8.6 
5 4-Hydroxyestradiol 4-OHE2 9.8 
6 2-Hydroxyestradiol 2-OHE2 10.5 
7 2-Hydroxyestrone 2-OHE1 11.4 
8 4-Hydroxyestrone 4-OHE1 11.7 
9 17β-Estradiol 17β-E2 12.9 
10 4-Methoxyestradiol 4-MeOHE2 13.5 
11 17α-Estradiol 17α-E2 14.3 
12 2-Methoxyestradiol 2-MeOHE2 14.8 
13 Estrone E1 16.0 
14 4-Methoxyestrone 4-MeOHE1 17.5 
15 2-Methoxyestrone 2-MeOHE1 18.6 
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 Extraction of estrogen metabolites-method development 4.2.11
Estrogen metabolites are hydrophobic compounds that require extraction from their sample 
matrix (to remove non-specific interference) by either SPE or solvent extractions. The goal 
was to identify the most efficient method to extract all the 15 estrogen metabolites with the 
best recoveries. For the solvent extractions, we tested ethyl acetate, dichloromethane and 
ether in the ratios (aqueous: solvent) 1:1, 1:5, 1:10 with the sample medium (not all sample 
extractions were successful). Extraction recoveries of the 15 standards were assessed by 
comparisons of extracted samples with samples without an extraction step and samples 
where the estrogen standards were added after the extraction (See Chapter 2). The 
recoveries of the estrogens using solvent extractions was inconsistent and relatively poor 
(Figure 4-23-Figure 4-25; ranging from 0 – 95% recoveries, although only few metabolites 
were recovered to this level). We tested the application of SPE to extract our samples using 
Oasis® HLB columns (Waters, UK). This was also an advantage due to the large sample 
volumes (10ml) that we were working with. The extraction recoveries using the Oasis® 
HLB columns were consistent across all estrogen metabolites and had excellent recoveries 
(85 - 100%; Figure 4-26). This was therefore our chosen extraction method for all samples. 
The extractions were much more consistent in the pre-spiked vs. post-spiked samples 
compared to the pre-spiked vs. the control samples. The former is however the most 
representative as both samples contain the sample matrix (the cell culture medium) which 
may affect the chromatographic profile.  
 Extraction and recovery of 14C-17β-estradiol 4.2.12
We had developed a robust methodology for the extraction of the estrogen metabolites. We 
confirmed that this methodology was equally efficient at extracting radiolabelled 17β-E2 
(14C-17β-E2; Figure 4-27).  




Figure 4-23 Extraction recoveries of estrogen metabolites with a ethyl acetate solvent 
extraction 
Estrogen metabolite extractions was assessed with a solvent extraction using ethyl acetate in the 
ratios 1:1, 1:5 and 1:10 (sample: ethyl acetate) and the percentage extraction recoveries were 
calculated. Estrogen metabolites (2.5μg of each metabolite) were added to the sample matrix (1% 
charcoal-stripped phenol red free DMEM) and then extracted using ethyl acetate. Percentage 
















































































































































































































































































































Figure 4-24 Extraction recoveries of estrogen metabolites with a dichloromethane solvent 
extraction 
Estrogen metabolite extractions was assessed with a solvent extraction using dichloromethane in 
the ratios 1:5 and 1:10 (sample: dichloromethane) and the percentage extraction recoveries were 
calculated. Estrogen metabolites (2.5μg of each metabolite) were added to the sample matrix (1% 
charcoal-stripped phenol red free DMEM) and then extracted using dichloromethane. Percentage 











































































































































































































Figure 4-25 Extraction recoveries of estrogen metabolites with a diethyl ether solvent 
extraction 
Estrogen metabolite extractions was assessed with a solvent extraction using diethyl ether in the 
ratios 1:1, 1:5 and 1:10 (sample: diethyl ether) and the percentage extraction recoveries were 
calculated. Estrogen metabolites (2.5μg of each metabolite) were added to the sample matrix (1% 
charcoal-stripped phenol red free DMEM) and then extracted using diethyl ether. Percentage 





































































































Figure 4-26 Extraction recovery of estrogen metabolites using Oasis® HLB columns 
Estrogen metabolite extractions was assessed by solid phase extraction using the Oasis® HLB 
columns and the percentage extraction recoveries were calculated. Estrogen metabolites (2.5μg of 
each metabolite) were added to the sample matrix (1% charcoal-stripped phenol red free DMEM) 
either before (pre-spiked) or after the extraction (post-spiked) Percentage recoveries were 
calculated by expressing the extracted metabolite over the un-extracted metabolite (control) or the 
post-spiked sample. Extraction recoveries of estrogen metabolites in pre-spiked samples vs. post-
spiked samples (a). Extraction recoveries in pre-spiked samples vs. control samples (b) A few 
peaks merged together making it more suitable to analyze the peaks together. Each extraction was 






































































































































































































Figure 4-27 Percentage extraction recovery of radiolabelled 17β-estradiol 
Extraction recovery of radiolabelled 17β-estradiol (14C-17β-E2) using Oasis® HLB columns. Pre-
spiked samples represent samples where the estrogen metabolites were added prior to extraction. 
In the post-spiked samples, the estrogen metabolites were added after the extraction and in the 
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 Estrogen metabolism over time in human pulmonary 4.2.13
arterial smooth muscle cells 
For clarity, this data is presented in two ways. Firstly, the data is represented as the 
depletion of 17β-E2 and metabolite formation over time in individual cell lines and 
secondly, the data is represented as comparisons across female and male, control and PAH 
hPASMCs within each time-point.  
In female control hPASMCs (Figure 4-28) there was no evidence of enzymatic activity 
between 10 minutes and 1 hour. After 2 hours, there was a small amount of E1 present 
within the sample. This implicates activity of 17β-HSD2, which converts 17β-E2 to E1. 
This gradually increased over time until 48 hours where ~50% of the 17β-E2 had been 
converted to E1. This was the only metabolite that appeared in female control hPASMCs. 
In male control hPASMCs (Figure 4-29) there was substantially more enzymatic activity in 
comparison to female control hPASMCs. After 10 minutes, E1 and the 2 and 4-
methoxylated estrogens were present within the samples. This indicates activity of 17β-
HSD2, CYP and COMT. Whilst there were no hydroxylated metabolites present within the 
sample, the presence of methoxylated estrogens provides evidence that hydroxylated 
estrogens had been formed prior to the sample collection. Over time, there was direct 
evidence of 17β-HSD2, CYP and COMT activities with the most abundant metabolite 
formed being E1. After 1 hour incubation, ~50% of the parent 17β-E2 had been 
metabolised (predominantly to E1). After 48 hours, there was no 17β-E2 left within the 
sample. Interestingly, formation of 17-Epi-E3 was observed at 30 minutes, yet was 
undetected at any other time-point. 
In female PAH hPASMCs (Figure 4-30), there was evidence of 2-hydroxylation and 
methylation as well as 17β-HSD2 activity between the time-points 10 minutes and 2 hours. 
At 4 hours, ~50% of the 17β-E2 had been metabolized and there was evidence of 4-
hydroxylation and methylation activities. Again, the most predominant metabolite was E1. 
Interestingly at 24 hours and 48 hours, 16-hydroxylated estrogens, predominantly 16α-
OHE1 appeared within the sample, increasing with time. 
In male PAH-hPASMCs (Figure 4-31), 17β-E2 was converted to E1 and 4-OHE1 between 
10 minutes and 4 hours. At 24 hours, ~50% of the parent 17β-E2 had been metabolized. 
Here there was a small formation of 16α-OHE2 which increased at 48 hours. At 48 hours, 
there was also a small formation of 16α-OHE1. In this cell line, there was no evidence of 
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COMT activity as no methylated metabolites were observed. As with the other cell lines, 
the predominant metabolite formation was E1. 
 





Figure 4-28 Metabolism of 17β-estradiol over time in control female human pulmonary 
arterial smooth muscle cells (PASMCs) 
Female control (59 year-old) PASMCs were incubated with 17β-estradiol (17β-E2; 50nM, 
136.19ng) for various time-points in 1% charcoal-stripped (estrogen-free) phenol red free DMEM. 
Samples were extracted by solid phase extraction with Oasis® HLB cartridges and analyzed by 
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Figure 4-29 Metabolism of 17β-estradiol over time in control male human pulmonary arterial 
smooth muscle cells (PASMCs) 
Male control (62 year-old) PASMCs were incubated with 17β-estradiol (17β-E2; 50nM, 136.19ng) 
for various time-points in 1% charcoal-stripped (estrogen-free) phenol red free DMEM. Samples 
were extracted by solid phase extraction with Oasis® HLB cartridges and analyzed by HPLC with 

















































































































































































































































































































































Figure 4-30 Metabolism of 17β-estradiol over time in PAH female human pulmonary arterial 
smooth muscle cells (PASMCs) 
Female PAH (24 year-old with IPAH) PASMCs were incubated with 17β-estradiol (17β-E2; 50nM, 
136.19ng) for various time-points in 1% charcoal-stripped (estrogen-free) phenol red free DMEM. 
Samples were extracted by solid phase extraction with Oasis® HLB cartridges and analyzed by 
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Figure 4-31 Metabolism of 17β-estradiol over time in PAH male human pulmonary arterial 
smooth muscle cells (PASMCs) 
Male PAH (43 year-old with APAH) PASMCs were incubated with 17β-estradiol (17β-E2; 50nM, 
136.19ng) for various time-points in 1% charcoal-stripped (estrogen-free) phenol red free DMEM. 
Samples were extracted by solid phase extraction with Oasis® HLB cartridges and analyzed by 
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 Evidence for an altered estrogen metabolic profile in 4.2.14
pulmonary arterial hypertension 
HPASMCs from both female and male, control and PAH (Figure 4-32 - Figure 4-38) 
actively metabolize 17β-E2, with key differences in rates and product formation. In all the 
groups studied the metabolic screen indicates a prominent role for 17β-HSD2. 
Interestingly, the rate at which E1 was formed was highly variable with the highest rate in 
male control hPASMCs followed by female PAH-PASMCs and then male PAH 
hPASMCs. The lowest rate of conversion was evident in female control hPASMCs. 
Whilst male control, female PAH and male PAH hPASMCs displayed evidence for CYP 
activity, there was no measurable CYP activity in female control hPASMCs. In fact, there 
was no observable enzymatic activity in female controls apart from the formation of E1. 
Both male control and female PAH hPASMCs demonstrated COMT activity; this was 
undetected in male PAH hPASMCs. Male control hPASMCs metabolised 17β-E2 to both 
the 2- and 4-hydroxyestrogens and methoxyestrogens. In female PAH hPASMCs, 17β-E2 
was also metabolized to the 2- and 4-hydroxyestrogens. However, the metabolic profile 
after 24 and 48 hours revealed a clear formation of the pathogenic CYP metabolite, 16α-
OHE1 (7% at 24 hours and 16% at 48 hours). In addition, there was a small formation of 
16α-OHE2 (1% at 24 hours and 4% at 24 hours). In male PAH hPASMCs, there was no 
evidence for 2-hydroxy/methylation. However, there was evidence of 4-hydroxylation and 
the predominant CYP metabolite formed at 24 and 48 hours was 16α-OHE2 (2% and 13% 
respectively). Key enzymatic activities within each cell line have been summarized in 
Table 4-6. 
 




Figure 4-32 Estrogen metabolic profile in control- and pulmonary arterial hypertension-
pulmonary arterial smooth muscle (PASMCs) cells after 10 minutes 
Female and male, control and PAH PASMCs were incubated with 17β-estradiol (17β-E2; 50nM, 
136.19ng) for 10 minutes in 1% charcoal-stripped (estrogen-free) phenol red free DMEM. Samples 
were extracted by solid phase extraction with Oasis® HLB cartridges and analyzed by HPLC with 



























Figure 4-33 Estrogen metabolic profile in control- and pulmonary arterial hypertension-
pulmonary arterial smooth muscle cells (PASMCs) after 30 minutes 
Female and male, control and PAH PASMCs were incubated with 17β-estradiol (17β-E2; 50nM, 
136.19ng) for 30 minutes in 1% charcoal-stripped (estrogen-free) phenol red free DMEM. Samples 
were extracted by solid phase extraction with Oasis® HLB cartridges and analyzed by HPLC with 


























Figure 4-34 Estrogen metabolic profile in control- and pulmonary arterial hypertension-
pulmonary arterial smooth muscle cells (PASMCs) after 1 hour 
Female and male, control and PAH PASMCs were incubated with 17β-estradiol (17β-E2; 50nM, 
136.19ng) for 1 hour in 1% charcoal-stripped (estrogen-free) phenol red free DMEM. Samples were 
extracted by solid phase extraction with Oasis® HLB cartridges and analyzed by HPLC with ultra-














































Figure 4-35 Estrogen metabolic profile in control- and pulmonary arterial hypertension-
pulmonary arterial smooth muscle cells (PASMCs) after 2 hours 
Female and male, control and PAH PASMCs were incubated with 17β-estradiol (17β-E2; 50nM, 
136.19ng) for 2 hours in 1% charcoal-stripped (estrogen-free) phenol red free DMEM. Samples 
were extracted by solid phase extraction with Oasis® HLB cartridges and analyzed by HPLC with 
ultra-violet and radiolabeled detection. n=1 patient per group, repeated twice in different passages. 
 




Figure 4-36 Estrogen metabolic profile in control- and pulmonary arterial hypertension-
pulmonary arterial smooth muscle cells (PASMCs) after 4 hours 
Female and male, control and PAH PASMCs were incubated with 17β-estradiol (17β-E2; 50nM, 
136.19ng) for 4 hours in 1% charcoal-stripped (estrogen-free) phenol red free DMEM. Samples 
were extracted by solid phase extraction with Oasis® HLB cartridges and analyzed by HPLC with 




























Figure 4-37 Estrogen metabolic profile in control- and pulmonary arterial hypertension-
pulmonary arterial smooth muscle cells (PASMCs) after 24 hours 
Female and male, control and PAH PASMCs were incubated with 17β-estradiol (17β-E2; 50nM, 
136.19ng) for 24 hours in 1% charcoal-stripped (estrogen-free) phenol red free DMEM. Samples 
were extracted by solid phase extraction with Oasis® HLB cartridges and analyzed by HPLC with 

































Figure 4-38 Estrogen metabolic profile in control- and pulmonary arterial hypertension-
pulmonary arterial smooth muscle cells (PASMCs) after 48 hours 
Female and male, control and PAH PASMCs were incubated with 17β-estradiol (17β-E2; 50nM, 
136.19ng) for 48 hours in 1% charcoal-stripped (estrogen-free) phenol red free DMEM. Samples 
were extracted by solid phase extraction with Oasis® HLB cartridges and analyzed by HPLC with 
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Table 4-6 Summary of metabolite formation in human pulmonary arterial smooth muscle 
cells 
hPASMCs 17β-HSD2 CYP Enzymes COMT Dehydrogenases 
Female Control E1    



















Overall summary of metabolites formed in human pulmonary arterial smooth muscle cells 
(hPASMCs). Metabolites highlighted in blue were specific to pulmonary arterial hypertension (PAH) 
samples whereas metabolites highlighted in red were specific to male control hPASMCs. (E1, 
estrone; 2-OHE2, 2-hydroxyestradiol; 2-OHE1, 2-hydroxyestrone; 4-OHE2, 4-hydroxyestradiol; 4-
OHE1, 4-hydroxyestrone; 16α-OHE2, 16α-hydroxyestradiol; 16α-OHE1, 16α-hydroxyestrone; 2-
MeOHE2, 2-methoxyestradiol; 2-MeOHE1, 2-methoxyestrone; 2-MeOHE2, 2-methoxyestradiol; 4-
MeOHE2, 4-methoxyestradiol; 4-MeOHE1, 4-methoxyestrone; 17α-E2, 17α-estradiol; 17-Epi-E3, 
17-epiestriol.) 
 




PAH is predominantly observed in females but the molecular events that govern this effect 
remain obscure. Understanding the biological basis of this sex difference would offer a 
new treatment paradigm in this devastating cardiovascular disorder that currently has no 
cure with a pressing need for more effective therapies (Archer et al., 2010). We have 
provided evidence that dysregulated estrogen metabolism may underlie this (Chapter 3). 
We therefore investigated the effects of estrogen metabolites in vitro and in vivo, providing 
evidence that the smooth muscle cell mitogen 16α-OHE1 is associated with the 
pathogenesis of PAH. Yet the dynamic estrogen metabolic profile in PAH remained 
undetermined. It was therefore of importance to examine and measure estrogen metabolism 
in hPASMCs. We challenged the concept that estrogen metabolism is pathologically 
altered in PAH.  To address these challenges, we developed a high-fidelity quantitative 
technique to measure estrogen metabolism by HPLC, which can be used as a platform to 
investigate effects of PH insults and therapies on the fate of estrogen in the lung 
vasculature. We provide the first direct evidence that estrogen metabolism is pathologically 
altered in PAH and this highlights a novel therapeutic paradigm that can be targeted in the 
management of this devastating disease. 
17β-E2 is metabolised to both pro- and anti-proliferative metabolites by CYP1B1. TMS 
inhibits 17β-E2-induced proliferation of hPASMCs, suggesting that CYP1B1 metabolism 
mediates the proliferative effects of 17β-E2 (White et al., 2012). The 16α-hydroxylated 
CYP1B1 metabolites induce proliferation of hPASMCs, with the most profound 
proliferation observed with 16α-OHE1. Furthermore, the proliferative effects of this 
mitogen were exaggerated in PAH-PASMC (White et al., 2012). In line with this, urinary 
levels of 16α-OHE1 were increased in mice exposed to chronic hypoxia (Figure 4-2). 
Importantly, increased urinary 16α-OHE1 has also been reported in patients with HPAH 
associated with a BMPR-2 mutation (Austin et al., 2009), supporting a functional role of 
this metabolite in PAH pathogenesis. Moreover, we provide direct evidence that both 
female and male hPASMCs metabolize 17β-E2 to the 16-hydroxylated estrogens (Figure 
4-38). Whether this metabolite is a candidate biomarker is yet to be ascertained. To 
establish a direct pathological link with 16α-OHE1 and PAH, both male and female mice 
were dosed with 16α-OHE1 (Figure 4-4). Whilst 16α-OHE1 had no effects on the 
pulmonary haemodynamics measured in male mice, increased RVSP and RVH was 
observed in female mice. In a recent report by Fessel and colleagues (Fessel et al., 2013a), 
16α-OHE1 induced a PAH phenotype in male BMPR-2 deficient transgenic mice, whilst 
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no effect was observed in their respective male wild-type mice. Thus, it appears that 16α-
OHE1 is a PAH insult in genetically-susceptible and female mice. Interestingly, male mice 
dosed with 16α-OHE1 had significantly reduced mSAP, highlighting a gender-specific and 
divergent effect of this metabolite in the systemic vasculature. 
The precise mechanism by which 16α-OHE1 contributes to PAH pathogenesis is yet to be 
fully investigated. Here we provide evidence that 16α-OHE1 induced proliferation is 
attenuated with a ROS scavenger and an ERK inhibitor (Figure 4-7). Unpublished data 
from our lab have provided evidence that 16α-OHE1 increases superoxide production in 
hPASMCs. Elevated oxidative stress is associated with PAH pathogenesis, yet the 
mechanisms that precede this remain uncertain (Bowers et al., 2004;Fessel et al., 
2013b;Hemnes et al., 2011). Increased metabolism of 17β-E2 to 16α-OHE1 by increased 
CYP1B1 activity may be one mechanism of elevated ROS in PAH. In other studies, 16α-
OHE1 has been shown to have a  high binding affinity for ERβ (Zhu et al., 2006) which is 
increased following hypoxic exposure (Lahm et al., 2012). However, in pre-clinical 
models, ERβ agonists have proven effective in alleviating PH-phenotypes (Umar et al., 
2011). Additionally, the protective effects of 17β-E2 in hypoxic-induced PH are attenuated 
with an ERβ antagonist (Lahm et al., 2012). Independent of estrogen receptor binding, 
16α-OHE1 in MCF-7 cells has been shown to induce cell proliferation via increased 
expression of the cell cycle regulator, cyclin D1 (Lewis et al., 2005). This may be relevant 
to the pathological effects of 16α-OHE1 in PAH as cyclin D1 is an important mediator in 
PAH pathogenesis, where it promotes proliferation and vascular remodeling (Zeng et al., 
2013) 
CYP1B1 is a putative pathological mediator in cancer. Divergent insults such as serotonin 
(White et al., 2011a), hypoxia (White et al., 2012), shear stress (Conway et al., 2009) and 
the dioxin, TCDD robustly alter the expression of CYP1B1. The enzymatic activity of 
CYP1B1 favours the hydroxylation at the C4 position of estrogens (Lee et al., 2003). 
Furthermore, co-treatment with TCDD (a potent CYP1B1 inducer) and 17β-E2 in human 
lung cells leads to an accumulation of 4-MeOHE2 (Cheng et al., 2007), further supporting 
activity of 4-hydroxylation by CYP1B1. Although the 4-hydroxylated estrogens do not 
stimulate proliferation of hPASMCs (White et al., 2012), we wished to investigate its 
function in vivo due to its vast role in cancer (Liehr & Ricci, 1996) and its potential 
influence on redox signaling. Perhaps surprisingly, 4-OHE2 had no effect of RVSP or 
RVH. Interestingly, chronic dosing with 4-OHE2 attenuated serotonin-induced 
vasoconstriction of the intra-pulmonary arteries, suggesting that it mediates vasodilatory 
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effects in the pulmonary arteries. This merits further investigation in tandem with the 
effects of 4-OHE2 in hypoxic conditions. However, there are several experimental 
limitations that need reviewed. Both estrogen metabolites (16α-OHE1 and 4-OHE2) were 
administered by intra-peritoneal injections which has several limitations as a route of 
administration. Intra-peritoneal injections are primarily absorbed through the portal 
circulations (Lukas et al., 1971) which suggests that all drugs injected by this route will 
initially undergo first-pass metabolism by the liver. COMT expression and activity is 
substantial within the liver of mice (Myöhänen et al., 2010) which would breakdown 4-
OHE2 into 4-MeOHE2. Thus the effects observed may not be due to 4-OHE2, but rather 4-
MeOHE2, which has growth inhibitory effects on lung epithelial cells (Cheng et al., 2007) 
and renal cancer cells (Chang et al., 2012). Additionally, the methoxyestrogens have also 
been reported to exert feedback inhibition on both CYP1B1 and CYP1A1 (Dawling et al., 
2003). In contrast, 16α-OHE1 is less likely to be substantially altered whilst passing 
through the liver, thus giving a stronger possibility that the parent metabolite is reaching 
the target tissue (the lung). 
In a more recent comprehensive study of estrogen metabolites in the lungs of wild-type and 
CYP1B1-/- mice, 4-OHE1 appeared as the predominant CYP1B1 metabolite (Peng et al., 
2013). Our previous screen that identified 16α-OHE1 as a disease-modifying metabolite 
was limited to thymidine incorporation and did not address other effects that metabolites of 
17β-E2 may have on cellular function (White et al., 2012). Thus, we sought to investigate 
the functional consequence of increased CYP1B1 hydroxylation activity by stimulating 
naïve hPASMCs with 4-OHE1 and measuring DNA replication and cell viability (Figure 
4-12 - Figure 4-15). In line with our previous findings, 4-OHE1 did not increase 
proliferation, but actually inhibited DNA replication, whilst having no effect on cell 
viability. Following longer incubations (5 days), 4-OHE1 had no significant effects on 
DNA replication, suggesting that these effects were either transient, or had been overcome 
by a different mechanism. 
In the CYP1B1-/- mouse, levels of 2-MeOHE2 in the lungs are increased compared to 
wild-type mice, suggesting that CYP1B1 may be counteracting COMT activity (Peng et 
al., 2013). 2-MeOHE2 is a putative protective estrogen metabolite. Thus, the protective 
effects observed on CYP1B1 inhibition may be mediated via increased formation of 2-
MeOHE2. 2-MeOHE2 has previously been reported to have strong anti-mitogenic effects 
in lung fibroblasts and hPASMCs (Tofovic et al., 2009b) and can attenuate bleomycin 
(Tofovic et al., 2009b), monocrotaline (Tofovic et al., 2005;Tofovic et al., 2006) and SU-
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hypoxic (Tofovic & Rafikova, 2009) induced PH. Our findings are consistent with these 
reports, with 2-MeOHE2 having an inhibitory effect on DNA replication and reducing cell 
viability (Figure 4-12 - Figure 4-15). Whilst 2-MeOHE2 has proven to be beneficial in this 
setting and appears to represent a promising therapeutic strategy in PAH, this has been 
compromised by phase I clinical trials in cancer that were prematurely stopped due to the 
very low bioavailability of this metabolite (Dahut et al., 2006). To circumvent this, 2-
MeOHE2 levels may be increased by CYP1B1 inhibition. 
The metabolic conversion of 17β-E2 by the 4-hydroxylation pathway is recognized to 
contribute to DNA damage by superoxide production (Acharya et al., 2010). We have 
recently provided evidence that 4-hydroxylation induces profound superoxide production 
in hPASMCs (up to 6 fold higher after incubations for 5 minutes compared to control) 
(unpublished data). Thus, CYP1B1 may be inducing its pathogenic effects via increased 
superoxide production. Others have identified a role for serotonin (Lee et al., 1998) and 
endothelin-1 (Wedgwood et al., 2001) in superoxide production in hPASMCs. 
Additionally, other metabolic pathways of CYP1B1 may alter redox cycling. For example, 
arachidonic can be metabolized by CYP1B1 to HETEs (Choudhary et al., 2004). 20-HETE 
increases superoxide production in human pulmonary arterial endothelial cells (Medhora et 
al., 2008). Also, angiotensin-II can increase superoxide production via CYP1B1 (Yaghini 
et al., 2010). Thus multiple pathways may interplay to cause injurious ROS production via 
CYP1B1 activity. In tandem, increased 16α-hydroxylation activity results in increased 
hPASMC proliferation (White et al., 2012), leading to a pathogenic environment in the 
lung. Overall, these pathogenic effects may be reversed by CYP1B1 inhibition.  
Others have provided evidence for 17β-E2 and E1 within the lung (Meireles et al., 
2010;Peng et al., 2013). Here, we provide the first evidence for high intracellular 17β-E2 
concentrations within hPASMCs ranging from ~25nM to 30nM per mg of protein (Figure 
4-16). Patients with PAH did not have significantly different 17β-E2 levels compared to 
control hPASMCs, nor was there any effect on gender. An increased risk of PPHTN is 
associated with increased plasma 17β-E2 as a consequence of a polymorphism in the gene 
encoding for aromatase (Roberts et al., 2009). Recent studies have confirmed that 
aromatase inhibition can reverse severe experimental PAH in females, but not in males 
(Mair et al., 2013). In the absence of changes in 17β-E2 levels within hPASMCs, this 
suggests that it is the metabolic route of 17β-E2 and/or altered signaling through estrogen 
receptors that is adversely affecting the pathogenesis of PAH. Thus the beneficial effects of 
aromatase inhibition may be attributable to a lack of substrate for subsequent metabolism 
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by pathogenic CYP enzymes, such as CYP1B1. We have previously reported interactions 
of the estrogen and serotonin pathways in PH (White et al., 2011b). It was therefore of 
interest to investigate whether serotonin could alter estrogen levels within hPASMCs. 
Serotonin had no effect on intracellular 17β-E2 levels after 48-hour incubation (Figure 
4-16). This supports our patient data, where no changes were observed in 17β-E2 levels. 
There is evidence that estrogen metabolism is dysregulated in PH and that certain estrogen 
metabolites provide protective effects in vivo and in vitro, such as the 2-methoxyestradiol 
(Tofovic et al., 2009b;Tofovic et al., 2006). In contrast, other estrogen metabolites exert 
pathogenic effects in vivo and in vitro, such as the potent smooth muscle cell mitogen, 16α-
OHE1 (White et al., 2012). However, the in vivo effects of 16α-OHE1 on the pulmonary 
hypertensive phenotype was only evident in female mice and genetically susceptible 
mouse models (Fessel et al., 2013a;White et al., 2012). Thus, it is clear that the metabolic 
fate of 17β-E2 can have dramatic consequences on vascular cell fates and one may 
hypothesize that 17β-E2 is differentially metabolized in the severest forms of PH such as 
PAH. Abnormal PASMC proliferation is a key event that drives PAH-pathobiology 
(Archer et al., 2010;Schermuly et al., 2011) and was therefore our chosen vascular cell 
type to study. We initially measured estrogen depletion from the extracellular medium by 
hPASMCs to ascertain if 17β-E2 is differentially metabolized in female control and PAH 
hPASMCs (Figure 4-17). After 24 hours, it was evident that female PAH hPASMCs 
rapidly depleted extracellular levels of 17β-E2 suggesting a greater metabolic rate 
compared to control hPASMCs. This provided preliminary evidence for altered 17β-E2 
metabolism in PAH, but to what effect was still unknown. To answer this question, we 
determined the metabolic fate of 17β-E2 in hPASMCs using the principles of 
metabolomics and metabolic flux analysis. A homogenous population of PASMCs were 
exposed to radiolabelled 17β-E2 to quantitatively measure their unique metabolic profiles. 
50nM (136.19ng) of 17β-E2 was selected as the optimal concentration for three primary 
reasons. First, the concentration was identified as the optimal concentration to sufficiently 
detect 17β-E2 metabolism in the cells. Second, we have provide evidence that intracellular 
levels of 17β-E2 in hPASMCs is predictably higher than circulating levels, which are 
approximately in the range of 0.4nM to 2.2nM (Mendelsohn & Karas, 1999). Third, we 
have reported that there are no differences in 17β-E2 concentrations between females and 
males providing rationale to utilize the same concentration in both sexes. 
The enzymatic kinetics of CYP enzymes in the lung is largely unknown and it therefore 
remains essential to perform a time-point analysis to get a broad window of estrogen 
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metabolism within hPASMCs. This was an extremely fruitful exercise as there appeared to 
be key differences in rates of metabolism across both males and females and controls and 
PAH (Figure 4-32-Figure 4-38). To the best of our knowledge, this is the first study to 
provide direct evidence that hPASMCs actively metabolize 17β-E2. In addition, it revealed 
a prominent role for 17β-HSD2, the enzymatic isoform that converts 17β-E2 into E1. 17β-
HSD enzymes play an important role in the regulation of ‘active’ estrogens within tissues. 
17β-HSD1 converts E1 into 17β-E2 and therefore plays a role in determining the 
availability of 17β-E2 and E1 within specific cell types. 17β-HSD2 also catalyses the 
formation of androstenedione from testosterone. Androstenedione can then be converted to 
E1 by the activity of aromatase. Increased activity of 17β-HSD1 is associated with 
increased levels of 17β-E2 and the pathogenesis of breast cancer (Gunnarsson et al., 
2008;Oduwole et al., 2004) and lung cancer (Verma et al., 2013). Interestingly, it appeared 
that female PAH PASMCs had a higher activity of 17β-HSD2 compared to control 
hPASMCs. In contrast, male PAH-PASMCs had reduced activity of 17β-HSD2 compared 
to non-PAH cells. Thus, E1 (and androstenedione) may play a prominent role in PAH 
pathogenesis in females whereas 17β-E2 (and testosterone) may play a prominent role in 
male PAH. E1 has thus far been assumed to have less estrogenic activity that serves as a 
reservoir for 17β-E2 within tissues and few studies have addressed its cellular effects in 
hPASMCs. In male control hPASMCs E1 has no effects on cell proliferation (White et al., 
2011), yet its effects in female hPASMCs remains to be determined. Whilst E1 itself may 
be a less active estrogen, its hydroxylated products by activity of CYP enzymes can have 
profound effects on cellular fates. For example, the formation of the 16α-OHE1 from the 
hydroxylation of E1 would promote PASMC proliferation (White et al., 2012).  
Whilst male control, female PAH and male PAH hPASMCs displayed evidence for CYP 
activity, there was no measurable CYP activity in female control hPASMCs (Figure 4-28). 
Interestingly, the highest CYP activity was evident in both male and female PAH 
hPASMCs at 24 and 48 hours and curiously, 16α-hydroxylation was only evident in PAH 
hPASMCs (Figure 4-32-Figure 4-38). The most prominent isoform in female PAH was 
16α-OHE1 and the most prominent isoform in male hPASMCs was 16α-OHE2. 16α-
OHE1 levels are increased in the urine of mice exposed to hypoxia and clinically, the ratio 
of 16α-OHE1 to 2-OHE1 is increased in female patients with heritable PAH associated 
with a mutation in the BMPR-2 (Austin et al., 2009). Cellular proliferation screens have 
provided evidence that 16α-OHE1 is a potent inducer of PASMC proliferation (White et 
al., 2012). In vivo, 16α-OHE1 induces a PH phenotype in female mice only and 
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genetically susceptible mice (BMPR-2 mutant mice), providing direct evidence that 16α-
OHE1 may contribute to PAH pathogenesis (Fessel et al., 2013a;White et al., 2012). 
The activity of COMT represents a key deactivation process of hydroxylated estrogens, in 
particular by reducing the ability of 4-hydroxylated estrogens to generate quinones and 
semiquinones that can lead to DNA damage, which contributes to the pathogenesis of PAH 
(Meloche et al., 2013). In female control hPASMCs, there was no evidence for COMT 
activity (Figure 4-28) as measured by the absence of methylated metabolites (albeit CYP 
activity would have been necessary to determine COMT activity). COMT activity was 
present in both male control (Figure 4-29) and female PAH hPASMCs (Figure 4-30) whilst 
no activity was detected in male PAH hPASMCs (Figure 4-31). However, the activity of 
CYP enzymes can also interconvert methoxyestrogens back into their hydroxylated 
estrogens (Dawling et al., 2003). We can therefore not entirely conclude that there was no 
COMT activity within male PAH hPASMCs. 
We have previously provided evidence that estrogen metabolism is dysregulated in PAH 
by numerous studies highlighting increased CYP1B1 expression in pulmonary arteries of 
patients with severe PAH and inhibition studies in various experimental models (Chapter 
3, 4 and White et al., 2012). Furthermore, there is now evidence that aromatase inhibition 
(the estrogen-synthesizing enzyme) can reverse severe experimental PH (Mair et al., 
2013). In contrast, in both the hypoxic and MCT models of PH, exogenous estrogens have 
protective effects mediated via ERα (Lahm et al., 2012) in the hypoxic model and via ERβ 
in the MCT model of PH (Umar et al., 2011). Furthermore, ERα mediates the protective 
effects of 17β-E2 on right ventricular function in hypoxia-induced PH, evident by a 
reduced cardiac output in animals co-treated with the ERα antagonist, 1-methyl-4-phenyl 
pyridinium (MPP) (Lahm et al., 2012). The cardioprotective effects of 17β-E2 may 
contribute to the improved survival in female patients compared to males. Indeed, 
improved right ventricular systolic function is superior in both healthy and PAH-affected 
women compared to men and is associated with higher circulating levels of 17β-E2 (Kawut 
et al., 2009;Ventetuolo et al., 2011). In a small cohort of PAH patients, increased 
expression of ESR1, the gene encoding ERα, is reported in  lungs derived from both male 
and female PAH patients (Rajkumar et al., 2010). A conserved evolutionary binding site 
for ERα is present within the BMPR-2 promoter and can thereby alter its expression profile 
(Austin et al., 2012). In support of this, 17β-E2 (1µM) can reduce the expression of 
BMPR-2 in human pulmonary arterial endothelial cells (Austin et al., 2012) where it is 
predominantly expressed (Atkinson et al., 2002). This supports the gender differences in 
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HPAH associated with BMPR-2 mutations, whereby there is incomplete penetrance (27%) 
with females much more likely to present with PAH (42% females compared with 14% 
males) (Larkin et al., 2012). Whilst protective effects of exogenous estrogens have been 
reported in both the hypoxic and MCT-models of PH (Lahm et al., 2012;Umar et al., 
2011), in models that display heightened activity of the serotonergic system (Dempsie et 
al., 2013;White et al., 2011b), endogenous estrogen is associated with the development of 
PH. In the female mouse model that over-expresses the serotonin transporter (SERT+ 
mice) the ERα inhibitor can reverse its spontaneous PH phenotype (Wright et al. 2013, 
unpublished).  
Interestingly, whilst estrogen metabolites can mediate receptor-independent effects on 
cellular functions, they retain strong binding affinities at the estrogen receptors. Thus, the 
differential effects of 17β-E2 in the hypoxic-, MCT and SERT+ models may be 
attributable to differential metabolism of 17β-E2 (as well as differences in estrogen 
concentrations, gender and species used). Whilst inhibition of CYP1B1 can attenuate both 
hypoxic (Chapter 3 and White et al., 2012) and SERT+ - PH (Chapter 4), it has a much 
less pronounced effect in MCT-induced PH despite dramatically improving survival 
(Chapter 3). A comprehensive analysis of the binding affinities of estrogen metabolites to 
estrogen receptors revealed striking differences suggesting that the unique physiological 
function of 17β-E2 may be dependent on its metabolism. Whilst 17β-E2, 4-OHE2, 4-
OHE1 and 2-OHE2 have an equal binding affinity for both ERα and ERβ, E1 and 2-OHE1 
have a preferential binding affinity for ERα (Zhu et al., 2006). In contrast, the 16-
hydroxylated estrogens (16α-OHE1 and 16α-OHE2) have a preferential binding affinity for 
ERβ (Zhu et al., 2006). Interestingly, ERα lung expression is unchanged in the hypoxic-rat 
model of PH, whilst ERβ expression is increased (Lahm et al., 2012). In contrast, in the 
SERT+ model of PH, ERα levels are increased (Wright et al. 2013, unpublished). Thus, 
there appears to be a two-tiered process by which estrogen signaling may contribute to 
PAH pathology. First, the route by which it is metabolized by aberrant CYP/COMT 
activity. Second, the effects mediated by the metabolite formation will depend, in part, on 
the tissue specific expression of ERs. Overall, this highlights a multi-level complex axis 
and may explain the controversies within the field that report both protective and 
pathogenic effects of estrogens. This is challenged by the study by Lahm and colleagues 
providing evidence that the protective effects of 17β-E2 in the hypoxic-rat model of PH are 
not mediated via metabolite formation as the general CYP inhibitor, ABT does not 
attenuate the protective effects of 17β-E2 (Lahm et al., 2012). This suggests that the 
protective effects of 17β-E2 in this model are not mediated via the formation of protective 
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17β-E2 metabolites. However, in models where 17β-E2 is causative, 17β-E2 metabolism 
may figure prominently by the formation of 16α-hydroxylated estrogens.  
Here, we developed a method to measure the dynamic metabolism of 17β-E2 in 
hPASMCs. This methodology can be easily applied to other cell types of interest. Beyond 
this study, we can utilize in silico analysis to identify specific CYP enzymes that may 
underlie the altered estrogen metabolic phenotype in patients with PAH. For example, at 
48 hours, the key metabolite formed in female PAH hPASMCs was 16α-OHE1. This 
implicates potential activity of CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, 
CYP3A5 and CYP3A7 (Badawi et al., 2001;Hanna et al., 2000;Lee et al., 2003). We can 
then use this as a platform to investigate potential therapeutic targets that may rescue the 
estrogen metabolic phenotype. For example, we can utilize highly selective inhibitors and 
siRNA to CYP1A1 and CYP1B1 to see if this can prevent the metabolism of 17β-E2 to 
16α-OHE1. Successful CYP candidates can then be investigated for their therapeutic 
potential in vivo. Whilst microarray screens are useful in detecting aberrant gene 
expression, the activities of CYP enzymes do not always correlate with their expression. 
Thus, the sensitivity of such screens in detecting potentially pathological estrogen 
metabolic pathways is limited. We are therefore hopeful that this metabolite screen may be 
useful in identification of novel therapeutic targets for the treatment of PAH. 
The enzymes that are involved in the catalytic metabolism of 17β-E2 have variable kinetics 
in terms of the maximum velocity of the reaction (Vmax) and the affinity of the enzyme for 
the substrate (Km). High catalytic activity is reflective of a high Vmax and a low Km. The 
enzymes that are predominantly involved in 17β-E2 metabolism are CYP1A1, CYP1A2, 
CYP3A4 and CYP1B1. CYP1A1 and CYP1A2 have high catalytic activities for 2-
hydroxylation of 17β-E2 (Badawi et al., 2001;Lee et al., 2003). Our results implicate that 
the activity and expression of these enzymes in hPASMCs from both control and PAH 
samples are negligible as only a small percentage of 2-hydroxylated estrogens was 
detected. However, in contradiction it has recently been found that CYP1A1 is a highly up-
regulated gene in the SU-hypoxic rat model of PAH (unpublished data from Novartis 
Pharmaceuticals, Horsham). Although all estrogen metabolizing enzymes have low 
catalytic activities for 16α-hydroxylation, CYP1A1, CYP1A2 and CYP3A5 are the 
principle source of this metabolite, with a minor contribution by CYP1B1 (Badawi et al., 
2001). CYP1B1 has an overall lower catalytic activity for 17β-E2 than CYP1A1 and 
CYP1A2, but has the highest activity for 4-hydroxylation with a low Km and a high Vmax 
(Badawi et al., 2001). Evidence for CYP1B1 was detected in all samples except for female 
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control hPASMCs. 17β-HSD1 (which interconverts E1 into 17β-E2) has a very low Km 
and uses NADPH as a cofactor. On the other hand, 17β-HSD2 utilises NAD as a co-factor 
and has a higher Km although its catalytic activity is still high. Thus, the tissue-specific 
expression of 17β-HSD and the availability of co-factors are crucial in regulating the 
balance between 17β-E2 and E1. Here, we provided evidence for variable activity of 17β-
HSD2 by the formation of E1. However, the activity of 17β-HSD2 may be counteracting 
the effects of 17β-HSD1, thus we cannot entirely conclude that its activity is the highest in 
male control hPASMCs, as appears to be the case. Future studies investigating the role of 
17β-HSD enzymes in PAH are merited. 
The purpose of this project was to develop a method to track estrogen metabolism in 
pulmonary vascular cells and to determine the optimal time-point to assess estrogen 
metabolism. One key limitation of the data obtained from this study is that the metabolic 
profile generated was only obtained from one patient in each category. It would be 
essential to assess estrogen metabolism in a larger cohort of patients to ascertain whether 
estrogen metabolic profiles are consistently altered in PAH. This is hampered by a general 
lack of available samples due to the low prevalence of PAH. To overcome this, control 
PASMCs could be stimulated with a known PAH insult (such as knockdown of BMPR-2, 
endothelin-1, serotonin) to assess if this can alter the estrogen metabolic profile. PAH 
PASMCs are generally end-stage disease as they are obtained from patients either 
undergoing transplant or post-mortem. These samples may therefore not be reflective of 
on-going PAH pathogenesis and molecular pathways may have been altered by the 
therapies that the patient would have been receiving. This variable would also be overcome 
by studying control PASMCs with a PAH insult. However, it would be challenging to truly 
mimic a PAH profile in vitro as it is likely that numerous pathways contribute to PAH 
pathogenesis. Age may also be an important contributor to extra-gonadal estrogen 
metabolism and as the control samples used in this study were from older patients whereas 
the PAH samples were from younger patients, we cannot disregard that the results obtained 
may be attributable to the different age groups studied. 
The data shown here is the first study to measure the dynamic metabolism of estrogen in 
PAH specifically in the PASMCs. To date, estrogen metabolites have only been 
preliminarily measured by mass spectrometry in serum from post-menopausal patients with 
severe PAH (Chhatwani et al., 2010). In this study, E1 and the E1+17βE2/total estrogen 
metabolites were significantly decreased in post-menopausal PAH patients compared to 
controls. PAH patients also had greater plasma levels of 2-methoxyestrogens. This study 
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did not report detections of the 4- or the 16α-hydroxyestrogens suggesting that they did not 
measure them. Mass spectrometry is considered the gold-standard analytical technique, yet 
it carries selective bias as you have to specify what compounds you are interested in 
detecting. The methodology described here is a sensitive and quantitative technique that 
can measure estrogen metabolism in vascular cells. Furthermore, all metabolites that are 
formed by the reaction will be radio-labelled and will therefore be detected. Furthermore, 
this assay allows for absolute quantification as the percentage of radioactive product 
formed directly correlates with the amount of metabolite formation. In LC-MS, absolute 
quantification would require pure authentic standards for each analyte, which are currently 
unavailable. It is challenging to correlate the sensitivity of this assay in comparison to 
other assays available as it employs radioactivity to measure metabolism whereas other 
assays measure relative abundance of unlabelled metabolites. In other assays, estrogens are 
often derivitised in order to improve their detection. This is not necessary in our assay as 
we have incorporated a radioactive label which can be measured in counts per million and 
is extremely sensitive. However, this methodology requires the undesired use of 
radioactive compounds. Furthermore, it restricts future experimental procedures that 
involve tracking of 17β-E2 in vivo and endogenous tissue sample concentrations of 
estrogen metabolites. Additionally, all estrogen metabolites identified by radio-labelled 
HPLC need to be validated by LC-MS to confirm metabolite identity. Ultimately, we will 
develop a LC-MS approach to address these questions and a general metabolomics 
approach to identify all substrates and metabolites within the steroidogenic pathway. 
Together, this will identify the unique steroidogenic profile that is associated with PAH. 
Estrogen metabolism may be integral to a wide span of diseases and may offer targets for 
therapeutic intervention in the management of PAH. We have provided direct evidence 
that estrogen metabolism is dysregulated in PAH, in particular by increased 16α-
hydroxylation. This pathway has already been associated with the development of PAH 
(Austin et al., 2009;White et al., 2012). Current PAH therapies do not encompass this 
well-defined gender disparity that occurs in PAH, or the potential divergent response to 
current therapies that may be affected by gender. Future therapies that target dysregulated 
estrogen metabolism may have a favourable outcome in this highly neglected, devastating 
disease. 
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 General Discussion 5.1
In general, females are less likely to develop cardiovascular diseases compared to males. 
However, the risk for cardiovascular diseases increases after menopause, when estrogens 
are ~20-fold lower (Mendelsohn & Karas, 1999). In contrast, in several lung diseases, 
estrogens are associated with the development and disease progression. Female gender is 
now the most established risk factor in PAH. Although long recognised (Dresdale et al., 
1951), it is only in the last decade that we have started to appreciate the potential impact of 
steroid hormones in PAH. There are currently no treatments available that target the 
steroidogenic pathway nor do any treatments encompass any gender-related effect on 
treatment response. A recent study highlighted the importance of the latter, where they 
reported that females had much greater responses to endothelin receptor antagonists than 
males (Gabler et al., 2012). Furthermore, the REVEAL registry recently reported sex 
differences in the diagnosis, treatment response and outcome in patients with PAH 
(Shapiro et al., 2012). This highlights the importance of understanding the role of the 
steroidogenic pathway in PAH. 
Although the incidence of PAH is more common in women than in men, in older patients 
(>60 years old) the estimated 2-year survival in males is significantly less than female 
patients (Shapiro et al., 2012). In patients younger than 60 years, there are no sex 
differences in the estimated 2-year survival rates (Shapiro et al., 2012). However, there are 
sex differences in haemodynamics between young (<45 years) female and male patients, 
with male patients presenting with higher mean PAPs and pulmonary vascular resistance 
compared with females, whilst these differences are attenuated in older patients 
(Ventetuolo et al., 2014). Interestingly, in older patients (>45 years) with IPAH, mean 
PAPs and pulmonary vascular resistance are lower than younger patients in both sexes 
(Ventetuolo et al., 2014) despite having worse survival rates (Shapiro et al., 2012). These 
sexual dimorphisms suggest that both estrogens and androgens may influence the 
pathogenesis of PAH.  
The fact that PAH is more common in women than in men has led to the hypothesis that 
estrogens, in particular 17β-E2, the main pre-menopausal hormone, may be facilitating the 
development and pathogenesis of PAH. Despite this, numerous pre-clinical studies have 
provided evidence for a protective role for 17β-E2 in the pulmonary vasculature (Lahm et 
al., 2007;Lahm et al., 2008b;Lahm et al., 2012;Umar et al., 2011;White et al., 2011b;Yuan 
et al., 2013). Furthermore, female rats have been shown to develop less severe PH 
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compared to male rats (Rabinovitch et al., 1981). 17β-E2 is a potent vasodilator of the 
pulmonary vascular bed (English et al., 2001) and physiological increases in circulating 
estrogens can attenuate pulmonary arterial vasoconstriction under both normoxic and 
hypoxic conditions (Lahm et al., 2007). 
However, there is controversial data that indicates a pathogenic function of estrogen that 
suggests it may contribute to the pathogenesis of PAH. 17β-E2 can induce proliferation in 
a variety of cell types including PASMCs and may therefore contribute to pulmonary 
vascular remodeling (White et al., 2011b;White et al., 2012). We have recently 
characterised novel murine models of PH that show female susceptibility to the 
development of PH, including SERT+ mice, mts100/A4 overexpressing mice and mice 
treated with dexfenfluramine (Dempsie et al., 2010;Dempsie et al., 2013;White et al., 
2011b). In these models, only females develop a PH phenotype and this is dependent on 
circulating (gonadal) estrogens. More recently, we and others have provided unique 
evidence that suggests that locally produced estrogens within the lung are associated with 
the pathogenesis of PAH (Mair et al., 2013;Tofovic et al., 2012). Certain tissues can 
modulate their own estrogenic milieu by the local conversion of testosterone or 
androstenedione to 17β-E2 and E1 respectively by the activity of aromatase (Harada et al., 
1999). Aromatase synthesizes estrogens from testosterone and androstenedione and is 
expressed within the pulmonary arteries (Mair et al., 2013). Furthermore, inhibition of 
aromatase attenuates hypoxia-induced and SU-hypoxia-induced PH (Mair et al., 2013). 
Interestingly, aromatase expression is unchanged in pre-clinical models of PAH, 
suggesting that the protective effects are either mediated by an increase in testosterone or a 
decrease in subsequent metabolism. Recently, we have shown that testosterone levels are 
unchanged following aromatase inhibition (Mair et al. unpublished), suggesting that 
estrogen metabolism may be altered in PAH. 
17β-E2 is metabolised by various CYP enzymes to both pro- and anti-proliferative 
metabolites. Others have previously provided evidence that alterations in estrogen 
metabolism by aberrant CYP1B1 expression may contribute to the development of HPAH 
(Austin et al., 2009). Furthermore, in the female susceptible SERT+ model of PH and in 
IPAH, CYP1B1 expression is increased (White et al., 2011a). This led us to hypothesize 
that the effects of estrogens in the pulmonary vasculature may be mediated by altered 
estrogen metabolism by increased activity of CYP1B1. Increased activity and expression 
of CYP1B1 had already been reported in many diseases including breast cancer (McKay et 
al., 1995), lung cancer (Murray et al., 1997), ovarian cancer (McFadyen et al., 2001), and 
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systemic hypertension (Jennings et al., 2010). It was therefore the aim of this project to 
investigate the contribution of CYP1B1 and estrogen metabolism in PH/PAH. 
Here, we provide evidence that a dysregulated estrogen metabolic axis via elevated 
CYP1B1 activity may contribute to the pathogenesis of PAH and represents an attractive 
novel therapeutic strategy (Chapter 3). Pulmonary arterial CYP1B1 expression was 
increased in both experimental models and in human PAH. CYP1B1-/- mice and CYP1B1 
inhibition attenuated the development of hypoxia-induced PH. This provided the first 
evidence that dysregulated estrogen metabolism by up-regulation of CYP1B1 contributed 
to the pathogenesis of PH/PAH. In the MCT-model of PH, CYP1B1 inhibition had no 
statistically significant therapeutic effects, although it improved survival in both male and 
female rats and appeared to reduce pulmonary arterial neointimal formation. The classical 
models of PH do not show female selectivity. One animal model that displays a unique 
female susceptibility is the mouse model that overexpresses the human SERT gene (White 
et al., 2011b). Recent evidence has highlighted that 17β-E2 is a critical steroid hormone in 
the development of PH in this model (White et al., 2011b). CYP1B1 expression is 
increased in the pulmonary arteries from these mice (White et al., 2011a), suggesting that 
altered estrogen metabolism may underlie this phenotype in these mice. Here, we 
established that aromatase and CYP1B1 expression was heightened in the lungs of these 
mice compared to wild-type mice. 17β-E2 levels in the lungs were however unaffected. 
CYP1B1 inhibition in these mice reverses the elevated RVSP and pulmonary vascular 
remodeling under both normoxic and hypoxic conditions. Female SERT+ mice fail to 
develop compensatory RVH in response to the increased remodeling in the pulmonary 
vasculature and this was unaffected by CYP1B1 inhibition. 
CYP1B1 activity is recognised to contribute to the pathogenic effects of estrogens by 
altering estrogen metabolism towards the formation of pro-proliferative, pro-oxidative 
metabolites capable of inducing DNA damage. However, the beneficial effects of CYP1B1 
inhibition in vivo may also be mediated by subsequent increases in estrogen that can signal 
through genomic and non-genomic pathways. Estrogens have been shown to mediate 
protective effects via estrogen receptors in both acute and chronic vascular injury. The 
relative expression profile of estrogen receptors may vary in a clinical setting and 
determine the effects of estrogens. For example, 17β-E2 exerts differential effects in 
normoxic and hypoxic (1% oxygen) rat pulmonary arterial endothelial cells (Lahm et al., 
2012). In hypoxic but not normoxic cells, 17β-E2 decreases ERK1/2 activation and 
increases the expression of the cell cycle inhibitor p27
kip1
. 17β-E2 has been shown to 
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induce eNOS expression in pulmonary vascular cells by non-genomic mechanisms through 
ERα and ERβ (Austin et al., 2013). In the fetal pulmonary endothelium, 17β-E2 rapidly 
stimulates NO production via a non-genomic mechanism that is dependent on calcium 
(Lantin Hermoso et al., 1997) and MAP kinases (Chen et al., 1999). In fetal pulmonary 
arterial endothelial cells, 17β-E2 rapidly and dramatically increases prostacyclin synthesis 
via ERβ and is dependent on calcium and independent on MAP kinase signaling (Sherman 
et al., 2002). In isolated pulmonary arterial rings, both endogenous and exogenous 
estrogens mediate vasodilation and selective activation of either ERα or ERβ can also 
attenuate pulmonary vasoconstriction via increased NO (Lahm et al., 2008a). These 
vasodilatory effects are rapid and are therefore presumed to be mediated via a non-
genomic mechanism. In vivo, 17β-E2 rescues established PH induced by MCT and 
completely abolishes mortalities in male rats (Umar et al., 2011). In this study, 17β-E2 had 
angiogenic effects restoring the loss of blood vessels in the lungs and the right ventricle. 
Furthermore, these effects were inhibited by an ERβ antagonist and mimicked by an ERβ 
agonist suggesting that ERβ is a critical mediator in the protective effects of 17β-E2 in this 
model (Umar et al., 2011). In contrast, in the hypoxic model of PH, exogenous 17β-E2 
mediates protective effects, and these effects can be blocked by ERα antagonism (Lahm et 
al., 2012). Taken together, the beneficial effects observed by CYP1B1 inhibition may be 
related to increases in 17β-E2. However, we also provided evidence for a protective role 
for CYP1B1 inhibition in the female susceptible SERT+ model of PH, where 17β-E2 has 
been shown to mediate pathogenic effects (White et al., 2011b). This suggests that the 
protective effects observed by CYP1B1 inhibition may not be mediated via increases in 
17β-E2 within this model. Future studies addressing the effects of CYP1B1 inhibition on 
levels of 17β-E2 are merited for further clarification.  
CYP1B1 also catalyses the metabolic conversion of arachidonic acid into EETs and 
HETEs (Choudhary et al., 2004). The metabolism of arachidonic acid results in the 
formation of eicosanoids that have been associated with the pathogenesis of both cancers 
and cardiovascular diseases, including PAH (Capdevila & Falck, 2001). Arachidonic acid 
stimulates endothelium-dependent contractions in both male and female pulmonary arteries 
from rabbits and these effects are potentiated in females and are mediated by 17β-E2 
(Pfister, 2011). Arachidonic acid is metabolized by CYP450 mediated oxidation, 
lipoxygenases, cyclooxygenases, epoxygenases and hydroxylases. Lipoxygenases 
metabolise arachidonic acid into the leukotrienes and cyclooxygenases metabolize 
arachidonic acid into the prostaglandins. The formation of 15-HETE by upregulation of 
15-lipoxygenase has been associated with pulmonary arterial contraction and cell 
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proliferation (as reviewed by Zhu & Ran, 2012). 15-HETE is a metabolite of both CYP1B1 
metabolism and the lipoxygenase pathway. The expression of 15- and 5-lipoxygenase is 
greater in female rabbit pulmonary arteries and 15-HETE synthesis is increased in female 
rabbit pulmonary arteries and stimulates vascular contraction (Pfister, 2011). Furthermore, 
a specific 15-lipoxygenase inhibitor can attenuate the vasoconstrictor response to 
arachidonic acid in pulmonary arteries (Pfister, 2011). In male rabbit pulmonary arteries, 
incubations with 17β-E2 increases 15-lipoxygenase expression and 15-HETE production 
(Pfister, 2011). In the systemic vasculature, EETs are associated with their vasodilatory 
and anti-inflammatory properties. However, in the pulmonary circulation, EETs potentiate 
vasoconstriction (Loot & Fleming, 2011). Thus, the therapeutic effects associated with 
CYP1B1 inhibition may also be via a reduced formation of HETEs and EETs that mediate 
pulmonary arterial vasoconstriction.  
In the vasculature, CYP1B1 is predominantly expressed within smooth muscle cells, yet its 
expression is increased by shear stress within the vascular endothelium (Conway et al., 
2009). In vascular smooth muscle cells, Ang II and arachidonic acid cause migration, 
proliferation and hypertrophy which is inhibited with TMS (Yaghini et al., 2010). This is 
associated with a reduced formation of ROS and its downstream signaling molecules 
ERK1/2 and p38MAPK (Yaghini et al., 2010). Moreover, the therapeutic effects 
associated with CYP1B1 inhibition may be mediated by subsequent increases in 
prostacyclin synthesis from arachidonic acid by the COX pathway. Prostacyclin is a potent 
vasodilator of the pulmonary vasculature and prostacyclin analogues are widely used in the 
management of PAH. 
Taken together, CYP1B1 may be considered a hub for the formation of pathogenic 
metabolites and inhibition may provide multiple therapeutic effects by increasing levels of 
17β-E2, arachidonic acid availability for prostacyclin synthesis whilst preventing the 
formation of genotoxic and proliferative estrogen metabolites, EETs, and HETEs. Future 
studies comparing the concentrations of pre-cursers within the pulmonary vasculature 
together with the catalytic activity (Km and Vmax) of CYP1B1 for each substrate would 
provide insight in to which pathway predominates.  
CYP1B1 is also a key enzyme in the metabolism of polyaromatic hydrocarbons 
(atmospheric pollutants). Polycyclic aromatic hydrocarbons are activated by the activity of 
CYP1B1 (and CYP1A1) into highly toxic compounds that have tumorigenic properties by 
inducing DNA damage. Whilst polyaromatic hydrocarbons may contribute to the 
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pathogenesis of PAH (although such data is lacking), in our experimental models, animals 
were not exposed to environmental toxins suggesting that the therapeutic effects of 
CYP1B1 inhibition were not related to this metabolic pathway.  
Cell proliferation screens of the CYP1B1 estrogen metabolites revealed that the 16α-
hydroxylated estrogens (16α-OHE1 and 16α-OHE2) are potent hPASMC mitogens (White 
et al., 2012). In chapter 4, we showed that urinary concentrations of 16α-OHE1 were 
increased following exposure to chronic hypoxia. Interestingly, chronic dosing with 16α-
OHE1 in mice resulted in the development of a PH phenotype in female mice only. A 
recent study supported these findings, where 16α-OHE1 induced a PH phenotype in male 
BMPR-2 mutant mice but not in wild-type mice (Fessel et al., 2013a). This suggests that in 
females and genetically-susceptible mouse models, 16α-OHE1 mediates pathogenic 
effects. In BMPR-2 mice with a R899X mutation, 16α-OHE1 suppressed cytokine and 
inflammatory pathways whilst promoting platelet adhesion gene expression and genes 
associated with insulin resistance and angiogenesis (Fessel et al., 2013a). The authors 
concluded that the latter effect may be the mechanism by which 16α-OHE1 may be 
promoting vascular injury.  
CYP1B1 has the highest catalytic activity for the 4-hydroxylation of 17β-E2 (Badawi et 
al., 2001;Lee et al., 2003) and 4-hydroxylated estrogens are associated with the generation 
of semi-quinones and quinones which are associated with the initiation of tumorigenesis. 
We were therefore interested in investigating the effects of 4-OHE2 in vivo. Cellular 
proliferation screens have indicated that 4-OHE2 does not induce cell proliferation (White 
et al., 2012). However, unpublished data from our lab indicate that 4-OHE2 induces 
oxidative damage by increased superoxide production in hPASMCs. 4-OHE2 had no 
effects on RVSP, RVH and pulmonary vascular remodeling. In contrast, 4-OHE2 reduced 
serotonin-induced vasoconstriction of the intra-pulmonary arteries, suggesting that it may 
be mediating a protective effect. This is supported by a more recent study that provides 
evidence for beneficial effects of 4-OHE2 in the SU-hypoxic rat model of PH (Tofovic et 
al., 2013). This data suggests that the CYP1B1 mediates its pathogenic effects via the 
formation of the 16α-hydroxylated estrogens. 
A recent study examined estrogen metabolite levels in wild-type and CYP1B1-/- mice. The 
two metabolites that were most profoundly affected by CYP1B1 deletion were 4-OHE1 
and 2-MeOHE2 (Peng et al., 2013). 4-OHE1 was decreased and 2-MeOHE2 was 
increased. Hence we were interested in investigating the effects of these two metabolites 
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on cellular proliferation and viability in hPASMCs. Both 4-OHE1 and 2-MeOHE2 reduced 
cellular proliferation, but only 2-MeOHE2 reduced cell viability at 3 days. Following 
longer incubations (5 days), the proliferative effects were reduced and 4-OHE1 no longer 
caused a significant inhibition of proliferation. Further studies examining the role of these 
two metabolites in human vascular cells require further investigation. Studies on-going in 
our lab have highlighted a potential for ROS species derived from 4-OHE1, which may 
contribute to CYP1B1-induced pathogenesis. 
 The therapeutic potential of CYP1B1 inhibition in the 5.1.1
management of PAH 
The therapeutic strategy in PAH is aimed at developing pulmonary specific therapies to 
prevent off-target effects whilst inhibiting vascular cell proliferation and promoting 
regeneration of the lost distal pulmonary arteries. We have provided evidence that estrogen 
metabolism is dysregulated in PAH by up-regulation of CYP1B1 and that inhibition of this 
pathway can prevent the onset of experimental PH (Chapter 3 and Chapter 4). Moreover, 
we have shown that CYP1B1 inhibition with TMS attenuates 17β-E2 induced-proliferation 
in hPASMCs and this inhibitory effect is ~100 fold more potent in hPASMCs isolated 
from PAH patients (White et al., 2012). 
Increased activity and expression of CYP1B1 has already been reported in many diseases 
including breast cancer (McKay et al., 1995), lung cancer (Murray et al., 1997), ovarian 
cancer (McFadyen et al., 2001) and systemic hypertension (Jennings et al., 2010). From a 
therapeutic perspective, CYP1B1 is highly expressed within most cancers with only 
minimal expression in non-cancerous, healthy tissues (Maecker et al., 2003;Murray et al., 
1997) providing a basis for selective targeting. However, of some concern is the presence 
of positive CYP1B1 cells within healthy fallopian tubes, breast, uterine and ureter 
specimens (Maecker et al., 2003). CYP1B1 is also commonly expressed in the human lung 
(Spivack et al., 2001), where it is an important enzyme in the metabolism of xenobiotics, 
such as polycyclic aromatic hydrocarbons. Paradoxically, the metabolism of xenobiotics 
results in the activation of these compounds by formation of epoxides that generate DNA 
adducts - an early step in tumorigenesis. Inhibition of this pathway in the lung, where 
CYP1B1 is expressed, would therefore be considered advantageous.  
A phase I clinical trial assessing the feasibility, safety, tolerability and the generation of 
CYP1B1 immunity in patients with breast, ovarian, prostate, colon and renal cancer using 
ZYC300 has been evaluated with promising results (Gribben et al., 2005;Luby, 2008). 
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ZYC300 is a plasmid DNA encoding an inactivated form of CYP1B1 that was developed 
as a vaccination to stimulate the immune system to elicit a cytotoxic T lymphocyte 
mediated  response against CYP1B1, resulting in the lysis of CYP1B1 positive cells 
(Gribben et al., 2005;Luby, 2008). Importantly, vaccination with ZYC300 in patients with 
advanced stage cancer has been reported to be well tolerated, safe and patients that 
developed anti-CYP1B1-immunity responded better to therapy and appeared to have a 
clinical benefit (Gribben et al., 2005). The application of ZYC300 in the management of 
PAH is appealing and should be considered as adjunct therapy, given the high pulmonary 
arterial expression of CYP1B1. In addition, others have provided evidence that CYP1B1 
inhibition can attenuate Ang II and DOCA-salt induced hypertension, cardiac hypertrophy 
and fibrosis (Jennings et al., 2010;Sahan-Firat et al., 2010). The increased vascular 
reactivity associated with Ang II and DOCA-salt induced hypertension in aortic, 
mesenteric and femoral arteries is inhibited in CYP1B1-/- mice and by TMS treatment 
(Jennings et al., 2010;Sahan-Firat et al., 2010). Ang II induces aortic endothelial 
dysfunction as assessed by an impairment in the vasorelaxant response to acetylcholine and 
this is prevented with TMS (Jennings et al., 2010). This provides evidence that CYP1B1 
inhibition may be beneficial in numerous cancers and cardiovascular diseases. 
Of caution is the importance of CYP1B1 in normal eye functions and reduced CYP1B1 
activity has been associated with the development of glaucoma (Vasiliou & Gonzalez, 
2008). Thus, in the development of drugs that target CYP1B1, it is important to determine 
the ability of the drug/vaccine to cross the blood brain barrier, so as to prevent off-target 
effects in the ocular region. 
The therapeutic potential of the CYP1B1 inhibitor TMS has yet to be clinically evaluated. 
TMS is a synthetic derivative of a stilbene which was created as an anti-cancer agent with 
a high inhibitory potency for CYP1B1 to prevent the formation of highly genotoxic 
estrogen metabolites (Chun et al., 2001). TMS is a potent and selective CYP1B1 inhibitor, 
with an IC50 value of 6nM and displays 50-fold selectivity over CYP1A1 and 500-fold 
selectivity over CYP1A2 (Chun et al., 2001). TMS was originally developed as an 
inhibitor of the 4-hydroxylation of 17β-E2, and ultimately tumour formation. However, 
TMS has also been shown to induce cell apoptosis and inhibition of microtubule 
polymerisation (Park et al., 2007). It appears to have relatively low toxicity in vivo whilst 
displaying potent anti-tumour and anti-hypertensive effects, making this a good therapeutic 
candidate in cancers and cardiovascular diseases, including PAH that merits consideration.  
  Chapter 5 – General Discussion 
227 
 
TMS is a derivative of trans-resveratrol which is abundant in grapes and other berries. 
Resveratrol is proposed to be a major factor contributing to the ‘French Paradox’, which is 
the observation that despite having diets high in saturated fats, the French have a relatively 
low incidence of cardiovascular disease (Zern & Fernandez, 2005). Resveratrol is a potent 
inhibitor of CYP1B1, CYP1A1 and CYP1A2 activities with Ki values of ~0.8μM, 1.2μM 
and 15.5μM, respectively (Chang et al., 2001). Resveratrol is well tolerated and safe in 
humans and has been tested in numerous clinical trials. The therapeutic potential of 
resveratrol in PAH has been assessed in the MCT model of PAH with remarkable efficacy 
in attenuating increased RVSP and pulmonary vascular remodeling (Csiszar et al., 2009). 
Furthermore, it decreased the expression of inflammatory cytokines, exerted anti-oxidant 
and anti-proliferative effects (Csiszar et al., 2009). The extent to which these effects are 
mediated by CYP1B1 activity are yet to be evaluated, but it certainly highlights an 
attractive therapeutic avenue in PAH  that has already been successfully applied in other 
cardiovascular diseases and cancers. 
 Targeting estrogen metabolism in the management of PAH 5.1.2
We have provided evidence that estrogen metabolism is dysregulated in PAH by increased 
activity of CYP1B1. Yet the dynamic estrogen metabolic profile in pulmonary vascular 
cells remained undetermined. Whilst gene and protein expression are powerful tools in 
understanding molecular pathways that are altered in disease, they are often just a small 
component of a more complex cellular process. Furthermore, the availability of co-factors 
that are required for the activities of enzymes, the possibility of epigenetic alterations and 
polymorphisms are not taken into consideration. We were therefore interested in adopting 
a metabolomics approach to provide the unique estrogen metabolic profile that is the final 
product of the many complex cellular processes that may be occurring within a given cell. 
We utilized a quantitative HPLC approach to ‘fate-map’ estrogen metabolism in 
hPASMCs (Chapter 4). We report high intracellular concentration of 17β-E2 within both 
male and female hPASMCs and this is unaffected by PAH status. We provide the first 
direct evidence that male and female, non-PAH and PAH hPASMCs actively metabolize 
17β-E2. In all groups studied, the predominant metabolite formation was E1 indicating the 
activity of 17β-HSD2. E1 is less estrogenic and is considered a reservoir for the synthesis 
of 17β-E2. Thus, the activity of 17β-HSD2 could be considered as a deactivation process 
of the highly estrogenic 17β-E2. Of importance, only PAH hPASMCs (from both male and 
female samples) metabolized 17β-E2 to the potent mitogens 16α-OHE1 and 16α-OHE2. 
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Although these findings are preliminary and require validation in a larger cohort of PAH 
patients, these studies fit closely with already published data. We have provided evidence 
that urinary levels of 16α-OHE1 are increased in mice exposed to chronic hypobaric 
hypoxia (Chapter 4 and White et al., 2012) and Austin et al. reported a 2.3 fold lower 2-
OHE/16αOHE1 ratio in PAH patients with a BMPR-2 mutation compared to patients 
without any evidence of PAH (Austin et al., 2009). In addition, 16α-OHE1 is a potent 
inducer of PASMC proliferation and is associated with the development of a PAH 
phenotype in murine models (Fessel et al., 2013a;White et al., 2012). The formation of 
16α-hydroxylated metabolites may be associated with increased CYP1B1 expression 
and/or CYP1B1 polymorphisms (Badawi et al., 2001;Hanna et al., 2000). However, we 
cannot exclude the activities of other enzymes that have been reported to metabolize 17β-
E2 and E1 to 16α-OHE2 and 16α-OHE1, respectively. In particular, CYP1A2 has been 
shown to have a prominent role for 16α-hydroxylation (Badawi et al., 2001). With the 
application of selective inhibitors of these enzymes, including TMS, we will be able to 
determine the prominent enzyme/s that is associated with this unique ‘finger-print’ in PAH 
PASMCs. This discovery would highlight a novel therapeutic target that merits 
investigation in vivo. 
16α-hydroxylated estrogens have also been postulated to be important in carcinogenesis. 
Low urinary 2-OHE: 16α-OHE1 levels are associated with a high risk of breast cancer (Im 
et al., 2009;Kabat et al., 1997;Kabat et al., 2006). Furthermore, 16-hydroxylated 
metabolites stimulate proliferation of breast cancer cells (Seeger et al., 2006;Lippert et al., 
2003). 16α-OHE1 has previously been shown to induce cell proliferation by upregulating 
cyclin D1 expression in breast cancer cells (Lewis et al., 2005). This may be relevant to the 
pathological effects of 16α-OHE1 in PAH as cyclin D1 is an important mediator in PAH 
pathogenesis, where it promotes proliferation and vascular remodeling (Zeng et al., 2013). 
A successful candidate that attenuates the metabolic conversion of 17β-E2 into the 16α-
hydroxylated estrogens may therefore be applicable to a wider span of disease states, 
including PAH. 
 Concluding remarks 5.1.3
In summary of these findings, we have provided evidence for a dysregulated estrogen 
metabolic axis, particularly via increased CYP1B1 activity, in both pre-clinical models of 
PH and human PAH. CYP1B1 expression was increased in the pulmonary arteries of both 
IPAH and HPAH, independent of sex. 17β-E2 is historically regarded as a female gonadal 
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hormone. However, we have provided evidence for local production of 17β-E2 in both 
male and female hPASMC creating a local estrogenic milieu (Chapter 4). In healthy blood 
vessels, 17β-E2 promotes vasodilation and provides atherogenic protection. Cellular 
insults, such as hypoxia, that dysregulate estrogen signaling by altering estrogen receptor 
profiles and estrogen metabolism may perturb the beneficial effects of 17β-E2 promoting a 
pathogenic environment. Here we provide the first direct evidence that 17β-E2 is 
metabolized by hPASMCs. Importantly, we noticed a unique metabolic profile in both 
male and female PAH hPASMCs. Specifically, the smooth muscle cell mitogens, the 16α-
hydroxylated estrogens were only formed in PAH samples, independent of sex, 
highlighting that altered estrogen metabolism may be a crucial mediator in the 
pathogenesis of PAH. 
Inhibition of CYP1B1 with the highly potent and selective CYP1B1 inhibitor displayed 
impressive results in preventing PH onset in both the hypoxic and SU-hypoxic murine 
models of PH. This highlights CYP1B1 as a disease modifying enzyme that can be 
pharmacologically inhibited with TMS. TMS appears to have relatively low toxicity in 
vivo whilst displaying potent anti-tumour and anti-hypertensive effects, making this a good 
therapeutic candidate in cancers and cardiovascular diseases, including PAH that merits 
consideration. 
PAH is a disease of women that currently has no cure. Altered estrogen metabolism may 
be a key disease driver in females (and males) by shifting the protective effects of 
estrogens to pathogenic effects by altered enzymatic profiles. We have reinforced a 
pathogenic role for estrogen metabolism in the genesis and pathogenesis of PAH and we 
propose that clinical trials investigating the safety, tolerability and effectiveness of TMS in 
cancer and cardiovascular diseases including PAH are strongly encouraged. 
















Figure 5-1 Summary diagram 
Under normal physiological conditions, estrogens are metabolized towards the formation of anti-
proliferative metabolites. Up-regulation of CYP1B1 results in the formation of pro-proliferative 
metabolites which represent a pulmonary hypertensive (PH) insult, which can be rescued by 




 Future Perspective 5.2
Future studies investigating the safety, tolerability and effectiveness of TMS in cancer and 
cardiovascular diseases including PAH strongly encouraged. Understanding the molecular 
basis of the therapeutic effects of CYP1B1 inhibition is critical. Multiple pathogenic 
pathways are activated by CYP1B1 activity – the formation of genotoxic estrogen 
metabolites, pathogenic eicosanoids and ROS. Furthermore, the inhibition of CYP1B1 may 
increase levels of 17β-E2 and arachidonic acid that may signal by protective or pathogenic 
mechanisms depending on the cellular composition of enzymes and receptors. Delineating 
these effects is crucial in our understanding of the therapeutic effects and potential of 
CYP1B1 inhibition in cancers and cardiovascular diseases. 
We have developed a platform to investigate estrogen metabolism in pulmonary vascular 
cells. This can now be utilized to investigate estrogen metabolism in other cell types and 
the effect of PAH insults on metabolism in control cells. Furthermore, using in silico 
analysis we can predict potential enzymes that may be responsible for the altered estrogen 
metabolism in PAH. We can then target these enzymes in vitro to assess if we can reverse 
this metabolic phenotype. Effectively, this can be utilized as a screening method to identify 
novel therapeutic targets that can beneficially rescue the altered metabolic profile. 
Ultimately, we need to validate our results with the gold standard analytical technique, LC-
MS. 
We have highlighted a key role for CYP1B1 in PAH pathogenesis and future studies will 
examine the contribution of CYP1B1 to the formation of 16α-hydroxylated estrogens in 
hPASMCs. Future studies will also address the molecular mechanisms associated with 
CYP1B1 pathogenesis and specifically the effects of 16α-OHE1 and 16α-OHE2 on cellular 
signalling pathways.  
We anticipate that future therapies that target the estrogen pathway in PAH will show 
promising therapeutic effects on the basis of the evidence that we have provided here and 
that have been shown by other researchers within the field. We strongly encourage the 
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Figure 8-1 Full western blots for effect of hypoxia on protein expression of CYP1B1, COMT 
and 17β-HSD1 
Female control human pulmonary arterial smooth muscle cells (hPASMCs) were quiesced for 24 
hours and then exposed to either normoxic or hypoxic conditions (1% oxygen) for 24 hours. Cell 
homogenates were assayed for protein expression by western blotting for CYP1B1, COMT and 
17β-HSD1. CYP1B1 (a), 17β-HSD1 (b), COMT (c). The first two samples are normoxic controls 
and the latter two samples are hypoxic (1% samples). 
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Figure 8-2 Full western blots of aromatase and CYP1B1 expression in normoxic, hypoxic 
and SERT+ mice 
5-6 month old female wild-type (C57BL/6 x CBA), hypoxic and SERT+ mice lung homogenates 
were analyzed for aromatase and CYP1B1 expression by western blotting. Aromatase (a), 
CYP1B1 (b). Note that in Chapter 3, hypoxic samples were not included to retain focus on SERT+ 
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Figure 8-3 The effect of tempol and UO126 on thymidine incorporation 
Female hPASMCs were quiesced for 24 hours in 0.2% charcoal-stripped FBS (estrogen free) 
phenol red free DMEM. HPASMCs were then incubated with either a vehicle (water), an ERK 
inhibitor (UO126, 1μM) or tempol (ROS scavenger, 1mM) in the presence of 2.5% charcoal-
stripped FBS phenol red free DMEM. Thymidine was added for the last 24 hours (0.1μCi) and 
thymidine incorporation was assessed after 72 hours. n=1, repeated 3 times, One-way ANOVA 
with a Bonferroni’s post-hoc test. Data is expressed as the mean ± SEM. 
